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A B S T R A C T
Background
Vitamins and minerals play multiple functions within the central nervous system which may help to maintain brain health and optimal
cognitive functioning. Supplementation of the diet with various vitamins and minerals has been suggested as a means of maintaining
cognitive function, or even of preventing dementia, in later life.
Objectives
To evaluate the effects of vitamin and mineral supplementation on cognitive function in cognitively healthy people aged 40 years or
more.
Search methods
We searchedALOIS, theCochrane Dementia and Cognitive Improvement Group’s (CDCIG) specialised register, as well asMEDLINE,
Embase, PsycINFO, CINAHL, ClinicalTrials.gov and the WHO Portal/ICTRP from inception to 26th January 2018.
Selection criteria
We included randomised controlled trials that evaluated the cognitive effects on people aged 40 years or more of any vitamin or mineral
supplements taken by mouth for at least three months.
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Data collection and analysis
Study selection, data extraction, and quality assessments were done in duplicate. Vitamins were considered broadly in the categories of
B vitamins, antioxidant vitamins, and combinations of both. Minerals were considered separately, where possible. If interventions and
outcomes were considered sufficiently similar, then data were pooled. In order to separate short-term cognitive effects from possible
longer-term effects on the trajectory of cognitive decline, data were pooled for various treatment durations from 3months to 12 months
and up to 10 years or more.
Main results
In total, we included 28 studies with more than 83,000 participants. There were some general limitations of the evidence. Most
participants were enrolled in studies which were not designed primarily to assess cognition. These studies often had no baseline cognitive
assessment and used only brief cognitive assessments at follow-up. Very few studies assessed the incidence of dementia. Most study
reports did not mention adverse events or made only very general statements about them. Only 10 studies had a mean follow-up >
5 years. Only two studies had participants whose mean age was < 60 years at baseline. The risk of bias in the included studies was
generally low, other than a risk of attrition bias for longer-term outcomes. We considered the certainty of the evidence behind almost
all results to be moderate or low.
We included 14 studies with 27,882 participants which compared folic acid, vitamin B12, vitamin B6, or a combination of these to
placebo. The majority of participants were aged over 60 years and had a history of cardio- or cerebrovascular disease. We found that
giving B vitamin supplements to cognitively healthy adults, mainly in their 60s and 70s, probably has little or no effect on global
cognitive function at any time point up to 5 years (SMD values from -0.03 to 0.06) and may also have no effect at 5-10 years (SMD -
0.01). There were very sparse data on adverse effects or on incidence of cognitive impairment or dementia.
We included 8 studies with 47,840 participants in which the active intervention was one or more of the antioxidant vitamins: ß-
carotene, vitamin C or vitamin E. Results were mixed. For overall cognitive function, there was low-certainty evidence of benefit
associated with ß-carotene after a mean of 18 years of treatment (MD 0.18 TICS points, 95% CI 0.01 to 0.35) and of vitamin C after
5 years to 10 years (MD 0.46 TICS points, 95% CI 0.14 to 0.78), but not at earlier time points. From two studies which reported on
dementia incidence, there was low-certainty evidence of no effect of an antioxidant vitamin combination or of vitamin E, either alone
or combined with selenium. One of the included studies had been designed to look for effects on the incidence of prostate cancer; it
found a statistically significant increase in prostate cancer diagnoses among men taking vitamin E.
One trial with 4143 participants compared vitamin D3 (400 IU/day) and calcium supplements to placebo.We found low- to moderate-
certainty evidence of no effect of vitamin D3 and calcium supplements at any time-point up to 10 years on overall cognitive function
(MD after a mean of 7.8 years -0.1 MMSE points, 95% CI -0.81 to 0.61) or the incidence of dementia (HR 0.94, 95% CI 0.72 to
1.24). A pilot study with 60 participants used a higher dose of vitamin D3 (4000 IU on alternate days) and found preliminary evidence
that this dose probably has no effect on cognitive function over six months.
We included data from one trial of zinc and copper supplementation with 1072 participants. There was moderate-certainty evidence
of little or no effect on overall cognitive function (MD 0.6 MMSE points, 95% CI -0.19 to 1.39) or on the incidence of cognitive
impairment after 5 years to 10 years. A second smaller trial provided no usable data, but reported no cognitive effects of six months of
supplementation with zinc gluconate.
From one study with 3711 participants, there was low-certainty evidence of no effect of approximately five years of selenium supple-
mentation on the incidence of dementia (HR 0.83, 95% CI 0.61 to 1.13).
Finally, we included three trials of complex supplements (combinations of B vitamins, antioxidant vitamins, and minerals) with 6306
participants. From the one trial which assessed overall cognitive function, there was low-certainty evidence of little or no effect on the
TICS (MD after a mean of 8.5 years 0.12, 95% CI -0.14 to 0.38).
Authors’ conclusions
We did not find evidence that any vitamin or mineral supplementation strategy for cognitively healthy adults in mid or late life has
a meaningful effect on cognitive decline or dementia, although the evidence does not permit definitive conclusions. There were very
few data on supplementation starting in midlife (< 60 years); studies designed to assess cognitive outcomes tended to be too short to
assess maintenance of cognitive function; longer studies often had other primary outcomes and used cognitive measures which may
have lacked sensitivity. The only positive signals of effect came from studies of long-term supplementation with antioxidant vitamins.
These may be the most promising for further research.
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P L A I N L A N G U A G E S U M M A R Y
Vitamin and mineral supplementation for preventing cognitive deterioration in cognitively healthy people in mid and late life
Review question
This review aimed to find out whether people aged 40 years or older could maintain their mental abilities or reduce their risk of
dementia by taking vitamin or mineral supplements.
Background
There is great interest in anything people might do to keep themselves mentally healthy as they age and, especially, to reduce their risk
of developing dementia. Various vitamin and mineral supplements have been suggested as ways to do this. Vitamins and minerals have
many functions in the body and the ways they might affect brain health are not well understood. Therefore, we were interested in the
effects of any vitamins or minerals, either alone or in combination.
What we did
We searched up to January 2018 for all trials which had studied the effect on cognition (thinking and remembering) of any vitamin or
mineral supplements in people aged 40 years or more who had no cognitive problems at the beginning of the study. The studies had
to include a comparison group which had not taken the supplement being studied and, to be sure the comparison was fair, it should
have been decided at random whether people got the supplement or not.
What we found
We grouped the 28 included trials according to the kind of supplement they used and how it might work.
Most of the trials were not originally designed to study cognition or dementia and used only simple measures of cognition. Very few
studies investigated whether participants developed dementia. Long-term studies are probably needed to find effects on the risk of
dementia or cognitive decline but only 10 studies had an average length of follow-up longer than five years. The studies were generally
well-conducted although the longer trials had difficulty following up all of the participants and this could have biased some of the
longer-term results.
There were 14 trials of B vitamins (folic acid, vitamin B6, vitamin B12) with nearly 28,000 participants, mainly in their 60s and 70s.
Most of these trials were quite short (less than two years). We found no evidence that B vitamins had any effect on cognition.
There were 8 trials of antioxidant vitamins (beta-carotene/vitamin A, vitamin C, vitamin E) with approximately 47,000 participants.
These trials tended to be longer than the B vitamin trials so may have had more chance of detecting effects on dementia and cognitive
decline. The results were mixed. We found low-certainty evidence of better overall cognitive function after an average of 18 years
taking beta-carotene and after five years to 10 years taking vitamin C, but no effects after shorter periods of treatment. There were also
small benefits of beta-carotene, vitamin C, and antioxidant combinations on memory at some time points but not others. There was
no evidence of any benefits from vitamin E alone. Two studies examined the risk of developing dementia. One found no effect of a
combination of antioxidant vitamins and the other found no effect of vitamin E, either alone or combined with the mineral selenium.
Most of the studies did not report any information about harmful effects. One included trial was designed to look for an effect on the
risk of prostate cancer; it found a higher risk among the men taking vitamin E.
There was a small trial of vitamin D supplements which found they probably had no effect on cognition over six months. There were
longer trials of vitamin D with calcium (one trial), zinc and copper (one trial), and complex multivitamins (three trials). All lasted
between five and 10 years, but none of them found any evidence of beneficial effects on cognition. One trial found no effect of selenium
taken for approximately five years on the risk of developing dementia.
Conclusions
We found no good evidence to suggest that middle-aged or older people can preserve cognitive function or prevent dementia by taking
vitamin or mineral supplements. There were a few positive results associated with long-term use of antioxidant vitamins, particularly
beta-carotene and vitamin C, although the effects were small. Further research into the effects of these vitamins may be worthwhile.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
B Vitamins compared to placebo for maintaining cognitive function in cognitively healthy people in mid and late life
Patient or population: cognit ively healthy people in mid and late lif e
Setting: community
Intervention: B Vitamins (folic acid, vitamins B6 and vitamin B12, alone or in combinat ion)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with B Vitamins
Overall cognit ive func-
t ioning 3 to 12 months
of supplementat ion (f i-
nal measurement data)
assessed with: MMSE
or TICSm
- SMD 0
(0.08 lower to 0.08
higher)
- 2556
(3 RCTs)
⊕⊕⊕©
MODERATE 1
Overall cognit ive func-
t ioning 3 to 12
months of supplemen-
tat ion (change f rom
baseline data)
assessed with: MMSE
or TICSm
- SMD 0.03 lower
(0.26 lower to 0.19
higher)
- 317
(2 RCTs)
⊕⊕©©
LOW 12
Overall cognit ive func-
t ioning > 1 to 2 years
of supplementat ion (f i-
nal measurement data)
assessed with: MMSE,
TICS, or TICSm
- SMD 0.15 higher
(0.17 lower to 0.47
higher)
- 6956
(5 RCTs)
⊕⊕⊕©
MODERATE 1
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Overall cognit ive func-
t ioning > 1 to 2
years of supplementa-
t ion (change f rom base-
line data)
assessed with MMSE
- SMD 0.06 higher
(0.2 lower to 0.31
higher)
- 241
(1 RCT)
⊕⊕©©
LOW 12
Overall cognit ive func-
t ioning > 2 to 5 years
of supplementat ion (f i-
nal measurement data)
assessed with MMSE,
TICS,F-TICSm or a com-
posite score
- SMD 0.01 lower
(0.11 lower to 0.09
higher)
- 3985
(4 RCTs)
⊕⊕⊕©
MODERATE 1
Overall cognit ive func-
t ioning - > 5-10 years
of supplementat ion (f i-
nal measurement data)
assessed with MMSE,
TICS or TICSm
- SMD 0.01 lower
(0.09 lower to 0.07
higher)
- 10249
(3 RCTs)
⊕⊕©©
LOW 13
Incidence of MCI or de-
mentia > 2 to 5 years of
supplementat ion
assessed with: MMSE <
24 on 2 or more occa-
sions
follow-up: median 2.8
years
Study populat ion RR 0.89
(0.67 to 1.18)
1803
(1 RCT)
⊕⊕⊕©
MODERATE 1
103 per 1.000 91 per 1.000
(69 to 121)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
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GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded for indirectness due to restricted inclusion criteria for part icipants in included studies
2 Downgraded for imprecision due to small sample size and wide conf idence intervals
3 Downgraded for study lim itat ions due to missing data f rom 26% of part icipants in SEARCH 2010
MMSE:MiniMentalStateExamination
T ICS:T elephoneInterviewf orCognitiveStatus
T ICSm:modif iedT elephoneInterviewf orCognitiveStatus
F−T ICSm:modif iedT elephoneInterveiwf orCognitiveStatus(Frenchversion)
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B A C K G R O U N D
Description of the condition
Cognitive health, mild cognitive impairment, and
dementia
There is no consensus definition of cognitive health or successful
cognitive ageing, but it has been described as “not just the absence
of cognitive impairment, but the development and preservation
of the multidimensional cognitive structure that allows the older
adult to maintain social connectedness, an ongoing sense of pur-
pose, and the abilities to function independently, to permit func-
tional recovery from illness and injury, and to cope with residual
cognitive deficits” (Depp 2012; Hendrie 2006). Successful cogni-
tive ageing is distinct frommild cognitive impairment (MCI) and
dementia.
Dementia is a syndrome of cognitive and functional decline that is
usually progressive. It affects multiple cognitive domains, among
which memory is usually prominent, but orientation, executive
function, language, perception, and social cognition are also often
affected. In most cases, the onset of dementia is gradual. It is
usually preceded by a stage of mild cognitive impairment when
cognitive deficits beyond those of normal ageing are detectable,
but function is not significantly impaired. The term dementia is
used once the cognitive deficits begin to have a significant effect on
daily activities. As the syndrome progresses, those affected become
increasingly dependent on others for all activities of daily living.
Types of MCI and dementia
Subtypes of dementia are distinguished by the underlying pathol-
ogy. The four most common subtypes are Alzheimer’s disease de-
mentia (AD) (accounting for an estimated 60% to 70% of all de-
mentia cases); vascular dementia (VaD); dementia with LewyBod-
ies (DLB); and frontotemporal dementia (FTD). Accurate diagno-
sis of the subtypes may be difficult. Mixed pathology is common,
with more than 80% of cases having some features of Alzheimer’s
disease (Jellinger 2006; WHO 2012). However, the proportion
of dementia attributable to Alzheimer’s disease reduces with age
(Savva 2009).
There are numerous different operational definitions of MCI,
with different scope (e.g. memory or non-memory impairments)
(Matthews 2007), prevalence (Stephan 2007), and risk of progres-
sion to dementia (Matthews 2008). Currently, there is no single,
universally accepted definition of MCI (Stephan 2013), but adap-
tations of the criteria suggested by Petersen 1999 are commonly
used in clinical trials. Categorisation of MCI may also be based
on the suspected underlying cause of the cognitive deficits, e.g.
MCI due to Alzheimer’s disease and MCI due to vascular disease
(termed ’vascular cognitive impairment, no dementia’: VCIND).
It is increasingly recognised that some dementia syndromes, in-
cluding AD, have a very long preclinical phase with pathologi-
cal changes beginning years, or even decades, before the onset of
symptoms (Sperling 2011). Attempts have been made to develop
criteria to capture preclinical states as early as possible. For exam-
ple, the label ’pre-MCI’ has been applied to people with impaired
executive function and language, elevated apathy scores, and re-
duced volumes of left brain areas of the hippocampus, an area in-
volved in consolidation of information from short-term memory
to long-term memory but also spatial memory, enabling orien-
tation. (Duara 2011). It is likely that biomarker tests, tests that
measure some biological state, will be needed to identify people
in the earliest stages of dementing illnesses.
Prevalence of MCI and dementia
In the UK Medical Research Council’s population-based Cogni-
tive Function and Ageing Study (CFAS), which mapped 18 dif-
ferent definitions of MCI, the range of prevalence estimates was
found to be variable (0.1% to 42.0%), and conversion rates to de-
mentia generally low (Stephan 2007). Prevalence rates and rates of
conversion to dementia have been reported to be higher in special-
ist settings than in population-based studies (adjusted conversion
rate from MCI to dementia 9.6% versus 4.9%) (Mitchell 2009).
The risk of dementia increases with age. According to a World
Health Organization (WHO) report, only 2% to 10% of cases
start before the age of 65 years (WHO 2012). The same report es-
timated that there were 35.6 million people with dementia in the
world in 2010, and that this figure would double every 20 years
to reach 65.7 million in 2030 (WHO 2012). However, there is a
degree of uncertainty about the expected increase in prevalence of
dementia. Recent research by Matthews 2013 in the UK and by
Christensen 2013 in Denmark indicates that age-specific preva-
lence of dementia may be falling in developed countries, suggest-
ing the possibility that dementia risk may be modifiable. Never-
theless, because of population ageing, the overall prevalence con-
tinues to rise.
Risk factors
Generally, risk factors for dementia can be divided into modifi-
able and non-modifiable categories. Non-modifiable risk factors
include age, genetic factors, and gender (females are at higher risk).
At a population level, age is the most significant risk factor. In
people older than 65 years, the risk of AD (the commonest cause
of dementia) doubles every five years (Launer 1999; McCullagh
2001; Van den Berg 2012; Van der Flier 2005). A pooled analysis
of four prospective studies in Europe found that the incidence of
AD among people aged 90 years and over was 63.5/1000 person-
years (Launer 1999). Genetics plays a major role in early onset
AD, but a lesser role in the much commoner late onset disease.
Many potentially modifiable risk factors are common to AD and
vascular dementia. These include diabetes mellitus, midlife obe-
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sity,midlife hypertension, smoking„and physical inactivity (Prince
2014; WHO 2012). The fact that risk factors are active in midlife
is consistent with what is known of the long preclinical phase of
dementia and implies that there is a long period in which preven-
tive efforts could be effective.
At present, there is no cure for any subtype of dementia, but iden-
tifying and targeting modifiable risk factors might offer oppor-
tunities to modify its onset and course. Studies to test this hy-
pothesis have investigated cognitive stimulation, exercise, diet, and
other nutritional interventions, and the management of vascular
risk factors, such as hypertension, diabetes, obesity, smoking, and
physical inactivity (Lindsay 2002; Lourida 2013; Norton 2014;
Wilson 2002).
Description of the intervention
This review focusses on the effect of vitamins or minerals (or both)
on cognitive functioning. Vitamins are organic compounds that
are essential for the normal physiological process in the body and
play important roles in growth and development (Kennedy 2011).
MInerals are inorganic elements and as nutrients are also needed
by the body to grow and develop normally (Centers for Disease
Control and Prevention 2014). Most of these essential nutrients
are available naturally in the diet. Dietary supplements are any
consumed products that aim to provide nutrients additional to
those obtained in the regular diet.
How the intervention might work
Vitamins and minerals have numerous important roles in human
physiology. Recognised biological roles of all those considered for
this review are summarised briefly in Appendix 1.
The most commonly cited mechanisms by which vitamins and
minerals may influence cognitive function are (1) via effects on
specific plasma amino-acids called homocysteine for B vitamins
(folic acid, vitamin B6, and vitamin B12) and (2) via antioxidant
effects, reducing the concentration of free radicals that may dam-
age human cells, for vitamins C, E, and ß-carotene, possibly vi-
tamin D, and some minerals such as selenium. These hypotheses
about possible mechanisms are based largely on preclinical studies
and on observations of associations between elevated homocys-
teine levels or elevated markers of oxidative stress and cognitive
decline or dementia (Clarke 2007a, Bennett 2009). Detailed un-
derstanding of mechanisms is, however, lacking.
Why it is important to do this review
The prevalence and high societal costs of dementia are such that
even small reductions in its age-specific incidence would have a
large impact on healthcare costs and on the overall burden it causes
to patients, their families, and communities. In order to decide
where preventive efforts should be concentrated, robust assess-
ments are needed of the effects of interventions and of the ‘dose’
and duration of intervention necessary to achieve an effect.
For individuals, fear of cognitive decline and dementia may be
powerfulmotivators to seek preventive interventions. Vitamin and
mineral supplementation and cognitive activities (e.g. comput-
erised ‘brain training’ games), in particular, are subject to promo-
tion by those with commercial interests. It is important for people
to know whether time, effort, and money they might invest to
prevent cognitive decline is likely to be well spent. Information
about adverse effects is also important. Although nutritional and
behavioural interventions are often perceived to be ‘low risk’, they
are not necessarily without the potential to cause harm. For ex-
ample, trials have found high doses of vitamin E to be associated
with higher rates of side effects than placebo (Bjelakovic 2012;
Brigelius-Flohe 2007; Miller 2005).
O B J E C T I V E S
To evaluate the effects of vitamin and mineral supplementation
on cognitive function in cognitively healthy people aged 40 years
or more.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised or quasi-randomised controlled trials,
published or unpublished, reported in any language. We included
trials with a duration of intervention of 12 weeks or more. Trials
in cognitively healthy people with a duration as short as 12 weeks
typically investigate cognitive enhancement rather than mainte-
nance of cognitive function. We included these trials in order to
give a full picture of the data, although it is recognised that the re-
lationship between short-term cognitive enhancement and main-
tenance of cognitive function over longer periods of time, or inci-
dence of dementia, is unclear.
Types of participants
We included trials in which the participants were cognitively
healthy people from midlife onwards, i.e. participants aged 40
years and over without a dementia diagnosis or cognitive impair-
ment at baseline (’midlife’ was defined for the purposes of dis-
ease classification, in DSM-IV 1994, as between 40 years and 65
years).The cognitive status of participants was determined by the
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trialists’ own definitions of ‘cognitively healthy’. These definitions
were recorded. We contacted trialists if further clarification was
needed to determine health status. If trials included a cognitively
mixed population, we required at least 80% of participants to be
free of cognitive impairment (including subjective cognitive im-
pairment) at baseline.
Types of interventions
We included studies comparing the effect of orally-administered
vitamin or mineral supplements (or vitamin and mineral supple-
ments) with control interventionswhichwere not expected to have
an effect on cognition (placebo or no intervention/usual care). El-
igible vitamins and minerals are listed in Appendix 1. These vita-
mins and minerals could be given singly or in combination and
at any dose, for a minimum of 12 weeks. Trials of vitamins or
minerals (or vitamins and minerals) given in combination with
other nutrients (e.g. fatty acids, amino acids) or with drugs were
excluded unless the design allowed the effects of vitamins or min-
erals to be isolated. For example, a trial comparing vitamin X to
amino acid Y was ineligible, but a trial comparing vitamin X and
amino acid Y to amino acid Y only was eligible.
Types of outcome measures
Primary outcomes
Mean overall cognitive functioning measured with any interna-
tionally accepted and validated measure: for example, Alzheimer’s
Disease Assessment Scale - cognitive subscale (ADAS-cog); Mini
Mental State Examination (MMSE); Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS); Cambridge
Cognition Examination (CAMCOG).
Secondary outcomes
Any internationally accepted and validated measures of:
• specific cognitive functioning subdomain: episodic
memory;
• specific cognitive functioning subdomain: executive
functioning;
• specific cognitive functioning subdomain: speed of
processing;
• incidence of MCI or all-cause dementia;
• quality of life, either generic or disease-specific;
• clinical global impression (a scale measuring a clinician’s
judgement on overall symptom severity);
• functional performance;
• number of participants experiencing one or more serious
adverse events (SAE);
• mortality.
If a trial provided data on more than one cognitive scale for a
specific outcome, we applied a hierarchy of cognition-related out-
comes and used data on the cognitive scale that was highest on this
hierarchy. For example, if a trial reported results on both the Mini
Mental State Examination and the Clinical Dementia Rating scale
(CDR), we used the outcome data from MMSE in our quantita-
tive analyses. The rank of a scale in the hierarchy was determined
by the frequency of its use in a large set of 79 trials, evaluating
vitamin and mineral supplementation, dietary interventions, and
physical exercise interventions.
Search methods for identification of studies
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois), the
Cochrane Dementia and Cognitive Improvement Group’s (CD-
CIG) specialised register.
ALOIS is maintained by the Information Specialist for the CD-
CIG, and contains studies that fall within the areas of dementia
prevention, dementia treatment and management, and cognitive
enhancement in healthy elderly populations. The studies are iden-
tified through:
1. Monthly searches of a number of major healthcare
databases: MEDLINE, Embase, CINAHL, PsycINFO and
LILACS;
2. Monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials and the Netherlands National Trials Register, plus
others);
3. Quarterly search of The Cochrane Library’s Central Register
of Controlled Trials (CENTRAL);
4. Six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to
Theses; Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website (www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia, cognitive
improvement, and cognitive enhancement trials, can be viewed in
the ‘methods used in reviews’ section within the editorial informa-
tion about the Cochrane Dementia and Cognitive Improvement
Group.
We ran additional searches in MEDLINE, Embase, PsycINFO,
CINAHL, ClinicalTrials.gov and the WHO Portal/ICTRP to en-
sure that the searches for each suite of reviews was as comprehen-
sive and as up-to-date as possible to identify published, unpub-
lished, and ongoing trials. The search strategies that we created
and used can be seen in Appendix 2.
9Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Searching other resources
We screened reference lists of all included trials. In addition, we
screened reference lists of recent systematic reviews, health tech-
nology assessment reports, and subject-specific guidelines identi-
fied through www.guideline.gov.The searchwas restricted to those
guidelines meeting National Guideline Clearinghouse’s (NGC)
2013 inclusion criteria published in this year or later.
We contacted experts in the field and companies marketing in-
cluded interventions, in order to provide additional randomised
trial reports that were not identified by the database search.
Data collection and analysis
Selection of studies
We used crowdsourcing to screen the search results. Details of
this have been described here: http://www.medicine.ox.ac.uk/
alois/content/modifiable-risk-factors. In brief, teams of volunteers
performed a ‘first assessment’ on the search results. The volun-
teers were recruited through the author team’s institutions. They
screened the results using an online tool developed for Cochrane
Embase project but tailored for this programme of work. The
crowd decided, based on a reading of title and abstract, whether the
citation was describing a randomised or quasi-randomised trial,
irrespective of the citations topic. It is estimated that this removes
75% to 90% of results retrieved. The remaining titles and ab-
stracts were then screened by the author team, followed by full
text screening. Two clinicians in the author team screened inde-
pendently (AA, DD, RA). In the event of disagreement that could
not be resolved by discussion, a methodologist (LYC) and addi-
tional clinician (NT or JA) arbitrated on eligibility and reasons
for exclusion. All consensus rulings and reasons for exclusion were
subsequently verified by methodologists (AR and MdN or LYC).
Citations and full text papers from the update searches conducted
in 2017 and 2018 were screened independently by two clinicians
(JM and GM), who reached consensus through discussion if nec-
essary.
Data extraction and management
Two review authors, working independently, extracted trial infor-
mationusing a structured data extraction form.Discrepancieswere
resolved by discussion, or by the involvement of a third reviewer.
Where possible, we extracted (as a minimum) the following infor-
mation related to characteristics of participants, intervention, and
study design:
Participant characteristics:
• gender;
• baseline age (range, median, mean);
• baseline cognitive function;
• cognitive diagnostic status.
Intervention characteristics:
• nature of the intervention; generic and trade name of
intervention;
• description of the control condition;
• duration of treatment;
• dosage and frequency;
• any concomitant treatments;
• treatment adherence.
Methodological characteristics:
• trial design (individual or cluster randomisation; parallel
group, factorial, or crossover design);
• number of participants;
• outcome measures used;
• duration of follow-up as measured from randomisation;
• duration of follow-up as measured from end of treatment;
• source of financial support;
• publication status.
If eligible cognitive outcome data were available at multiple time
points, we grouped outcomes into short-term (12 weeks/three
months to one year), medium-term (> one year to two years) and
longer-term results (> two to five years, > five to 10 years and >10
years). For the secondary outcome all-cause dementia, only out-
come data after one or more years of follow-up were considered.
Within these time periods, the longest available data reported by
the study were extracted (for example, if study reported data at
six months, 9 months and one year, only the one-year data were
extracted and analysed for the short-term time point.
For dichotomous outcomes (such as incident dementia or mortal-
ity), we extracted from each trial the number of participants with
each outcome.
For continuous outcomes, we extracted the number of participants
in whom the outcome was measured, and the mean and standard
deviation of the change from baseline or of the mean value at
each relevant time point. When necessary, means and measures of
dispersion were approximated from figures in the reports.
For crossover trials, we extracted data on the first treatment period
only.
Whenever possible, we extracted intention-to-treat data i.e.
analysing all patients according to the group randomisation. If this
was not available, then we extracted and reported data from avail-
able case analyses. If these data were also not available, we consid-
ered data from ’per protocol’ analyses. We contacted the trialists
if we could not obtain the necessary data from the trial report.
Assessment of risk of bias in included studies
Two authors independently assessed the risk of bias in each of the
included trials using Cochrane’s ’Risk of bias’ tool (Higgins 2011).
We resolved disagreements by consensus. We assessed the risk of
bias potentially introduced by suboptimal design or conduct in
the domains of sequence generation, concealment of allocation,
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blinding of participants and caregivers, blinding of outcome asses-
sors, selective outcome reporting, and incomplete outcome data,
including the type of statistical analyses used (true intention-to-
treat versus other). The general definitions that were used are re-
ported in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011); the review-specific definitions described
in Appendix 3 are in part derived from a previously published sys-
tematic review (Rutjes 2012).
Measures of treatment effect
The measure of treatment effect for continuous outcomes was a
mean difference (MD) if all studies measuring that outcome used
the same scale and a standardised mean difference (SMD), defined
as the between-group difference in mean values divided by the
pooled standard deviation (SD), if an outcome was measured with
a variety of scales. The treatment effect for dichotomous outcomes
was expressed as a relative risk (RR).
Unit of analysis issues
We included no cluster-randomised trials and identified no other
unit of analysis issues.
Dealing with missing data
Missing data in the individual trials may put the study estimates
of effects at a high risk of bias, and may lower the overall certainty
of the evidence according to GRADE (Higgins 2011). We dealt
with missing data in our ’Risk of bias’ assessments and planned to
evaluate attritionbias in stratified analyses of the primary outcomes
(Appendix 3). We thus analysed the available information and did
not contact authors with a request to providemissing information.
We did not impute missing data ourselves.
Assessment of heterogeneity
We considered differences in trial populations, interventions (in-
cluding duration of treatment), and outcomes when assessing clin-
ical heterogeneity and deciding which data to pool. We used vi-
sual inspection of forest plots and the tau2 and I2 statistics when
considering whether to downgrade our confidence in results for
inconsistency between trials, see also Data synthesis.
Assessment of reporting biases
Due to the low number of studies included in meta-analyses, we
did not perform any funnel plot analyses to explore possible re-
porting biases.
Data synthesis
We pooled interventions which have been postulated to share a
main mechanism of action in preventing development of demen-
tia. Specifically, we pooled data from trials of:
• the antioxidant vitamins C, E, and ß-carotene, and
• B vitamins (thiamine (B1), pyridoxine (B6), folic acid (B9)
and cobalamin (B12)) on the grounds that these are cofactors for
key metabolic processes and are involved in reducing high
homocysteine levels.
Whenever possible, we used standard inverse-variance random-
effects meta-analysis to combine outcome data across the trials
(DerSimonian 1986) (see Data extraction and management for
definitions of time points). When indicated, we converted scales
to a consistent direction of effect across all trials, so that negative
estimates of effect referred to those favouring active supplementa-
tion, while positive estimates referred to those favouring control.
We visually inspected forest plots for the presence of heterogeneity
and calculated the variance estimate tau² as a measure of between-
trial heterogeneity (DerSimonian 1986). We prespecified a tau² of
0.04 to represent low heterogeneity, 0.09 to represent moderate
heterogeneity, and 0.16 to represent high heterogeneity between
trials (Spiegelhalter 2004). The I² statistic and the corresponding
Chi² test were depicted in addition (Higgins 2003) for the benefit
of readers more familiar with this statistic. I² describes the percent-
age of variation across trials attributable to heterogeneity rather
than chance, with values of 25%, 50%, and 75% typically being
interpreted as low, moderate, and high between-trial heterogene-
ity. Tau² was preferred over I² in the interpretation of between-
trial heterogeneity, as the interpretation of I² can be affected by the
precision of trials included in themeta-analysis (Rücker 2008). All
P values were two-sided. Statistical analysis was done in Review
Manager 5 (Review Manager 2014); and in STATA, release 13
(StataCorp, College Station, Texas).
Subgroup analysis and investigation of heterogeneity
Where we identified substantial inconsistency between trials in a
meta-analysis, we inspected forest plots to look for obvious sources
of inconsistency and reviewed the trials for clinical heterogeneity.
Because of the small numbers of trials from which data could be
pooled, we conducted no subgroup analyses.
Sensitivity analysis
We did not conduct any sensitivity analyses.
GRADE and summary of findings table
We constructed ’Summary of Findings’ (SoF) tables for compar-
isons of B vitamins, antioxidant vitamins, Vitamin D + calcium,
Zinc + Copper and complex multivitamins with placebo. For each
comparison, we included in the SoF tables results related to over-
all cognitive function and the incidence of dementia at each time
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point. If a study presented results for the same participants at dif-
ferent time points, and these could not be pooled with results from
other studies, then we presented in the SoF table only the results
from the longest period of follow-up.
We used GRADE to describe the certainty of the overall body
of evidence for each outcome in the ’Summary of findings’ table
(Higgins 2011; Guyatt 2008).
Certainty refers to the degree of confidence which can be placed in
the estimates of treatment benefits and harms. There are four pos-
sible ratings: ’high’, ’moderate’, ’low’ and ’very low’. The GRADE
approach rates evidence from RCTs which do not have serious
limitations as ’high-certainty’. However, several factors can lead to
the downgrading of the evidence to ’moderate’, ’low’ or ’very low’.
The degree of downgrading is determined by the seriousness of
these factors: study limitations (risk of bias); inconsistency; indi-
rectness of evidence; imprecision; and publication bias (Higgins
2011; Guyatt 2008). Rating evidence ’high-certainty’ implies that
we are confident in our estimate of the effect, and further research
is very unlikely to change this. A rating of ’very low’-certainty in-
dicates that we are very uncertain about the obtained summary
estimate of the effect.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
We conducted searches in December 2014, July 2015, March
2016, August 2016, March 2017, and January 2018. In total, we
retrieved 7,257 records from the six searches. After de-duplica-
tion, 5211 records remained. A Crowd and the CDCIG infor-
mation specialist assessed these at title and abstract level. In total,
725 results remained after this assessment. The review team then
screened these records. Of these, we assessed 74 full-text articles
for eligibility and included 28 studies. One study was placed in the
section ’Awaiting classification’; although it was marked as ’com-
pleted’ in the trial registry, we were unable to find any results or
to get any response from the authors. This process is depicted in
Figure 1.
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Figure 1. Study flow diagram.
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Included studies
We included 28 studies with a total of more than 83,000 partici-
pants in the review.
Studies of B vitamins
We included 14 studies with 27,882 participants in which the ac-
tive interventionwas folic acid, vitaminB12, vitaminB6, or a com-
bination of these (Andreeva 2011; Dangour 2015; Durga 2007;
Eussen 2006; Ford 2010; Hankey 2013; Kang 2008; Lewerin
2005; McMahon 2006; SEARCH 2010; Stott 2005; Toole 2004;
Van der Zwaluw 2014; Walker 2012). Seven of the 14 studies had
been designed with cognition as a primary outcome.
• Study design. Nine studies compared the B vitamin or B
vitamin combination to placebo in a two-arm, parallel group
design. In one two-arm, parallel group study (Toole 2004), the
intervention was a multivitamin containing the United States’
Food and Drug Administration (FDA) recommended daily
allowances (RDA) of vitamins supplemented with high doses of
folic acid, vitamin B6, and vitamin B12 while the comparator
arm was a multivitamin containing the RDAs only. One study
(Eussen 2006) had a three-arm, parallel group design with active
intervention groups receiving B12 and (folic acid + B12); we
combined these to make a single active intervention group. Four
studies had factorial designs with placebo controls. SEARCH
2010 had a 2 x 2 factorial design including (folic acid + B12) and
simvastatin. Andreeva 2011 had a 2 x 2 factorial design
including (folic acid + B6 + B12) and omega fatty acids. Stott
2005 had a 2 x 2 x 2 factorial design including (folic acid + B12),
B2, and B6 and reported results for all eight groups separately;
for comparability with other studies, we included the (folic acid
+ B12) and the (folic acid + B12 + B6 groups), combining these
to make a single active intervention group. Kang 2008 had a 2 x
2 x 2 x 2 factorial design. It reported on a cognitive substudy of
the Women’s Antioxidant and Folic Acid Cardiovascular Study
(WAFACS), which was established by adding a fourth arm -
(folic acid + B6 + B12) - to the Women’s Antioxidant
Cardiovascular Study (WACS). The active interventions in
WAFACS were therefore (folic acid + B6 + B12), vitamin E,
vitamin C, and ß-carotene. Kang 2008 reported on the effects of
the B vitamins.
• Interventions. The active interventions varied in their
constituents and dose. In one trial, the active intervention of
interest was folic acid alone; in one trial, it was B12 alone. In five
trials, the active intervention was (folic acid + B12) and in six
trials (folic acid + B12 + B6), although in one of these trials the
B12 dose was minimal. Daily doses of folic acid ranged from 0.4
mg to 2.5 mg, of B6 from 3 mg to 50 mg and of B12 from 0.02
mg to 1 mg. All studies had a placebo control, although for most
of the factorial studies the comparison was ’B vitamin’ versus ’no
B vitamin’ where the ’no B vitamin’ group were taking a variety
of other interventions. In one trial, all participants were also
given 600 IU of vitamin D3 daily.
• Population. The study populations varied.
◦ Six studies recruited participants with a history of
cardio- or cerebrovascular disease (Andreeva 2011, Hankey
2013; MRC/BHF 2002, SEARCH 2010, Stott 2005, Toole
2004) and one recruited men with hypertension (Ford 2010).
Three studies included only participants with elevated serum
homocysteine levels (> 12 or 13 µmol/L) at baseline (Durga
2007, McMahon 2006, Van der Zwaluw 2014). Two studies
included only participants with mild to moderate B12 deficiency
(Dangour 2015; Eussen 2006). One study included only diabetic
participants (Anand 2011). In one study, participants were
selected on the basis of elevated psychological distress (Walker
2012).
◦ In all studies, there was evidence that most
participants were cognitively healthy at baseline, but inclusion of
small numbers of participants with cognitive impairment was
possible. The inclusion decision was marginal for two studies.
Stott 2005 reported median MMSE at baseline of 28 with an
IQR of 26 to 29; hence 25% of participants in this UK study
had an MMSE < 26. In Toole 2004, all participants had had a
’non-disabling’ ischaemic stroke and baseline MMSE was 26.9
(SD 3.4) so it is likely that some participants had a degree of
cognitive impairment at baseline. Only participants with ’severe
cognitive impairment’ were excluded. We decided to include
both of these studies, but to consider the population as a possible
source of heterogeneity.
◦ The age of participants also varied. In six studies, the
mean age at the onset of supplementation was between 60 years
and 70 years; in eight studies the mean age was between 70 years
and 80 years.
Studies of antioxidant vitamins
We included eight studies with 47,840 participants in which
the active intervention was one or more of the antioxidant vita-
mins: vitamin E, vitamin C, ß-carotene (Anand 2011; Grodstein
2007; Kang 2006; Kang 2009; Kesse-Guyot 2011; Kryscio 2017;
MRC/BHF 2002; Yaffe 2004). Only one of these studies had been
designed primarily to assess cognition.
• Study design. One study (Anand 2011) compared vitamin E
to no vitamin E in a randomised, open-label design. The
remaining studies were placebo-controlled. One (Kang 2006)
was a 2 x 2 factorial comparison of vitamin E and low dose
aspirin. One (Kryscio 2017) was a 2 x 2 factorial comparison of
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vitamin E and selenium supplements (this trial was also included
in a comparison of selenium with placebo, below). Grodstein
2007 reported data on ß-carotene. It started as a two-arm parallel
group study (ß-carotene and placebo, the Physicians’ Health
Study I (PHS-I)) which lasted for 13 years. After a gap of up to
18 months in some cases, approximately half the participants in
PHS-I and some new recruits entered the Physicians’ Health
Study II (PHS-II) and a cognitive assessment was added. The
original randomisation of participants in PHS-I to ß-carotene or
placebo was retained in PHS-II while vitamin C, vitamin E, and
a complex multivitamin were added in a factorial design. The
paper therefore reported data after both long-term (mean 18
years, range 15 to 20 years) and shorter-term (mean one year,
range three months to three years) treatment with ß-carotene.
Kang 2009 studied vitamin E, vitamin C, and ß-carotene in a 2 x
2 x 2 factorial design. In the remaining three studies, the active
intervention was a combination of antioxidant vitamins.
MRC/BHF 2002 had a 2 x 2 factorial design comparing
(vitamin E + vitamin C + ß-carotene) and simvastatin. Yaffe
2004 was a four-arm parallel group study; in this comparison, we
included the (vitamin E + vitamin C + ß-carotene) and placebo
arms (Yaffe 2004 had two additional arms: one treated with zinc
and cupric oxide, which we included in another comparison, and
one treated with the antioxidant combination plus zinc and
cupric oxide, which we excluded). Finally, Kesse-Guyot 2011
compared a combination of vitamin E, vitamin C, ß-carotene,
zinc, and selenium to placebo. In this case, it was not possible to
separate the antioxidant vitamins from the minerals. This study
also differed in the timing of the cognitive assessment which
took place six years after the end of the eight-year
supplementation period.
• Interventions. There were data on vitamin E from four
trials, on vitamin C from one trial, and on ß-carotene from two
trials. Most of these data were from factorial trials in which the
comparison group was receiving a variety of interventions. In
two trials, the active intervention was the antioxidant
combination (vitamin E + vitamin C + ß-carotene), in one trial,
it was the same combination with zinc and selenium and in one
trial there were both vitamin E and (vitamin E + selenium) arms.
All vitamin E was given as alpha-tocopherol. Doses of vitamin C
ranged from 120 mg to 500 mg daily, of vitamin E from 600 IU
on alternate days to 660 IU daily (except in Kesse-Guyot 2011 in
which the vitamin E dose in the combined antioxidant was only
45 IU daily) and of ß-carotene from 6 mg to 50 mg daily.
• Population. The study populations varied.
◦ Two studies included women only (Kang 2006, Kang
2009) and two studies included men only (Grodstein 2007;
Kryscio 2017). In Anand 2011, all participants had type 2
diabetes and were taking oral hypoglycaemics. In Kang 2009, all
participants had cardiovascular disease or three or more coronary
risk factors. In MRC/BHF 2002, participants were recruited on
the basis of a high risk of coronary heart disease death over the
next five years. In Yaffe 2004, all participants had age-related
macular degeneration.
◦ Reflecting the fact that these studies were
overwhelmingly cognitive ’add-ons’ to studies with other
purposes, only one study (Anand 2011) conducted any cognitive
assessment at baseline. In this study, which was conducted in an
economically-deprived population in India, a score of 24 or
more on the Tamil version of the MMSE was considered normal
cognition. Although we could not be sure that the other studies
did not include some participants with cognitive impairment, we
considered it likely in all cases that the study populations were
very largely free of dementia or significant cognitive impairment
and that the data were informative for our review question.
◦ The age of participants included in this comparison
was generally lower than in the B vitamin comparison. In three
studies (Anand 2011, the long-term component of Grodstein
2007 and Kesse-Guyot 2011), the mean age at randomisation
was between 50 and 60 years. In four studies, the mean or
median age at randomisation was between 60 and 70 years. For
the shorter-term component of Grodstein 2007, the mean age at
randomisation was 71 years. MRC/BHF 2002 did not report a
mean age of participants; the range at baseline was 40 years to 80
years.
Studies of vitamin D
We included one trial with 4143 participants which compared
(vitamin D3 + calcium carbonate) with placebo (Rossom 2012,
the Women’s Health Initiative Memory Study, or WHIMS) and
a small pilot study with 60 participants comparing vitamin D3
and placebo (Aspell 2017). Cognition was a primary outcome in
Aspell 2017. Although Rossom 2012 was an ancillary study to a
larger study with different primary aims, participants did have a
detailed assessment to exclude dementia or cognitive impairment
prior to enrolment in WHIMS.
• Study design. Both studies were two-arm parallel group
studies. The mean duration of treatment and follow-up in
Rossom 2012 was 7.8 years; in Aspell 2017, it was six months.
• Intervention. The doses differed markedly in these two
studies. In Rossom 2012, the experimental intervention was 400
IU vitamin D3 and 1000 mg calcium carbonate daily. Use of
personal supplemental vitamin D up to 600 IU (later 1000 IU)
and of calcium up to 1000 mg was also permitted. All
participants were also enrolled in WHI Hormone Therapy trials
and may have been taking estrogen with or without progestin
under those protocols. In Aspell 2017, the experimental
intervention was 4000 IU of vitamin D3 on alternate days.
• Population. The participants in Rossom 2012 were 4143
women with a mean age of 71 years (range 65 to 80 years). The
participants in Aspell 2017 were 60 community-dwelling men
and women with a mean age of 68.5 years.
15Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Studies of zinc and copper
We included two trials comparing zinc or zinc and copper sup-
plements with placebo (Maylor 2006, Yaffe 2004), but only Yaffe
2004 with 1072 participants reported usable data. Maylor 2006
was designed to assess cognitive function, but Yaffe 2004 was part
of a trial whose primary outcome was the effect of supplementa-
tion on age-related macular degeneration.
• Study design and interventions. Maylor 2006 was a three-
arm, parallel-group trial with 232 participants which compared
two doses of zinc gluconate (15 mg and 30 mg a day) with
placebo over six months. This study was eligible for inclusion,
but did not report data in sufficient detail for extraction and
inclusion in analyses. Yaffe 2004 was a four-arm, parallel group
trial in which participants were treated for a median of 6.9 years.
For this comparison, we used data from the active intervention
arm in which participants were treated with 80 mg of zinc as zinc
oxide and 2 mg of copper as cupric oxide.
• Population. The participants in Maylor 2006 were 387
people aged 55 to 87 years. The cognitive inclusion criterion was
MMSE > 23, but in fact mean MMSE among participants was >
28 with low variability.The participants in Yaffe 2004 were 2166
people with age-related macular degeneration. Their median age
at baseline was 69 years (range 55 to 80 years). There was no
baseline cognitive assessment.
Studies of selenium
Kryscio 2017 (PREADVISE) was a 2 x 2 factorial study of vita-
min E and selenium supplements. For this comparison (selenium
versus placebo), we considered only the 3711 participants in the
selenium only and placebo only groups. The participants who re-
ceived vitamin E and (vitamin E + selenium) were considered in
the antioxidant vitamins versus placebo comparison. This was an
ancillary trial to SELECT, the primary aim of which was the pre-
vention of prostate cancer.
Studies of supplementation with B vitamin, antioxidant
vitamin and mineral combinations (’complex multivitamins’)
We included three studies with 6306 participants in which the in-
terventionswere supplements which included both B vitamins and
antioxidant vitamins, with or without additional minerals (Cockle
2000, Grodstein 2013, Wolters 2005). For ease of reference, we
called these ’complex multivitamins’. Only the two smaller trials
(Cockle 2000, Wolters 2005, combined n = 359) were designed
to assess cognition.
• Study design. Cockle 2000 and Wolters 2005 were small,
two-arm, placebo-controlled, parallel group studies lasting 24
weeks and six months respectively. Grodstein 2013 reported the
multivitamin data from a cognitive substudy (n = 5947) of the
large Physicians’ Health Study II (PHS-II), which is described
under ’antioxidant vitamins’ above. It had a 2 x 2 x 2 x 2 factorial
design. The mean time from randomisation to first cognitive
assessment was 2.5 years (range 0.18 to 5.3 years) and to final
cognitive assessment 8.5 years (range 0.3 to 14.2 years).
• Interventions.
◦ In Cockle 2000, the daily dose of the experimental
intervention contained: vitamin A palmitate 3334 IU, thiamine
mononitrate (B1) 14 mg, riboflavin (B2) 16 mg, pyridoxine (B6)
22 mg, vitamin B12 0.03 mg, vitamin C 600 mg, dl-alpha-
tocopherol acetate (vitamin E) 100 mg, folic acid 4 mg, d-biotin
2 mg and nicotinamide 180 mg. The authors stated that “[t]he
dosing was calculated to provide the equivalent of one US RDA
(National Research Council, 1980) of vitamin A and ten US
RDAs of the remaining vitamins.” The study was planned to last
for 48 weeks, but due to very high dropout after week 24, no
data were reported after 24 weeks.
◦ In Grodstein 2013, the experimental intervention was
Centrum Silver ® (Pfizer). Its composition is shown in Appendix
4.
◦ In Wolters 2005, the experimental intervention was
Nobilin Q10 ® (Medicom Pharma) providing daily doses of 150
mg vitamin C (calcium ascorbate), 50 mg magnesium
(magnesium carbonate), 36 mg vitamin E (D- alfa-tocopherol
acetate), 34 mg niacin (nicotinamide), 16 mg pantothenic acid,
9 mg ß-carotene, 3.4 mg pyridoxine (pyridoxine hydrochloride),
3.2 mg riboflavin, 2.4 mg thiamine (thiamine mononitrate), 400
µg folic acid (pteroyl glutamic acid), 200 µg biotin, 60 µg
selenium (selenium-enriched yeast), and 9 µg cobalamin
(cyanocobalamin).
• Population.
◦ Cockle 2000 randomised 139 participants, Grodstein
2013 randomised 5947, and Wolters 2005 reported results for
220 (not clear how many were randomised).
◦ Wolters 2005 included women only and Grodstein
2013 included men only.
◦ The participants in Cockle 2000 had a mean MMSE
at baseline of 28.8 ± 1.5 years. There was no baseline cognitive
assessment in Grodstein 2013. In Wolters 2005, baseline
cognitive assessment supported the authors’ assertion that
subjects were cognitively healthy.
◦ The age of participants at baseline was median 63
years in Wolters 2005, median 70 years in Cockle 2000 and
mean 72 years in Grodstein 2013.
Excluded studies
Forty-five studies were excluded (See Characteristics of excluded
studies). Studies were excluded if they did not meet the inclu-
sion criteria relating to: population (ACTRN12607000321448,
Alavi 2014, Anonymous 2003, Benton 1995, Corless 1987, De
Jager 2012, Flicker 2011, Hvas 2004, Imaoka 2016, Krikorian
2010, Kwok 2017, Li 2015, Macpherson 2012, Murray-Kolb
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2011, NCT00903695, NCT02185222, Petersen 2005, Smith
1999, Van Uffelen 2007), outcomes (Abbasi 2013, Ford 2008,
Miller 2016, NCT02467153), intervention (Arwert 2003, Bryan
2002, Chan 2010, Chew 2015; Dhesi 2004, Harris 2015,
NCT01095211, NCT01708005, Ng 2017, Ong 2016, Pase
2015, Pathansali 2006, Pettersen 2017, Schietzel 2016, Summers
2010, Wouters-Wesseling 2005), or study design (Cheng 2016,
Quick 2013, Rietsema 2014). One study was withdrawn prior to
enrolment (Liu 2015). Maniam 2004 was a potentially eligible
RCT described in an abstract published in 2004, but we were un-
able to identify any related full report. Some of the studies were
excluded in this review, but were included in the Cochrane review
on vitamin andmineral supplementation in people with mild cog-
nitive impairment (McCleery 2018).
Risk of bias in included studies
Our judgments about the risks of bias in the included studies are
detailed in theCharacteristics of included studies tables and shown
graphically in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Overall, selection bias was not a major concern. We judged all
studies to be at low or unclear risk of bias in this domain. In a
number of papers, our judgment was ’unclear’ because there was a
lack of detail given about the allocationmethods used, but in some
cases these were large, multicentre studies in which the methods
of random sequence generation and allocation concealment were
likely to have been adequate.
Blinding
One study (Anand 2011) was explicitly an open-label study and
we therefore considered it to be at high risk of performance and
detection bias. All other studies were described by their authors as
being double-blind, although again there was, in some cases, a lack
of reporting of the methods used to ensure blinding, especially of
outcome assessment. In most cases, the experimental intervention
andplacebowere described as being identical.We judged all studies
other than Anand 2011 to be at either low or unclear risk of bias
in these domains.
Incomplete outcome data
Incomplete outcome data posed a significant risk of bias to the
longer-term results. For some studies (Ford 2010,Grodstein 2013,
Kang 2008), we judged the risk to be low or unclear for shorter-
term outcomes, but high for longer-term outcomes when there
had been greater loss of participants to follow-up.
Selective reporting
The included studies had a variety of primary outcomes, In a
number of large studies, cognitive outcomes were not specified in
protocols, but were added at a later stage. However, in these cases,
simple cognitive measures were generally used and were reported.
We judged five studies to be at high risk of selective reporting bias.
Cockle 2000 did not report all the relevant outcomes described
in the Methods section of the paper. Maylor 2006 did not report
results in sufficient detail for inclusion in analyses. Stott 2005
mentioned functional outcomes in the trial registry entry which
were not reported in the paper. Toole 2004 reportedMMSE scores
at 12 months but without the number of participants in each
group, so we could not include the data in meta-analysis, and did
not report the MMSE data at 24 months. Walker 2012 did not
report all outcomes in sufficient detail for inclusion.
Other potential sources of bias
We identified no high risks of bias due to other factors.
Effects of interventions
See: Summary of findings for the main comparison B vitamins
compared to placebo for maintaining cognitive function in
cognitively healthy people in mid and late life; Summary of
findings 2 Antioxidants compared to placebo for maintaining
cognitive function in cognitively healthy people in mid and
late life; Summary of findings 3 Vitamin D3 compared to
placebo for maintaining cognitive function in cognitively healthy
people in mid and late life; Summary of findings 4 Zinc +
copper compared to placebo for maintaining cognitive function
in cognitively healthy people in mid and late life; Summary
of findings 5 Complex multivitamin compared to control for
maintaining cognitive function in cognitively healthy people in
mid and late life
The minimum clinically important difference on cognitive tests
for healthy participants in prevention trials is unknown and is
likely to vary with the age of participants and the duration of
follow-up. We are therefore unable to judge the likely clinical
importance of differences detected on any cognitive test. When
describing the results, we refer to a difference between groupswhen
P < 0.05.
B vitamins
We compared B vitamins to placebo at four time points: 3-12
months of treatment, > 1-2 years, > 2-5 years and > 5-10 years.
Some studies did not assess cognitive function at baseline and re-
ported finalmeasurement data. Some studies reported only change
from baseline data. Because we were pooling outcomes measured
with a variety of instruments, we used standardised mean differ-
ences and therefore pooled final measurement and change from
baseline data separately.
Negative SMDs favoured B vitamins; positive SMDs favoured
placebo.
Overall cognitive function
See Figure 3; Analysis 1.1
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Figure 3. Forest plot of comparison: 1 B vitamins versus control, outcome: 1.1 Overall cognitive functioning.
3-12 months of supplementation:
Three studies providing final measurement data showed that there
is probably no effect of B vitamins on overall cognitive function
(SMD 0.00, 95% CI -0.08 to 0.08, n = 2556; moderate-certainty
evidence). A fourth study (Toole 2004) also provided final mea-
surement MMSE data on 3097 participants, but did not report
the number of participants in each intervention group; it reported
no significant difference between groups (P = 0.19). Two smaller
studies providing change from baseline data confirmed that there
may be no effect of B vitamins (SMD -0.03, 95% CI -0.26 to
0.19, n = 317; low-certainty evidence).
> 1-2 years of supplementation:
Five studies providing final measurement data showed that there
is probably no effect of B vitamins (SMD -0.01, 95% CI -0.08 to
0.06, n =6956;moderate-certainty evidence).One study reporting
only change from baseline data similarly showed that there may
be no effect of B vitamins (SMD 0.06, 95% CI -0.20 to 0.31, n
= 241; low-certainty evidence).
> 2-5 years of supplementation:
Four studies provided final measurement data and suggested that
there is probably no effect of B vitamins (SMD -0.01, 95% CI -
0.11 to 0.09, n = 3985; moderate-certainty evidence).
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> 5-10 years of supplementation:
Three studies contributed data to this comparison; low-certainty
evidence indicated that theremay be no effect of B vitamins (SMD
-0.01, 95% CI -0.09 to 0.07, n = 10249).
Episodic memory
See Analysis 1.2
3-12 months of supplementation:
Four studies providing final measurement data showed that B vi-
tamins probably have no effect on episodic memory (SMD 0.02,
-0.08 to 0.12, n = 1442; moderate-certainty evidence). Two stud-
ies providing change from baseline data confirmed that there may
be no effect (SMD 0.04, 95% CI -0.15 to 0.23, n = 430; low-
certainty evidence).
> 1-2 years of supplementation:
Four studies providing final measurement data suggested there
may be no effect of treatment (SMD 0.05, 95% CI -0.03 to 0.13,
n = 5626; low-certainty evidence). The one study providing only
change from baseline data on this outcome confirmed an absence
of effect (SMD0.06, 95%CI -0.19 to 0.32, n = 241; low-certainty
evidence).
> 2-5 years of supplementation:
Three studies providing final measurement data suggested there
may be no effect of treatment (SMD -0.05, 95% CI -0.15 to 0.05,
n = 3523; low-certainty evidence).
> 5-10 years of supplementation:
From one study, there was low-certainty evidence that there may
be little or no effect of treatment (SMD -0.10, 95% CI -0.22 to
0.02, n = 1053).
Executive function
See Analysis 1.3
3-12 months of supplementation:
From three studies providing final measurement data, the effect
estimate slightly favoured placebo, but there was uncertainty about
the size and direction of the effect (SMD 0.14, 95% CI -0.18 to
0.46, n = 536). A single study providing change from baseline data
also favoured placebo, but the certainty of this evidence was very
low (SMD 0.39, 95% CI 0.07 to 0.71, n = 171).
> 1-2 years of supplementation:
Very low-certainty evidence from three studies providing final
measurement data suggested no effect of treatment (SMD -0.01,
95% CI -0.15 to 0.13, n = 2976). There was inconsistency in this
analysis in which one study (McMahon 2006) tended to favour
placebo.
> 2-5 years of supplementation:
Two studies providing final measurement data showed that there
may be no effect of treatment (SMD -0.06, 95% CI -0.13 to 0.02,
n = 2648; low-certainty evidence).
> 5-10 years of supplementation:
From one study, there was low-certainty evidence that there may
be no effect of treatment (SMD 0.02, 95% -0.10 to 0.15, n =
1049).
Speed of processing
See Analysis 1.4
3-12 months of supplementation:
Two studies provided final measurement data on this outcome
and showed that there may be no effect of treatment (SMD -0.04,
95% CI -0.28 to 0.19, n = 289; low-certainty evidence). Pooled
data from three studies providing change from baseline data gave
a similar result, but with very low-certainty evidence (SMD 0.12,
95% CI -0.34 to 0.58, n = 487).
> 1-2 years of supplementation:
Two studies provided final measurement data and showed that
there is probably no effect of treatment (SMD 0.03, 95% CI -
0.09 to 0.15, n = 1030; moderate-certainty evidence). A further
study providing change from baseline data confirmed this (SMD
-0.04, -0.29 to 0.21, n = 241; low-certainty evidence).
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> 2-5 years of supplementation:
One study provided final measurement data and showed no effect
of treatment (SMD -0.08, 95% CI -0.22 to 0.06, n = 818; high-
certainty evidence).
Quality of life
> 1-2 years of supplementation:
Ford 2010 reported that participants in the B vitamin and placebo
groups did not differ significantly on any of the four mental sum-
mary scales of the SF-36 after 24 months.
No other included studies reported on quality of life.
Clinical global impression
No included studies reported on clinical global impression.
Functional performance
No included studies reported on functional performance.
Incidence of MCI or dementia
See Analysis 1.5.
Hankey 2013 (VITATOPS study) reported on the incidence of
cognitive impairment (defined as MMSE score < 24 during fol-
low-up on two or more occasions) after a median of 2.8 years of
supplementation. Of those who had at least two MMSEmeasure-
ments during follow-up, 50/908 (5.51%) in the B vitamin group
and 49/895 (5.47%) in the placebo group met this criterion for
cognitive impairment (RR 1.01, 95% CI 0.69 to 1.48, n = 1803;
moderate-certainty evidence).
Ford 2010 treated participants for two years, but also followed
up the participants who were still alive approximately eight years
after the baseline study assessment, assessing 73 of the 299 ran-
domised participants with the Telephone Interview for Cognitive
Status scale (TICS) and ascertaining dementia diagnoses from a
population register for all 172 survivors. Defining cognitive im-
pairment as TICS ≤ 27, they found an OR 0.72 (95% CI 0.25
to 2.09) favouring the B vitamin group. For either a dementia
diagnosis or TICS ≤ 27, the OR was 0.76 (95% CI 0.37 to 1.56)
also favouring B vitamins. Due to serious imprecision and risk of
attrition bias, this was very low-certainty evidence.
SEARCH2010 investigators recorded diagnoses of dementia at fi-
nal follow-up (after a mean of 6.7 person-years) “based on reports
from a participant/relative or doctor, there was no further confir-
mation or adjudication” (communication from author). The pa-
per stated that “similar numbers of participants in each treatment
group were reported to have developed dementia during follow-
up (vitamins, 43 (0.7%), vs placebo, 38 (0.6%))”.
Serious adverse events
Most papers made only general statements about an absence of
serious adverse events in both treatment groups.
All-cause mortality
See Analysis 1.6
3-12 months of supplementation:
In one study (Dangour 2015), one participant died in the placebo
group and no participants in the B vitamin group.
> 1-2 years of supplementation:
In Toole 2004, in which all participants had a history of recent
ischaemic stroke, 99/1821 participants (5.4%) died in the B vi-
tamin group compared to 117/1847 participants (6.3%) in the
comparator group over 2 years of follow-up (RR 0.9, 95% CI 0.7
to 1.1, n = 3668).
> 2-5 years of supplementation:
In one study (Andreeva 2011), 24/585 participants (4.1%) died
in the placebo group and 44/586 participants (7.5%) in the B
vitamin group (RR 1.8 favouring placebo, 95% CI 1.17 to 3.08,
n = 1171; very low-certainty evidence).
> 5-10 years of supplementation:
In SEARCH 2010, in which all participants had a history of my-
ocardial infarction, 983/6033 participants (16.3%) died in the B
vitamin group compared to 951/6031 participants (15.8%) in the
placebo group over a mean of 6.7 years of follow-up (RR 1.03,
95% CI 0.95 to 1.12, n = 12064; moderate-certainty evidence).
Mortality data was not clearly reported in any other study.
Antioxidant vitamins
We compared antioxidants to placebo at four time points: 3-12
months of treatment, > 2-5 years, > 5-10 years and >10 years. (We
had no data for the > 1-2 year time point).
Overall cognitive function
See Analysis 2.1; Figure 4
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Figure 4. Forest plot of comparison: 2 Antioxidants versus control, outcome: 2.1 Overall cognitive
functioning.
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Positive values favoured antioxidants; negative values favoured
placebo.
3-12 months of supplementation:
One study of vitaminE inmiddle-aged adultswith type 2diabetes (
Anand 2011) found ahigherMMSE in the intervention group, but
thiswas the only open-label study and the certainty of this evidence
was very low due to risk of bias, imprecision and indirectness (MD
1.4, 95% CI 1.18 to 1.62, n = 74).
One study of beta-carotene (Grodstein 2007) included an older
population (mean age 73 years) who were treated for a mean of
12 months, but a range of two months to three years. Among
these participants, there was probably no effect of beta-carotene
on overall cognitive function measured with the TICS (MD -0.14,
95% CI -0.37 to 0.09, n = 1904; moderate-certainty evidence).
> 2-5 years of supplementation:
One study using a combination of vitamin C, E, and beta-carotene
(MRC/BHF 2002) found that there was probably no effect of
the antioxidant treatment on the TICS after a mean five years of
follow-up (MD0.09, 95%CI -0.05 to 0.23, n = 20536;moderate-
certainty evidence).
Kang 2009 was a factorial study which reported TICS results sep-
arately for vitamin C, E, and beta-carotene after a mean of 3.5
years of treatment. It reported the mean difference (with 95% CI)
between each vitamin group and placebo, but reported only the
total number of participants (2824) and not the number in each
treatment group. This study showed that there may be no effect of
vitamin C (MD 0.16, 95% CI -0.08 to 0.40, n not reported; low-
certainty evidence), vitamin E (MD 0.01, 95% CI -0.23 to 0.25,
n not reported; low-certainty evidence) or beta-carotene (MD -
0.18, 95% CI -0.42 to 0.06; n not reported; low-certainty evi-
dence).
> 5-10 years of supplementation:
One study using a combination of vitamins C and E and beta-
carotene for a median of 6.9 years (Yaffe 2004) found that there
may be no effect on the modified MMSE (3MS) (MD 0.6, 95%
CI -0.2 to 1.40, n = 1100; moderate-certainty evidence).
Kang 2009 also reported outcome data from a final assessment
after a mean of 8.9 years. However, again it reported only the
total number of participants (n = 1586) at this time point and not
the number in each group. A second study (Kang 2006) reported
TICS data after approximately 10 years of treatment with vitamin
E. We were unable to pool data vitamin E data from these two
studies because of the unknown number of relevant participants
in Kang 2009. In Kang 2006, the first cognitive assessment was
conducted 5.6 years (range 4.4 to 6.8) after randomisation and
the last 4.0 (range 2.6 to 5.7) years later. The mean difference in
TICS scores between groups at final cognitive assessment was 0.04
points (95% CI -0.12 to 0.21, n = 5226). The mean difference in
cognitive decline on the TICS between the vitamin E and placebo
groups fromfirst to last cognitive assessment was 0.02 points (95%
CI -0.02 to 0.06; P = 0.31). In the vitamin E arm from Kang
2009, there was also no evidence of an effect on final TICS score
(MD -0.16, 95% CI -0.49 to 0.16; n not reported, P = 0.33). We
considered the overall certainty of this evidence on vitamin E to be
low. In the vitamin C arm fromKang 2009, there may have been a
small beneficial effect of vitamin C on final TICS score (MD 0.46,
95% CI 0.14 to 0.78, n not reported, P = 0.006; low-certainty
evidence). In the beta-carotene arm from Kang 2009, there was
no evidence of an effect of treatment (MD -0.13, 95% CI -0.46
to 0.19, n not reported, P = 0.42; low-certainty evidence).
> 10 years of supplementation:
Grodstein 2007 included 4052 participants who had been treated
with beta-carotene for a mean of 18 years (range 15 to 20 years),
starting at a mean age of 56 years. There was moderate-certainty
evidence of a very small beneficial effect of beta-carotene treatment
on the TICS (MD 0.18, 95% CI 0.01 to 0.35, n = 4052).
Episodic memory
See Analysis 2.2; Figure 5
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Figure 5. Forest plot of comparison: 2 Antioxidants versus control, outcome: 2.2 Episodic memory.
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3-12 months of supplementation:
Grodstein 2007 found that there was probably no effect of beta-
carotene (MD 0.01, 95% CI -0.05 to 0.08, n = 1904; moderate-
certainty evidence) on a composite verbal memory measure after
a mean of 12 months (range two months to three years).
> 2-5 years of supplementation:
From Kang 2009, there was probably a very small beneficial effect
of vitamin C on the TICS 10-word recall test (MD -0.05, 95%
CI -0.10 to 0; n = 2824; low-certainty evidence), but probably
no effect of vitamin E (MD -0.02, 95% CI -0.07 to 0.03, n =
2824; low-certainty evidence) or beta-carotene (MD 0.01, 95%
CI -0.05 to 0.07, n = 2824; low-certainty evidence).
> 5-10 years of supplementation:
Yaffe 2004, using combined vitamin C and E and beta-carotene,
found no evidence of an effect on the delayed recall logical memory
test (MD -0.30, 95% CI -1.30 to 0.70, n = 1100; low-certainty
evidence).
A pooled analysis of two studies using vitamin E provided very
low-certainty evidence of no effect (MD 0.02, 95% CI -0.05 to
0.09, n = 6812, 2 studies). There was low-certainty evidence from
a single study (Kang 2009) that there may be a small beneficial
effect of vitamin C (MD -0.14, 95% CI -0.22 to -0.06, n = 1583)
and no effect of beta-carotene (MD 0.02, 95% CI -0.05 to 0.09,
n = 1583).
Kesse-Guyot 2011 treated participants for eight years with a com-
bination of vitamin C, vitamin E, beta-carotene, zinc, and sele-
nium and assessed cognition six years after the end of treatment.
On a delayed cued-recall test (the RI-48), there was a small benefit
for the vitamin group (MD 0.61, 95% CI 0.02-1.20, n = 4447,
moderate-certainty evidence).
> 10 years of supplementation:
Grodstein 2007 found evidence of a small beneficial effect of beta-
carotene on a composite verbal memory measure after treatment
for a mean of 18 years (range 15 to 20 years), starting at a mean
age of 56 years (MD -0.06, 95% CI -0.11 to -0.02; n = 4052;
moderate-certainty evidence).
Executive function
See Analysis 2.3
3-12 months of supplementation:
There was moderate-certainty evidence fromGrodstein 2007 that
beta-carotene probably has no effect on executive function mea-
sured with a category fluency test after a mean of 12months (range
two months to three years) (MD 0.07, 95% CI -0.48 to 0.62, n
= 1904).
> 2-5 years of supplementation:
There was low-certainty evidence fromKang 2009 of a small detri-
mental effect of vitamin E on category fluency (MD 0.42, 95%
CI 0.06 to 0.78, n = 2819) and of no effect of vitamin C (MD
-0.03, 95% CI -0.39 to 0.33, n = 2819) or beta-carotene (MD
0.22, 95% CI -0.14 to 0.58, n = 2819).
> 5-10 years of supplementation:
Yaffe 2004 found no evidence of an effect of combined vitamin C
and E and beta-carotene on category fluency (MD -0.4, 95% CI
-0.99 to 0.19, n = 1100; low-certainty evidence)
Pooled data on vitamin E fromKang 2006 and Kang 2009 showed
no evidence of an effect on category fluency (MD 0.11, 95% CI
-0.26 to 0.48, n = 6808; low-certainty evidence). Kang 2009 also
found no evidence of an effect of vitamin C (MD -0.25, 95% CI -
0.7 to 0.2, n =1583; low-certainty evidence) or beta-carotene (MD
0.01, 95% CI -0.44 to 0.46, n = 1583; low-certainty evidence).
Kesse-Guyot 2011 treated participants for eight years with a com-
bination of vitamin C, vitamin E, beta-carotene, zinc, and sele-
nium and assessed cognition six years after the end of treatment.
There was no clear evidence of a difference between groups on
category fluency (MD 0.50, 95% CI -0.09 to 1.09, n = 4447,
moderate-certainty evidence).
> 10 years of supplementation:
Grodstein 2007 found that beta-carotene probably has no effect
on executive function measured with a category fluency test after
treatment for a mean of 18 years (range 15 to 20 years) (MD 0.01,
95% CI -0.36 to 0.38, n = 4052; moderate-certainty evidence).
Speed of processing
> 5-10 years of supplementation:
Kesse-Guyot 2011 treated participants for eight years with a com-
bination of vitamin C, vitamin E, beta-carotene, zinc, and sele-
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nium and assessed cognition six years after the end of treatment.
There was no difference between groups on time taken to complete
a trial-making task (TMT) (MD 0.00, 95% CI -0.59 to 0.59, n
= 4447, moderate-certainty evidence).
Incidence of dementia
See Analysis 2.4
> 2-5 years of supplementation:
One study (MRC/BHF2002) reported the number of participants
who developed dementia during follow-up. All participants were
at high vascular risk. There were 62 events, 31 in each group (RR
1, 95% CI 0.61 to 1.64, n = 20536; low-certainty evidence).
> 5-10 years of supplementation:
The mean duration of supplement use in Kryscio 2017 was 5.4
± 1.2 years although follow-up continued for up to six years af-
ter supplement discontinuation. The unadjusted cumulative in-
cidence of dementia was 3.95% in the vitamin E arm, 4.96% in
the (vitamin E + selenium) arm and 4.62% in the placebo arm. A
modified ITT analysis including all participants who had at least
one follow-up visit and adjusted for a variety of covariates showed
that neither arm had an incidence significantly different from the
placebo arm: vitamin EHR 0.88 (95%CI 0.64 to 1.20, P = 0.41);
(vitamin E + selenium) HR 1.00 (95% CI 0.74 to 1.35, P = 0.98).
We considered this to be low-certainty evidence due to impreci-
sion and indirectness.
All-cause mortality
See Analysis 2.5
> 2-5 years of supplementation:
In one study (MRC/BHF 2002), 1389/10267 participants died in
the placebo group and 1446/10269 participants in the antioxidant
group (RR 1.04, 95% CI 0.97 to 1.11, n = 20536; moderate-
certainty evidence).
Serious adverse events
Kryscio 2017 was an ancillary study to SELECT, in which the pri-
mary study was the incidence of prostate cancer. SELECT began
recruitment in 2002. By 2011, there was a statistically significant
17% increase in the risk of prostate cancer in the men taking vita-
min E only compared to those taking placebo only. After a mean
of seven years of follow-up (mean 5.5 years taking supplements)
there were 65 prostate cancer cases per 1000 men taking placebo
only and 76 prostate cancer cases per 1000 men taking vitamin E
only.
Other outcomes
Not reported.
Vitamin D
We considered data unsuitable for pooling because of the five-fold
difference in the daily dose of vitamin D3.
Overall cognitive function
See Analysis 3.1
There was moderate-certainty evidence from the small pilot study
(Aspell 2017) that the change in Montreal Cognitive Assessment
(MoCA) score over six months did not differ between the vitamin
D3 group (4000 IU on alternate days) and the placebo group (MD
0.76 points, SD not reported, n = 60, P = 0.186).
There was moderate-certainty evidence from one study (Rossom
2012) that there was probably no effect of treatment with a daily
dose of 400 IU vitamin D3 + calcium carbonate on the modified
MMSE (3MS) at any time point up to a mean follow-up of 7.8
years.
3-12 months of supplementation:
MD 0, 95% CI -0.24 to 0.24, n = 4122.
> 1-2 years of supplementation:
MD 0, 95% CI -0.25 to 0.25, n = 3910.
> 2-5 years of supplementation:
MD -0.2, 95% CI -0.53 to 0.13, n = 3515.
> 5-10 years of supplementation:
MD -0.1, 95% CI -0.81 to 0.61, n = 918 (low-certainty evidence,
additional downgrade due to incomplete outcome data).
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Episodic memory/executive function/speed of processing
Aspell 2017 reported results for executive function using the Trail
MakingTask but no results for episodicmemory, although the trial
registry entry indicated that it was to be measured with theWech-
sler Memory Scale. For change in TMT scores over six months,
there was probably little or no difference between the groups
(TMTB-A: MD 5.1, SD not reported, n = 60, P = 0.467).
In annual domain-specific cognitive assessments over approxi-
mately three to eight years, the authors of Rossom 2012 reported
that there were “no significant differences in any domain-specific
cognitive scores between treatment groups either in unadjusted
analyses or after adjustment for age, smoking, baseline 3MS, and
treatment assignment in the hormone or diet modification trials.”
Results were not fully reported. They included the California Ver-
bal Learning Test (episodic memory), letter and category fluency
(executive function) and finger tapping (speed of processing).
Incidence of MCI or dementia
In Rossom 2012, “[t]he incidence of MCI or all-cause dementia
did not differ significantly between placebo and treatment groups,
with 4.8% of calcium plus vitamin D subjects (62.2 per 10,000
person years) and 5.1% of placebo subjects (65.9 per 10,000 per-
son years) developing cognitive impairment during amean follow-
up time of 7.8 years (HR 0.94, 95% CI 0.72 to 1.24; P = 0.68)”.
The survival curve showed that the incidence did not differ over
the course of follow-up.We considered this to be low-certainty ev-
idence, downgraded due to imprecision and indirectness (women
only).
Other outcomes
Not reported.
Zinc and copper
For this comparison, the only data we were able to extract came
from Yaffe 2004 which treated participants with 80 mg zinc and
2 mg copper daily for a median of 6.9 years. No usable data were
available from Maylor 2006, but the authors reported finding no
cognitive effects of six months of supplementation with zinc glu-
conate.
Overall cognitive function
See Analysis 4.1
> 5-10 years of supplementation:
One study (Yaffe 2004) found no evidence of an effect of treatment
on the modified MMSE (MD 0.6, 95% CI -0.19 to 1.39, n =
1072; moderate-certainty evidence).
Episodic memory
See Analysis 4.2
> 5-10 years of supplementation:
One study (Yaffe 2004) found no evidence of an effect of treatment
on a delayed recall test (MD -0.7 95% CI -1.74 to 0.34, n = 1072;
moderate-certainty evidence).
Executive function
See Analysis 4.3
> 5-10 years of supplementation:
One study (Yaffe 2004) found no evidence of an effect of treatment
on category fluency (MD -0.3, 95% CI -0.89 to 0.29, n = 1072;
moderate-certainty evidence).
Incidence of dementia or MCI
Yaffe 2004 reported that at the time of administration of the cog-
nitive test battery, 4.5% of participants had a 3MS score < 80,
which was the authors’ definition of cognitive impairment, and
that “there was no significant effect of treatment group on likeli-
hood of having cognitive impairment.” We considered this to be
low-certainty evidence.
Other outcomes
Not reported.
Selenium
For this comparison, the only data came from the selenium arm
of Kryscio 2017. The only outcome reported was incidence of
dementia. Supplements - in this case, selenium 200 mcg per day
- were taken for a mean of 5.4 ± 1.2 years although follow-up
continued for up to six years after supplement discontinuation.
The unadjusted cumulative incidence of dementia was 4.15% in
the selenium arm and 4.62% in the placebo arm. A modified ITT
analysis including all participants who had at least one follow-up
visit and adjusted for a variety of covariates showed no significant
difference in incidence between the selenium and placebo arms
(HR 0.83, 95% CI 0.61 to 1.13, P = 0.23, n = 7388). We con-
sidered this to be low-certainty evidence due to imprecision and
indirectness.
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Complex multivitamins (containing B vitamins and
antioxidants +/- minerals)
Overall cognitive function
See Analysis 5.1
> 2-5 years of supplementation:
One study (Grodstein 2013) found no effect of a complex multi-
vitamin on the TICS over a mean of 2.5 years of treatment (range
0.18 to 5.3 years) (MD 0.04, 95% CI -0.09 to 0.18; n = 5947;
low-certainty evidence).
> 5-10 years of supplementation:
The same study found no effect of the complex multivitamin on
the TICS over a mean of 8.5 years (range 0.3 to 14.2 years) (MD
0.12, 95% CI -0.14 to 0.38; n = 2324; low-certainty evidence).
Episodic memory
See Analysis 5.2
3-12 months of supplementation:
One study (Cockle 2000) found no evidence of an effect of treat-
ment on a word scan (recognition) test (MD 33.17, 95% CI -
28.12 to 94.46; n = 124; low-certainty evidence). Another study
(Wolters 2005) used a pattern recognition subtest of the Berliner
Amnesie test (BAT) and reported the results as medians with 5th
to 95th percentiles; the difference between groups was ’not signif-
icant’ (no P value given).
> 2-5 years of supplementation:
One study (Grodstein 2013) found no evidence of an effect of
treatment on a composite verbal memory score after a mean of 2.5
years (range 0.18 to 5.3 years) (MD -0.01, 95% CI -0.05 to 0.03;
n = 5942; low-certainty evidence).
> 5-10 years of supplementation:
One study (Grodstein 2013) found no evidence of an effect of
treatment on a composite verbal memory score after a mean of 8.5
years (range 0.3 to 14.2 years) (MD -0.01, 95% CI -0.07 to 0.05;
n = 2324; low-certainty evidence).
Executive function
See Analysis 5.3
> 2-5 years of supplementation:
One study (Grodstein 2013) found no evidence of an effect of
treatment on verbal fluency after a mean of 2.5 years (range 0.18
to 5.3 years) (MD -0.02, 95% CI -0.33 to 0.29; n = 5942; low-
certainty evidence).
> 5-10 years of supplementation:
One study (Grodstein 2013) found no evidence of an effect of
treatment on verbal fluency after a mean of 8.5 years (range 0.3
to 14.2 years) (MD -0.22, 95% CI -0.65 to 0.21; n = 2324; low-
certainty evidence).
Speed of processing
See Analysis 5.4
3-12 months of supplementation:
One study (Cockle 2000) found no evidence of an effect of treat-
ment on a total reaction time (TRT) (MD -14.71, 95% CI -
57.22 to 27.80; n = 127; low-certainty evidence). Another study
(Wolters 2005) used the symbol search subtest from theWAIS-III
and reported the results as medians with 5th to 95th percentiles.
The vitamin group was significantly faster than the placebo group
(P = 0.015) at baseline and this difference persisted at the end of
the intervention (P = 0.01).
Other outcomes
Not reported.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Antioxidants compared to placebo for maintaining cognitive function in cognitively healthy people in mid and late life
Patient or population: cognit ively healthy people in mid and late lif e
Setting: community
Intervention: ant ioxidant vitamins (vitamins C, E, and beta-carotene, alone or in combinat ion)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with Antioxidants
Vitamin E supplemen-
tation
Overall cognit ive func-
t ioning
assessed with: MMSE
Scale f rom: 0 to 30
follow-up: 3 months
The mean MMSE score
was 26.6
MD 1.4 higher
(1.18 higher to 1.62
higher)
- 74
(1 RCT)
⊕©©©
VERY LOW 123
Higher score indicates
better cognit ive func-
t ion.
Vitamin E supplemen-
tation
Overall cognit ive func-
t ioning assessed with:
TICS
Scale f rom: 0 to 41
follow-up: range 6 years
to 10 years
Two studies found no evidence of an ef fect of
vitamin E
- (2 RCTs) ⊕⊕©©
LOW 45
Range of follow-up du-
rat ions was approxi-
mate. Mean in one
study was 9.6 years
and in the other study
was 8.9 years. There
were 5226 part icipants
in one study. The num-
ber in the other study
was not reported for
this t ime point (approx-
imately 800)
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Beta-carotene supple-
mentation
Overall cognit ive func-
t ioning
assessed with: TICS
Scale f rom: 0 to 41
follow-up: mean 12
months
The mean TICS score
was 34.29
MD 0.14 lower
(0.37 lower to 0.09
higher)
- 1904
(1 RCT)
⊕⊕⊕©
MODERATE 6
Higher score indicates
better cognit ive func-
t ion.
Beta-carotene supple-
mentation
Overall cognit ive func-
t ioning
assessed with: TICS
follow-up: mean 8.9
years
Not reported MD 0.13 lower
(0.46 lower to 0.19
higher)
- (1 RCT) ⊕⊕©©
LOW 47
Mean dif ference with
95% CI reported in pa-
per. Absolute values in
each treatment group
not reported. Number in
each treatment group
at f inal follow-up not re-
ported
Beta-carotene supple-
mentation
Overall cognit ive func-
t ioning
assessed with: TICS
Scale f rom: 0 to 41
follow-up: mean 18
years
The mean TICS score
was 34.23
MD 0.18 higher
(0.01 higher to 0.35
higher)
- 4052
(1 RCT)
⊕⊕⊕©
MODERATE 6
Vitamin C supplemen-
tation
Overall cognit ive func-
t ioning
assessed with: TICS
follow-up: mean 8.9
years
Not reported MD 0.46 higher
(0.14 higher to 0.78
higher)
- (1 RCT) ⊕⊕©©
LOW 47
Mean dif ference with
95% CI reported in pa-
per. Absolute values
in each group not re-
ported. Number in each
treatment group at f inal
follow-up not reported
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Supplementation with
beta-carotene + vit C +
vit E
Overall cognit ive func-
t ioning
assessed with: TICSm
Scale f rom: 0 to 39
follow-up: mean 5 years
The mean TICSm score
was 24.02
MD 0.09 higher
(0.05 lower to 0.23
higher)
- 20536
(1 RCT)
⊕⊕⊕©
MODERATE 8
Supplementation with
beta-carotene + vit C +
vit E
Overall cognit ive func-
t ioning
assessed with: 3MS
(modif ied MMSE)
Scale f rom: 0 to 100
follow-up: median 6.9
years
The mean 3MS score
was 92.1
MD 0.6 higher
(0.2 lower to 1.4 higher)
- 1100
(1 RCT)
⊕⊕⊕©
MODERATE 4
Higher score indicates
better cognit ive func-
t ion.
Incidence of all-cause
dementia
follow-up: mean ap-
proximately 5 years
Two studies, one using a combinat ion of beta-
carotene, vit C and vit E and one using vit E ±
selenium, found no signif icant dif f erence in the
incidence of dementia
- 25 993
(2 RCTs)
⊕⊕©©
LOW 89
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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1 Downgraded for risk of bias due to lack of blinding (open-label study)
2 Downgraded for indirectness (diabet ic part icipants only)
3 Downgraded for imprecision due to small sample size
4 Downgraded for risk of bias due to incomplete outcome data
5 Downgraded for indirectness (both studies included only women and in one study all part icipants also had cardiovascular
disease or 3 or more coronary risk factors)
6 Downgraded for indirectness (included men only)
7 Downgraded for indirectness (included only women with cardiovascular disease or ≥ 3 coronary risk factors)
8 Downgraded for indirectness (all part icipants had high risk of coronary heart disease death over the next 5 years)
9 Downgraded for imprecision due to wide conf idence interval
MMSE:MiniMentalStateExamination
T ICS:T elephoneInterviewf orCognitiveStatus
T ICSm:Modif iedT elephoneInterviewf orCognitiveStatus
3MS:T heModif iedMini−MentalStateExamination
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Vitamin D3 compared to placebo for maintaining cognitive function in cognitively healthy people in mid and late life
Patient or population: cognit ively healthy people in mid and late lif e
Setting: community
Intervention: vitamin D3 +/ - calcium carbonate
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with Vitamin D3
Overall cognit ive func-
t ioning
assessed with: MoCA
change f rom baseline
Scale f rom: 0 to 30
follow-up: 6 months
There was no signif icant dif f erence between
groups in the change in MoCA score (P=0.186)
60
(1 RCT)
⊕⊕⊕©
MODERATE 1
Experimental interven-
t ion was vitamin D3
4000 IU on alternate
days
Data not fully re-
ported (conference ab-
stract only).
Overall cognit ive func-
t ioning
assessed with: 3MS
Scale f rom: 0 to 100
follow-up: mean 7.8
years
The mean 3MS score
was 96.6
MD 0.1 lower
(0.81 lower to 0.61
higher)
- 918
(1 RCT)
⊕⊕©©
LOW 23
Experimental interven-
t ion was vitamin D3 400
IU/ day and calcium car-
bonate 1000 mg/ day
Incidence of probable
dementia or MCI
follow-up: mean 7.8
years
No signif icant dif f erence in incidence between
treatment groups. In an intent ion-to-treat analy-
sis, incidence was 62.2/ 10 000 person-years in
the vit D + Ca group and 65.9/ 10 000 person-
years in the placebo group (HR 0.94, 95%CI 0.72
to 1.24, P = 0.68)
- 4143
(1 RCT)
⊕⊕©©
LOW34
Experimental interven-
t ion was vitamin D3 400
IU/ day and calcium car-
bonate 1000 mg/ day
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded for imprecision (small sample size)
2 Downgraded for risk of bias due to incomplete outcome data
3 Downgraded for indirectness (study included women only)
4 Downgraded for imprecision due to wide conf idence interval
MCI :MildCognitiveImpairment
MOCA: Montreal cognit ive assessment
3MS: The Modif ied Mini-Mental State Examinat ion
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Zinc + copper compared to placebo for maintaining cognitive function in cognitively healthy people in mid and late life
Patient or population:cognit ively healthy people in mid and late lif e
Setting: Community
Intervention: Zinc + copper oxides
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with Zinc + copper
Overall cognit ive func-
t ioning
assessed with: 3MS
Scale f rom: 0 to 100
follow-up: median 6.9
years
The mean 3MS score
was 92.1
MD 0.6 higher
(0.19 lower to 1.39
higher)
- 1072
(1 RCT)
⊕⊕⊕©
MODERATE 12
Incidence of dementia
or MCI
assessed with: 3MS
score < 80
follow-up: median 6.9
years
4.5% of part icipants met the authors’ def init ion
of cognit ive impairment (3MS < 80) and ‘‘there
was no signif icant ef fect of treatment group on
likelihood of having cognit ive impairment.’’
- 1072
(1 RCT)
⊕⊕©©
LOW 3
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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1 Downgraded for risk of bias due to unclear select ive report ing and high risk of bias due to incomplete outcome data
2 Downgraded for indirectness (Yaf fe 2004 included part icipants with age-related macular degenerat ion)
3 Downgraded two levels for study lim itat ions due to incomplete outcome data and select ive report ing
3MS:T heModif iedMini−MentalStateExamination
MCI :Mildcognitiveimpairment
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Complex multivitamin compared to control for maintaining cognitive function in cognitively healthy people in mid and late life
Patient or population: cognit ively healthy people in mid and late lif e
Setting: community
Intervention: complex mult ivitamins (combinat ions of B vitamins and ant ioxidant vitamins +/ - m inerals)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with control Risk with Complexmul-
tivitamin
Overall cognit ive func-
t ioning
assessed with: TICS
Scale f rom: 0 to 41
follow-up: mean 2.5
years
The mean TICS score
was 34.3
MD 0.04 higher
(0.09 lower to 0.18
higher)
- 5947
(1 RCT)
⊕⊕©©
LOW 12
Follow-up ranged f rom
0.18 to 5.3 years.
Overall cognit ive func-
t ioning
assessed with: TICS
Scale f rom: 0 to 41
follow-up: mean 8.5
years
The mean TICS score
was 33.1
MD 0.12 higher
(0.14 lower to 0.38
higher)
- 2324
(1 RCT)
⊕⊕©©
LOW 12
Follow-up ranged f rom
0.3 to 14.2 years.
Incidence of MCI or all-
cause dementia - not
measured
- - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
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GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded for study lim itat ions due to incomplete outcome data and wide range of follow-up durat ions
2 Downgraded for indirectness (study included only men)
T ICS:T elephoneInterviewf orCognitiveStatus
MCI: m ild cognit ive impairment
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
B vitamins
Fourteen studies with 27,882 participants contributed data. Only
two studies lasted for longer than five years, although between
them these included more than 10,000 participants. We found no
evidence that giving B vitamin supplements to cognitively healthy
adults, mainly in their 60s and 70s, had any effect on global cogni-
tive function or on episodic memory, executive function, or speed
of processing. There were very sparse data on adverse effects or
on incidence of cognitive impairment or dementia, quality of life,
functional performance, or clinical global impression.
Antioxidant vitamins (vitamins C and E, and beta-
carotene)
Eight studies with 47,840 participants contributed data. Six stud-
ies had a mean treatment duration longer than five years. Two
studies followed participants up for more than 10 years. The re-
sults of these trials were more mixed than for B vitamins. There
was low-certainty evidence that vitamin C supplements may have
a small beneficial effect on episodic memory after 2 to 5 years of
treatment and on overall cognitive function after 5 to 10 years,
although effects were not seen at other time points. There were
no longer-term data on vitamin C. For vitamin E, there was low-
certainty evidence of a small detrimental effect on executive func-
tion after 2 to 5 years and no data beyond 10 years. For beta-
carotene, there was no evidence of any effects up to 10 years, but
moderate-certainty evidence from one large study with a duration
of 15 to 20 years of small benefits on overall cognitive function
and episodic memory after a mean of 18 years of treatment. There
were very few cognitive data from trials using combinations of
antioxidant vitamins. There was no evidence of an effect of 5 to
10 years of antioxidant combination treatment in two trials, but
one trial which assessed participants six years after the end of an
8-year treatment period (using vitamins C, E, beta-carotene plus
zinc and selenium) reported a small benefit on episodic memory.
Two studies found no effect of antioxidant vitamins on the inci-
dence of dementia. Other review outcomes were not reported in
these trials.
Vitamin D
One large trial in this comparison provided low to moderate-cer-
tainty evidence of no effect on cognitive outcomes or the incidence
of MCI or dementia of a relatively low dose of vitamin D3 with
calcium carbonate in any time period up to 10 years. It provided
no evidence on other review outcomes. There was also a small pilot
trial which used a much higher dose of vitamin D3 and found no
evidence of cognitive effects over six months.
Zinc and copper
One study contributed usable data, providing low-certainty evi-
dence of no effect on cognitive outcomes or the incidence of cog-
nitive impairment after 5 to 10 years, but no evidence on other
outcomes.
Selenium
One study found no evidence of an effect of approximately five
years of selenium supplementation on the incidence of dementia,
but there was no information on other outcomes.
Complex multivitamins (B vitamins and antioxidants
+/- minerals)
Two small, short-term studies and one large study with a mean
duration of treatment of 8.5 years at final follow-up found no
effects of complex multivitamins on cognitive outcomes. There
was no evidence on other review outcomes.
Overall completeness and applicability of
evidence
Our principal interest was in whether or not vitamin supplemen-
tation could be of benefit to the general middle-aged or older pop-
ulation in terms of maintaining cognitive function or preventing
dementia in late life. Some general points can be made about the
evidence across all the interventions.
Many of the included studies, especially the larger and longer ones,
were not designed primarily with cognitive outcomes in mind and
did not assess cognition at baseline. It is therefore possible that
some participants may not have been cognitively healthy at base-
line, although we considered it unlikely that people with known
dementia would have been recruited. In some cases, limited cog-
nitive assessments, using measures which lack sensitivity to detect
change in cognitively healthy people, were added to existing studies
some years after onset. Participation in these studies was often re-
stricted in ways which reflected the original aims, e.g. recruitment
limited to one gender, or to people with particular comorbidities
or risk factors, so the evidence was often not directly applicable to
the older population in general. Only three studies specifically as-
sessed the incidence of dementia. Studies which were designed to
assess cognition tended to be shorter (less than two years), which
may not be long enough to detect effects. If cognitive effects are
detected on this timescale, it is not clear what implications this
has for the incidence of dementia. There are problems inherent in
combining short-term studies, in which separation of groups may
only be seen if the intervention leads to cognitive improvement
(or harm), and studies which are long enough to detect a change in
the trajectory of age- or pathology-related decline. We considered
it important to separate studies into groups of different durations,
but our time divisions were inevitably somewhat arbitrary and this
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decision greatly limited the numbers of studies which could be
combined.
There is no well developed understanding of the mechanisms by
which any of these interventions might affect cognition, which
may be the reason that studies used a wide variety of doses and
treatment combinations. Thismakes it difficult to compare studies
and leaves open the possibility that different doses or combinations
could have different effects.
B vitamins
The body of evidence on vitamin B supplements addresses our
review question only indirectly. Many studies restricted participa-
tion to those with particular comorbidities or who had some evi-
dence of low vitamin B levels or exposure at baseline. Four of the
13 studies allowed inclusion of participants younger than 60 years,
but in all cases, the mean age of participants was > 60 years so the
data do not adequately address the effects of supplementation in
midlife.We excluded very short-term studies (< 3months), but the
majority of included studies treated participants for 2 years or less,
which may not be long enough to detect any effect. The particular
vitamin B subtypes and their doses differed between studies and
in several studies, particularly those with factorial designs, some
participants receiving B vitamins also received other potentially
active interventions. The studies were too heterogeneous to allow
these various characteristics to be explored in subgroup analyses.
Antioxidant vitamins
We considered vitamin C, vitamin E, and beta-carotene in this
group. The evidence on cognitive effects of antioxidant vitamins
is very largely from studies which had other primary aims and to
which very limited cognitive assessment was added after the studies
were underway. In two of the large trials, all participants were at
high vascular risk. However, the age of participants at recruitment
was generally lower and the duration of the trials was generally
longer than the B vitamin trials, so this body of evidence may
be more informative about the potential of prolonged treatment
to protect cognitive function against decline. Only two of these
studies assessed incidence of dementia so most of the results have
nomore than indirect implications for dementia prevention.There
was substantial variation in the doses of vitamins used. Again,
the use of factorial designs in some studies meant the comparator
groups included participants exposed to a variety of treatments.
Vitamin D
One study used a combination of vitamin D and calcium car-
bonate. Mean follow-up was 7.8 years. All participants were post-
menopausal women, but inclusion criteria were otherwise broad.
The dose of vitamin D was relatively low (400 IU/day). This was
one of very few studies that used a rigorous method to assess for
incident MCI or dementia. The other study used a higher dose
of vitamin D3 (4000 IU on alternate days), but was small and
provided only preliminary evidence on supplementation with this
dose.
Minerals (zinc and copper, selenium)
We found limited data from two studies of mineral supplements.
One used a combination of zinc and copper oxides. It was de-
signed to look for an effect on age-related macular degeneration,
but there is no reason to think that this limits generalisibility of
the cognitive results. Cognitive assessment was after a median of
6.9 years. Dementia incidence was not an outcome. The other
was a selenium-only arm of a factorial study in which dementia
incidence was the only relevant outcome reported. It found no
evidence of an effect of selenium.
Complex multivitamins with or without minerals
There were three included studies in this category. One used a
combination of B vitamins and antioxidant vitamins. Two used
commercially available multivitamin and mineral combinations.
Two studies were very small and lasted less than a year. In the large
study, all participants were men, treated for a mean of 8.5 years.
Dementia incidence was not an outcome.
Quality of the evidence
The large studies were generally well-conducted and we did not
consider that risk of bias was a major threat to the results, although
there were some gaps in reporting in all domains. Uncertainty
about the risk of selection bias and concerns about attrition bias led
us to downgrade the certainty of some results due to possible study
limitations. We considered much of the evidence to be indirect
with respect to our review question because participation in many
studies was restricted, e.g. by comorbidities, baseline biochemistry,
or gender. Overall, we considered the certainty of the evidence
behind almost all effect estimates to be moderate or low with
respect to our review question.
Potential biases in the review process
Particularly for B vitamins, bias may arise from pooling studies
which differed in participants (e.g. with or without elevated homo-
cysteine at baseline) and interventions (various constituents and
doses). This ’broad brush’ approach may disguise effects.
Agreements and disagreements with other
studies or reviews
A comprehensive systematic review and meta-analysis of the cog-
nitive effects of several years of treatment with B vitamins was
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published by the B-Vitamin Treatment Trialists’ Collaboration in
2014 (Clarke 2014). It included 11 trials for which datawere avail-
able by September 2010. All the included trials were also included
in this review. The authors investigated the effect of the interven-
tions on homocysteine levels as well as on cognition. Although
they found that the treatments effectively lowered homocysteine
levels (by slightly more than 25%), they also found no evidence
of significant effects on global (’MMSE-type’) cognitive function,
domain-specific cognitive function, or cognitive aging. We are not
aware of similar systematic reviews of the effects of treatment with
non-B vitamins or minerals.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found no evidence to support recommending any vitamin or
mineral supplement to middle-aged or older adults who wish to
maintain their cognitive function or prevent dementia.
Implications for research
All of the studies in this review differed in their population, inter-
ventions, and outcomes. Therefore, many questions about possi-
ble effects of different doses or treatment combinations on differ-
ent participants remain unanswered. In particular, there are very
few data on the long-term effects of supplementation started in
midlife. Identifying the most important questions is likely to de-
pend on a better understanding of the pathophysiology of cog-
nitive decline and dementia and of the mechanisms by which vi-
tamins and minerals might modify these processes. Moving for-
ward, there is a place both for investigating possiblemechanisms in
smaller trials, which can incorporate highly sensitive cognitive as-
sessments and possibly biomarker outcomes, and for larger, longer,
pragmatic trials in which it may be necessary to rely on simpler
and less sensitive outcome measures. Considering the data in this
review, the only real signals of effect were from long-term studies
of antioxidant vitamins (vitamin C and beta-carotene) so these
might be considered the most promising candidates for further
research.
A C K N OW L E D G E M E N T S
The protocol for this review was largely based on a general tem-
plate constructed for the development of a larger series of proto-
cols and reviews covered by a National Institute for Health Re-
search (NIHR) Systematic Reviews Programme Grant. The com-
mon protocol covered four types of intervention, for which some
evidence exists that these may modify the risk of developing cog-
nitive impairments or dementia. These include vitamin or min-
eral supplementation (or vitamin and mineral supplementation),
exercise, cognition, and dietary interventions. The general proto-
col was inspired by a generic protocol approved by the Cochrane
Musculoskeletal Group for another series of reviews (Da Costa
2012; Da Costa 2014; Nüesch 2009a; Reichenbach 2010; Rutjes
2009a; Rutjes 2009b; Rutjes 2010).
The authors are grateful to Professors Lisette de Groot, Simone
Eussen, and Jane Armitage for responding to enquiries about their
work and providing additional data.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anand 2011
Methods 2-arm, open-label RCT, with 3 months duration of treatment and follow-up
Participants Location: Ootacamund, Tamil Nadu India. Single centre
Recruitment: outpatient department, Government headquarters hospital, Ootacamund
Sample size:
• Number randomised: 38 in intervention, 36 in comparison
• Number completed: 38 in intervention, 36 in comparison
Participant baseline characteristics:
• Age: mean 54.65 ± 8.44 intervention and 56.61 ± 8.17 in comparison
• Total MMSE: 25.16 ± 0.66 in intervention, 25.3 ± 0.37 in comparison
• Gender: male/female 15/23 intervention and 14/22 in comparison
• Others: Most of the participants were from an economically deprived
background, non-vegetarians.
Inclusion criteria:
• Type 2 diabetes with no comorbidities
• Age between 35 and 65 of either sex
• On oral hypoglycaemic agents (metformin, glibenclamide and combination)
• Duration of disease less than or equal to 10 years
• HbA1c > 9%
Exclusion criteria:
• Dementia
• Antidepressant therapy
• Type 1 diabetes
• Juvenile diabetes
• Pregnancy/lactation
• Significant hepatic and renal dysfunction
Interventions Intervention group (n = 38): vitamin E 600 mg once daily for three months
Comparator group (n = 36): treatment-as-usual for three months
Treatment received by both groups: oral hypoglycaemic agents (glibenclamide 5 mg,
metformin 500 mg) for three months
Outcomes Outcomes of interest in the review:
Cognitive outcome: MMSE (Tamil version); MMSE 18-23 classified as MCI and 24-
30 classified as no cognitive impairment
Notes Funding Sources: “Nil”.
Declarations of interest: none declared.
Other: population was from a government hospital clinic in India and “most of the
enrolled patients were coming under economically deprived background.”
Risk of bias
Bias Authors’ judgement Support for judgement
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Anand 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Enrolled patients were random-
ized by using computer assisted random-
ization procedure and assigned to control
group and intervention group”
Comment: adequate generation of a ran-
domised sequence
Allocation concealment (selection bias) Unclear risk Comment: no description of allocation
concealment. The study was open-label.
Unknown whether allocation for the next
patient to be enrolled could be known in
advance
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label trial”
Comment: did not describe control group
receiving placebo of Vitamin E. No de-
scription of blinding and described as an
’open-label’ study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: no description of measures
used, if any, to blind personnel involved in
measuring outcomes. Since outcome mea-
sures depended on patient performance,
risk of bias was judged to be high
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: There was no description of
the completeness of outcome data for each
main outcome, nor of exclusions from the
analysis
Selective reporting (reporting bias) Low risk Comment: no evidence of selective report-
ing bias
Other bias Low risk No other risk of bias detected.
Andreeva 2011
Methods Multicentre, randomised, placebo-controlled, 2 x 2 factorial trial
An ancillary study of SU.FOL.OM3
Participants Main study took place from 2003-2009. Quote: ”As part of the SU.FOL.OM3 assess-
ment battery, the F-TICS-m was administered during 2007-2009 only to participants
who had completed 4 years of follow-up.“
Location: 257 participating centres in France
Recruitment: recruitment of subjects done through a network of 417 cardiologists and
neurologists from all over France, working either in general hospitals, independently or
in rehabilitation centres. Treatment with tablets at home
Sample size: 1881 participants were eligible for the cognitive study (had completed
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Andreeva 2011 (Continued)
4 years of follow-up in main study); 1748 completed the cognitive assessment.
· Number randomised in SU.FOL.OM3:
• 620 in group A (B vitamins and Omega-3 PUFA)
• 633 in group B (Omega-3 PUFA)
• 622 in group C (B vitamins)
• 626 in group D (placebo)
· Number completing cognitive study:
• 438 in group A (B vitamins and Omega-3 PUFA)
• 439 in group B (Omega-3 PUFA)
• 446 in group C (B vitamins)
• 425 in group D (placebo)
Group A (B Vitamins and Omega -3 PUFA) baseline characteristics:
• age (y): 61.6 ± 8.8
• gender, n (%) female: 80 (18.3)
Group B (Omega-3 PUFA) baseline characteristics:
• age: 60.1 ± 8.7
• gender, n (%) female: 88 (20.0)
Group C (B vitamins) baseline characteristics:
• age (y): 61.4±8.7
• gender, n (%) female: 93 (20.9)
Group D (Placebo) baseline characteristics:
• age (y): 60.9±8.9
• gender, n (%) female: 96 (22.6)
Inclusion criteria:
Men and women aged 45-80 y with a recent (1-12 months prior to inclusion) myocardial
infarction (MI), unstable angina, or ischaemic stroke were eligible for participation
Therewas nodiagnostic criterionused to detect dementia/cognitive impairment. Instead,
participants were given the Issac’s Set Test at baseline and results were stated as a Mean
± SD
Exclusion criteria:
Patients incapable of understanding the study protocol or who refused to sign the in-
formed consent, patients with a pathology that might interfere with homocysteine or
omega-3 fatty acid metabolism, in particular, those that use methotrexate for the treat-
ment of a cancer or rheumatoid arthritis, chronic renal failure (plasma level of creatinine
> 200 µmol/L or creatinine clearance < 40 mL/min), patients with a non-cardiovascular
pathology with a suspected survival time less than the 5 years period of the study (solid
cancer, evolved dementia, leukaemia) and patients taking B vitamins or omega-3 fatty
acids
Interventions Intervention (n = 1748): Study supplements were given as 2 capsules administered
orally once per day. The supplements were provided in a package containing 53 blisters
of 7 × 2 capsules, each corresponding to one week of both treatments. A year’s supply
was given at baseline and given again at each annual follow-up appointment for 5 years
in total
Group A (B vitamins and Omega-3 PUFA): 5-methyltetrahydrofolate (folate, 0.56 mg)
and vitamins B6 (3 mg) and B12 (0.02 mg) and eicosapentaenoic and docosahexaenoic
acids (600 mg) in a 2:1 ratio
Group B (Omega-3 PUFA): eicosapentaenoic and docosahexaenoic acids (600 mg) in a
2:1 ratio
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Andreeva 2011 (Continued)
Group C (B Vitamins): 5-methyltetrahydrofolate (folate, 0.56 mg) and vitamins B6 (3
mg) and B12 (0.02 mg)
Group D (placebo): 2 placebo Capsules
Comparator group (n = 425): 2 placebo tablets given once daily. The placebo capsules
looked and tasted identical to the active supplements (taken from SU.FOL.OM3 trial
paper)
Use of additional interventions (common to all treatment arms): no
Outcomes Outcomes of interest in the review:
Global cognitive functioning: French version of the modified Telephone Interview for
Cognitive Status (F-TICS-m)
Episodic memory: delayed recall subdomain from F-TICSm
Notes Funding sources: The SU.FOL.OM3 trial was supported by the French Ministry of
Research
(grant R02010JJ), the Ministry of Health, Sodexo, Candia, Unilever, Danone, Roche
Laboratories, Merck EPROVA AG, and Pierre Fabre Laboratories
Declarations of interest: none declared
Treatment adherence: Compliance with treatment was self-reported in the biannual
questionnaires (or by telephone interview). Compliance was defined as taking at least
80% of the allocated treatment. (taken from SU.FOL.OM3 trial paper)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”We used computerized block ran-
domisation (block size = 8) with stratifica-
tion by sex, age (45-54, 55-64, and 65-80
y), prior CVD, and city of residence.”
Comment: adequatemethod of random se-
quence generation.
Allocation concealment (selection bias) Low risk Comment: no information. Centralised,
computerised system, likely to be ade-
quately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The placebo capsules looked and
tasted identical to the active supplements“
Comment: probably blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: did not mention blinding of
study personnel including outcome asses-
sors
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 24.8% of participants in SU.
FOL.OM3 were lost to follow-up over the
first 4 years and before the onset of the cog-
nitive study. These participants appeared to
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Andreeva 2011 (Continued)
be well balanced between groups
133/1881 (7%) participants eligible for the
cognitive study were excluded: 72 (3.8%)
were unable to complete the cognitive as-
sessment and 61 refused to participate.
Treatment allocations of these participants
were not reported
Cognitive data were reported for 69.9% of
the randomised participants
Selective reporting (reporting bias) Unclear risk Quote: “No changes to the outcomes of
interestweremade after launching the trial”
Comment: The authors have stated no
changes to the outcomes were made, how-
ever, these were not previously published in
a protocol as this is an ancillary study and
the main study protocol did not mention
any cognitive outcomes
Other bias Low risk No other risks identified
Aspell 2017
Methods 2-arm, parallel group RCT
Participants Location: one site in Ireland
Recruitment: no details provided
Number randomised: 60
Participant characteristics:
• age: mean 68.5 years (SD 4.9 years)
• gender: 53.3% female
Inclusion criteria: community dwelling
Exclusion criteria: low or high serum vit D (defined as < 15nmol/L or > 125nmol/L),
current use of supplemental vitD≥ 800 IU/day, screen positive for cognitive impairment
using the Telephone Cognitive Screen (TCogS), hypercalcaemia, hyperparathyroidism,
epilepsy, stroke, renal disease, schizophrenia, bipolar affective disorder, recurrent psy-
chotic depression, alcohol and drug abuse within the past 5 years, anti-convulsants, anti-
psychotic medications, significant hearing difficulties even when wearing hearing aids,
illness that caused permanent decrease in memory or other mental function
Interventions 50 mcg/day of vitamin D3 administered as 4000 IU on alternate days or placebo
Outcomes Overall cognitive function: Montreal Cognitive Assessment (MoCA)
Executive function: (Trails Making Task A & B, B-A)
Episodic memory: Wechsler Memory Scale - in trial registry entry, not reported
Attention and visual reasoning: 2 validated measures (not included in review)
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Aspell 2017 (Continued)
Notes Described as a pilot study. Only conference abstract available
18.3% of participants were deemed vitamin D deficient at baseline according to Institute
of Medicine guidelines
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, no additional details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk From trial registry entry: masking: double (participant,
investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk From trial registry entry: masking: double (participant,
investigator)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “A retention rate of 93.8%was achieved.”No information
on treatment assignment of missing participants
Selective reporting (reporting bias) High risk Trial registry entry included ameasure of episodicmemory
whichwas not reportedwith other results in the conference
abstract
Other bias Low risk No other risks identified
Cockle 2000
Methods 2-arm, parallel group, double-blind, placebo-controlled RCT
(Intended duration was 48 weeks, but due to very high dropout after 24 weeks, no data
were reported beyond 24 weeks)
Participants Location: One site in UK
Recruitment: subjects recruited by newspaper advertisement
Number randomised: 69 in intervention, 70 in comparison
Participant baseline characteristics:
• Age:
◦ overall: median 70 years
◦ placebo: mean 70.2 (5.4) and median 70 (60-81)
◦ intervention: mean 70.7 (5.6 and median 70 (60-81)
• Gender:
◦ overall: 51 males and 88 females
◦ placebo (24 males and 46 females)
◦ intervention (27 males and 42 females)
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Cockle 2000 (Continued)
• Main diagnosis: All subjects were in good physical and mental health and had no
history of significant disease or mental illness, as determined by a medical examination
and health questionnaire.
• MMSE:
◦ intervention: 28.9 (SD:1.4)
◦ placebo: 28.6 (SD:1.5)
Inclusion criteria: not reported
Exclusion criteria: not reported
Interventions Intervention (n = 69):Multivitamin supplements: two gelatine capsules orally each day.
Each capsule contained vitamin A palmitate 3334 IU, thiamine mononitrate 14 mg,
riboflavin 16 mg, pyridoxine 22 mg, vitamin B12 0.03 mg, vitamin C 600 mg, dl-alpha-
tocopherol acetate 100 mg, folic acid 4 mg, d-biotin 2 mg and nicotinamide 180 mg
Quote: ”The dosing was calculated to provide the equivalent of one US RDA (National
Research Council, 1980) of vitamin A and ten US RDAs of the remaining vitamins.“
Capsules supply were provided at baseline and, in patients who were compliant, a second
supply was given at week 12 for an intended treatment duration of 24 weeks
Comparator group (n = 70): matching placebo (rape seed oil)
Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes: Relationship between vitamin status and cognitive function.
”At each visit, treatment compliance, blood vitamin levels and Critical Flicker Fusion,
Choice ReactionTimeTask, Sternberg Memory ScanningTask, Word ScanTask, and the
Profile Of Mood States questionnaire were carried out“
”MMSE, SundromKurtz Test, National Adult ReadingTest, AliceHeim’s 4, AliceHeim’s
5 and the Geriatric Depression Scale were assessed at baseline and at week 48.“
Eligible cognitive outcomes:
• episodic memory measured with Sternberg Memory Scanning Task (msec), lower
values indicated benefit
• episodic memory measured with Word scan task (msec), lower values indicated
benefit*
• speed of processing measured with Total reaction time (msec), lower values
indicated benefit*
• speed of processing measured with Recognition reaction time (msec), lower values
indicated benefit
• speed of processing measured with Motor reaction time (msec), lower values
indicated benefit
* outcome data used in statistical analyses
Notes Quote: ”the objectives of the study were to examine the relationship between vitamin
status and cognitive functioning and mood in healthy, elderly volunteers and to assess
the subsequent impact of multivitamin supplementation on these measures“
Funding sources: none stated
Declarations of interest: none stated, but second author from Roche Pharmaceutical
Risk of bias
Bias Authors’ judgement Support for judgement
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Cockle 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were allocated to each
treatment group according to a predeter-
mined randomization schedule.”
Comment: insufficient information about
the sequence generation method
Allocation concealment (selection bias) Unclear risk Quote: “Subjects were allocated to each
treatment group according to a predeter-
mined randomization schedule.“
Comment: insufficient information about
allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”The study was a double-blind,
placebo-controlled, parallel group study
with each subject receiving a multivitamin
supplement or placebo daily for up to 24
weeks.“
Quote: ”Treatments were given orally as
two soft gelatine capsules containing either
multivitamins or matching placebo (rape
seed oil)“
Comment: The study was reported as
double-blinded with the use of matching
placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ”at each visit, treatment com-
pliance, blood vitamin levels and Criti-
cal Flicker Fusion, Choice Reaction Time
Task, ...were carried out“
Comment: It was not reported whether
outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: ‘Due to circumstances not related
to the study treatment, there was a signif-
icant dropout of subjects after the first six
months of this study, with no participants
continuing through to visit 4. Data from
139 subjects was available at baseline, from
127 subjects at visit 1 and from 90 subjects
at visit 2. Due to the high dropout of sub-
jects between visit 2 and visit 3, data from
the latter visit was not included.”
Comment: There were 12 dropouts (8.6%)
at visit 1 (12 weeks) and 49 dropouts (35.
8%) at visit 2 (24 weeks). Outcome data
were completely missing from planned vis-
its 3 and 4 (36 and 48 weeks)
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Cockle 2000 (Continued)
Selective reporting (reporting bias) High risk Comment: A number of tests of cogni-
tion and functioning reported in theMeth-
ods to have been measured at baseline
and 48 weeks were not reported (including
MMSE)
Other bias Low risk No other risks identified
Dangour 2015
Methods 2-arm, double-blinded, multicentre, parallel group RCT, with 12 months of treatment
and follow-up
Participants Location: 7 general practices in South East England
Recruitment: recruited at GP by mail, baseline appointment and 12-month follow-up
at King’s College Hospital, London, treatment one tablet daily at home
Sample size:
· Number randomised: 99 in intervention, 102 in comparison
· Number completed: 91 in intervention, 92 in comparison
Group A (B vitamins) baseline characteristics:
• age (mean ± SD): 79.9±3.5
• gender (n) : 46 males, 54 females
• main diagnosis: no diagnosis
Group B (placebo) baseline characteristics:
• age: 80.1 ± 3.7
• gender: 48 males, 54 females
• main diagnosis: no diagnosis
(Inclusion criteria:)
Age: ≥ 75 years, Participants with a Mini-Mental State Examination score > 24 (maxi-
mum score 30) were asked to provide a blood sample to assess serum vitamin B12 and
haemoglobin concentration. Those with moderate vitamin B12 deficiency who did not
have anaemia (serum vitamin B12 concentrations≥ 107 and < 210 pmol/L were eligible
to join the trial
The diagnostic criterion used for dementia/cognitive impairment screening was the
MMSE. Only those with a score > 24 were eligible to join the trial
(Exclusion criteria:) Diabetes, dementia, epilepsy, alcohol addiction, pacemakers (and
other implanted metallic devices where central neurophysiologic testing was contraindi-
cated), residents of nursing homes, diagnosis of pernicious anaemia, current consump-
tion of vitamin B12 supplements and those who had received a vitamin B12 injection
within the previous 6 months. Individuals with very low vitamin B12 concentrations (<
107 pmol/L, which is a cutoff typically used for deficiency) or who were shown to have
anaemia (haemoglobin concentration, 110 g/L for women and 120 g/L for men) were
excluded
Interventions Intervention (n = 97): vitamin B12 (cyanocobalamin), oral administration, 1mg tablet/
day, 12 months
Comparator group (n = 97): placebo tablet administered once daily identical to inter-
vention in shape, size, colour, smell, taste, and identically packaged
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Dangour 2015 (Continued)
Use of additional interventions (common to both treatment arms): not reported
Outcomes Outcomes of interest in the review:
• Episodic memory measured with California Verbal Learning Test at delayed recall,
with higher values indicating benefit
• Executive function measured with verbal fluency, with higher values indicating
benefit
• Speed of processing measured with Choice Reaction time, with lower values
indicating benefit
Notes Funding sources: Supported by the Food Standards Agency (N05072) and the Depart-
ment of Health. National Health Service
Research and Development and King’s College Hospital Trust Research and Develop-
ment provided service support costs
Declarations of interest: none declared
Treatment adherence: Adherence was measured by counting the number of tablets
returned at the end of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Allocation codes were obtained
from a central computerized randomiza-
tion service.“
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Quote: “Allocation codes were obtained
from a central computerized randomiza-
tion service.”
Comment: adequate method of allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All study personnel were blinded
to the treatment allocation.“
“Allocated treatment consisted of a single
tablet administered daily that was identi-
cal in size, shape, color, smell, and taste
for both the intervention and placebo and
packaged into identical pots.”
Comment: As all participants were given
identical tablets this ensured blinding was
maintained
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All study personnel were blinded
to the treatment allocation.”
“Allocated treatment consisted of a single
tablet administered daily that was identi-
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cal in size, shape, color, smell, and taste
for both the intervention and placebo and
packaged into identical pots.”
Comment: Study mentions personnel were
blinded to treatment allocation and due
to identical tablets this would have main-
tained appropriate blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Cognitive outcome data were
available for 184/201 participants (92%).
Dropout rates and reasons were similar in
both groups
Selective reporting (reporting bias) Low risk Comment: followed study protocol, no re-
porting bias found
Other bias Low risk Comment: none found
Durga 2007
Methods 2-arm, placebo-controlled, randomised clinical trial, with 3-year duration of treatment
Participants Location: Gelderland region in the Netherlands, single centre
Recruitment: Division of Human Nutrition, Wageningen University, Wageningen,
Netherlands
Number randomised: 406 in intervention, 413 in comparison
Participant baseline characteristics:
• Age at baseline (years), mean (SD):
◦ placebo: 60 (6)
◦ folic acid: 60 (5)
• Male, n (%):
◦ placebo: 292 (70%)
◦ folic acid: 294(72%)
• MMSE (points):
◦ placebo: 29 (28-30)
◦ folic acid: 29(28-30)
Inclusion criteria:
• Participants were men and post-menopausal women aged 50-70 years.
• More than 80% self-reported compliance during a 6-week placebo run-in period
was required.
Exclusion criteria:
• homocysteine concentration less than 13 micromol/L and greater than 26
micromol/L
• self-reported medical diagnosis of renal or thyroid disease
• self-reported use of medications that influence folate metabolism
• participants reportedly used B vitamin supplements or drugs that could affect
atherosclerotic progression
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Durga 2007 (Continued)
Interventions Intervention (n = 405): 800 µg per day folic acid.
Comparator group (n = 413): placebo
Outcomes Cognitive outcomes:
5 cognitive tests were used: word learning test, concept shifting test, Stroop colour-word
test, verbal fluency test, letter digit substitution test
These 5 tests were used to construct 5 a priori defined cognitive domains using z-scores:
memory, sensorimotor speed, complex speed, information processing speed, and word
fluency
Outcomes used in this review were:
1. Global cognitive function (average of 5 domains);
2. Episodic memory: Memory
(Z15-Word Learning test ‘total immediate recall’ +Z15-Word Learning
3)
3. Executive function: Word fluency (ZV erbalF luencytest )
4. Speed of processing: Information processing speed
(ZLetter Digit Substitution test
)
Notes Funding sources:The researchwas fundedby a grant from theNetherlandsOrganisation
forHealth Research andDevelopment (ZonMw, grant number 20010002), Wageningen
University, and Wageningen Centre for Food Sciences. Wageningen Centre for Food
Sciences is an alliance of major Dutch food industries, research institutes and the Dutch
government. Wageningen Centre for Food Sciences does long-term strategic research for
the development of new and innovated food with attention to health aspects
Declarations of interest: Jane Durga currently works at Nestle Research Center in
Lausanne, Switzerland andPetraVerhoef currentlyworks at theUnilever Food andHealth
Research Institute in Vlaardingen, the Netherlands. The work at both food companies
entails examining the health benefits of a variety of food ingredients, including folic acid.
However, the study reported in the current manuscript was completed and submitted to
The Lancet before the authors joined the companies, when they were still employed by
Wageningen University and Wageningen Centre for Food Sciences. All authors declare
that they have no conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were allocated treatment
or placebo with permuted blocks of sizes
four and six, which varied randomly. Spe-
cialised staff who were not involved in the
study allocated and labelled the capsule
boxes with participants’ unique sequence
number. Participants in the same house-
hold received the same treatment.”
Comment:Method of sequence generation
was not reported.
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Durga 2007 (Continued)
Allocation concealment (selection bias) Low risk Quote: “Specialized staff who were not in-
volved in the study allocated and labelled
the capsule boxes with participants’ unique
sequence number”
Comment: appropriate allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The folic acid andplacebo capsules
... were indistinguishable in appearance”.
70% of participants in the folic acid group
and71% in the placebo group thought they
had been allocated to folic acid
Comment: well blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: All staff, including all authors,
were unaware of group assignment until
completion of the trial and after data anal-
yses
Quote: outcome assessment well blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: 17 participants lost to follow-up
were assigned the median test score of the
total population at the end of the study
Comment: Although there were imputa-
tions, the small proportion of loss to fol-
low-up unlikely to affect results
Selective reporting (reporting bias) Unclear risk Quote: From clinicaltrials.gov: “Cogni-
tive performance at year 3 (cognitive do-
mains: simple speed, cognitive flexibility,
and memory; and information processing
speed and semantic memory)”
Comment: unclear if the domains reported
were prespecified (authors were contacted
for further information)
Other bias Low risk No other risks detected
Eussen 2006
Methods 3-arm, parallel-group, randomised, placebo-controlled trial, 24 weeks duration
Participants Location: the Netherlands
Recruitment: free-living older persons and older persons living in care-facility homes,
recruited via mailed health questionnaires
Number randomised: 195 randomised, of whom 119 had CDR 0 at baseline and were
included in this review
”Randomization was stratified according to MMA concentration at the screening visit
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Eussen 2006 (Continued)
(< and > 0.45 µmol/L), age (< and > 80), sex and MMSE score (< and > 24 points).“
Vitamin B12: 38
Vitamin B12 + folic acid: 38
Placebo: 43
Participant baseline characteristics:
• Age, mean (SD):
◦ vitamin B12: 80.42 (5.52)
◦ vitamin B12 + folic acid: 80.82 (4.18)
◦ placebo: 79.86 (4.74)
• .Gender
◦ vitamin B12: female 29/38 (76%)
◦ vitamin B12 + folic acid: female 29/38 (76%)
◦ placebo: female 34/43 (79%)
• Baseline cognitive function - MMSE score (mean (SD))
◦ vitamin B12: 28.18 (1.43)
◦ vitamin B12 + folic acid: 28.34 (1.40)
◦ placebo: 27.93 (1.80)
Inclusion criteria: aged ≥ 70 y. Mild vitamin B12 deficiency defined as (1) a serum
vitamin B12 concentration between 100 and 200 pmol/L, or (2) a serum vitamin B12
concentration between 200 and 300 pmol/L, a plasma MMA concentration ≥ 0.32
µmol/L, and a serum creatinine concentration ≤ 120 µmol/L. Ingested 90% or more
of capsules during a 2-week placebo run-in period prior to randomisation
Exclusion criteria: history of cobalamin deficiency, use of cobalamin (> 50 µg/day)
or folic acid (> 200 µg/day) supplementation or injections, surgery or diseases of the
stomach or small intestine, anaemia, dementia, life-threatening diseases, or severe hearing
or visual problems
Interventions Intervention:
1. vitamin B12: 1000 µg vitamin B12 (cyanocobalamin) per day orally for 24 weeks
2. vitamin B12 and folic acid: 1000 µg vitamin B12 (cyanocobalamin) plus 400 µg
folic acid per day orally for 24 weeks
Comparator group:
• Placebo capsule
The placebo capsules contained AVICEL PH102 (Medipulp GmbH, Aschaffenburg,
Germany) as a filler
Use of additional interventions (common to all treatment arms): not reported
Outcomes Cognitive function
Cognitive function was assessed before and after 24 wk of treatment with the use of
an extensive neuropsychologic test battery that included the domains of attention, con-
struction, sensorimotor speed, memory, and executive function
Cognitive function was assessed by 6 trained and registered neuropsychologists during
the run-in period (baseline) and at week 24 of the intervention during a 1.5-2-h session
Neuropsychological test battery included:
• finger tapping, computerised
• motor planning 2 and 3, computerised
• Figure of Rey copy, immediate recall and delayed recall
• 15-word learning immediate recall, delayed recall and recognition
• Trail-making test, part A and part B
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Eussen 2006 (Continued)
• Digit span forward and backward
• Raven
• Stroop test
• Similarities, WAIS
• Word fluency, letter
• Word fluency, animals
Depression measured with GDS
Biochemical measures: vitamin B12, MMA, holoTC, homocystine, RBC folate
Compliance was checked by counting the number of unused capsules remaining in cap-
sule dispensers and by verifying pill counts in the participants’ diaries. Mean compliance
was 99%
Notes Professor Simone Eussen and Professor Lisette de Groot kindly provided data separately
on participants with CDR 0 at baseline for inclusion in this review
Study supported by grants fromZON-MW,TheHague,Netherlands; Kellogg’s Benelux,
Zaventem, Belgium; Foundation to Promote Research into Functional Vitamin B12
Deficiency and the European Union BIOMEDDemonstration Project; Nutricia Health
Foundation, Wageningen, Netherlands
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Randomized“, no further information
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quotes: ”The capsules given to the sepa-
rate treatment groups were identical in ap-
pearance, smell and taste.“ ”The study had
a double-blind design.“
Comment: participants and personnel
blind to allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”The study had a double-blind de-
sign.“ No specific mention of outcome as-
sessors”
Comment: outcome assessors probably
blind to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data varied between
cognitive tests. For included outcomes,
data available for minimum of 82% of par-
ticipants
In study as a whole, “16% ... were unable to
complete the trial,mostly because of illness,
and the dropout rate was slightly higher in
the vitamin B12 + folic acid group than in
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the other groups.”Dropout inwhole study:
10/64 B12, 15/66 B12 + folic acid, 8/65
placebo
Comment: major effect of differential
dropout unlikely
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods fully
reported
Other bias Low risk No other biases identified
Ford 2010
Methods 2-arm, double-blinded, parallel group RCT, with 2 years duration of treatment and 8-
year follow-up
The average follow-up time (time to event) was 8.3 years in both groups
Participants Location: Australia, number of sites not reported
Recruitment: community-representative hypertensivemen 75 years and older randomly
selected from a large population-based study of abdominal aortic aneurysm screening
(Health in Men Study)
Participants were recruited from July 18, 2000, to February 6, 2002
Number randomised: 150 in intervention, 149 in comparator
Participant (baseline) characteristics:
• Age, mean (SD):
◦ placebo: 78.7 (2.7)
◦ vitamin: 79.3 (2.8)
• Baseline cognitive function
◦ ADAS-cog, mean (SD)
⋄ placebo: 11.8 (6.0)
⋄ vitamin: 11.0 (5.1)
• MMSE score, mean (SD)
◦ placebo: 27.6 (1.9)
◦ vitamin: 27.5 (1.8)
Inclusion criteria: community-representative hypertensive men 75 years and older
Exclusion criteria: BeckDepression Inventory (BDI) score≥ 18 or aMini-Mental State
Examination (MMSE) score≤ 24, illness likely to cause severe disability or death within
12 months (for example, metastatic cancer, Parkinson disease, or a history of stroke),
non-English speaking, living in residential care facilities, or patients who were already
taking vitamin B supplements
Interventions Intervention (n = 150):
Vitamins: one capsule containing 400 µg B12, 25 mg B6, 2 mg folic acid, every morning
for 2 years
Comparator group (n = 149):
Placebo, one identical oral capsule every morning for 2 years
Use of additional interventions (common to both treatment arms): not reported
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Ford 2010 (Continued)
Outcomes Primary Outcomes: to ascertain whether treatment with vitamins B12, B6, and folic
acid over 2 years would improve cognitive performance (change in the cognitive subscale
of the Alzheimer’s Disease Assessment Scale) compared with placebo in older men
Secondary Outcomes:
Longer-term impact of B vitamin supplementation by comparing performance on the
TICS aswell as a diagnosis of dementia registered in theWesternAustralianData Linkage
System (WADLS) until September 30, 2009
A diagnosis of dementia was recorded if the death certificate contained one of the follow-
ing ICD-10 codes: F00 (dementia in AD), F01 (vascular dementia), F03 (unspecified
dementia), and G30 (AD). Additionally, a dementia diagnosis was sought from records
of inpatient admissions and outpatient contacts
Secondary measures of interest included also the California Verbal Learning Test, Mini-
Mental State Examination,DigitCancellationTest, ClockDrawingTest*, TICS, changes
in biochemical parameters (total plasma homocysteine, vitamin B12 and quality of life
(Short Form (SF)-36)
Eligible cognitive outcomes:
• global cognitive function measured with ADAS-cog at 1 and 2 years, with higher
values indicating benefit
• global cognitive function measured with MMSE at 1 and 2 years, with higher
values indicating benefit*
• episodic memory measured with California Verbal Learning Test 1 (CVLT 1) at 1
and 2 years, with higher values indicating benefit
• episodic memory measured with California Verbal Learning Test 2 (CVLT 2) at 1
and 2 years, with higher values indicating benefit*
• semantic memory measured with Clock Drawing Test at 1 and 2 years, with
higher values indicating benefit*
• speed of processing measured with Digit Cancellation Test (DCT) at 1 and 2
years, with higher values indicating benefit*
Function outcome extracted: none reported
Quality of life outcome: SF-36
Safety outcome: none reported
* outcome data used in statistical analyses
Notes Funding sources, quote: “Supported by the National Health and Medical Research
Council of Australia (139123 to L.F.). The vitamin and placebo tablets were provided
free of charge by Blackmores Ltd“
Declarations of interest, quote: ”Dr. Ford reports no disclosures. Dr. Flicker serves
as Internal Medicine Editor for Geriatric Medicine, Associate Editor for BMC Geri-
atrics, on the editorial board of the Australasian Journal on Ageing, and as Editor of
the Cochrane Dementia and Cognitive Improvement Group; and receives/has received
research support from Pfizer Inc. and NHMRC. Dr. Alfonso and J. Thomas report no
disclosures. Dr. Clarnette serves on scientific advisory boards for Lundbeck Inc., Pfizer
Inc., and Novartis; serves as an editorial advisor to Geriatric Medicine in General Prac-
tice; and estimates that 10% of his practice at Fremantle Hospital consists of cogni-
tive testing. Dr. Martins serves as Senior Editor for the Journal of Alzheimer’s Disease;
serves as a consultant for and holds stock in Alzhyme Ltd.; and receives research support
from Commonwealth Scientific and Industrial Research Organisation (Australia). Dr.
Almeida has received funding for travel from Blackmores Ltd.“
Treatment adherence
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Men who consumed at least 75% of the study tablets during this 2-year trial were
considered compliant. Compliance was determined by pill count and medication diaries
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were given consec-
utive numbers and allocated to active vs
placebo arms based on computer-generated
random permuted blocks. Blocks consisted
of 8 subjects (4 subjects allocated to each
group) so as to minimize the risk of hav-
ing unbalanced entry into each arm of the
study during the period of recruitment.”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “An external and independent aca-
demic controlled the randomization proce-
dures of the trial.“
Comment: adequate method of allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Vitamins and placebo were ad-
ministered in the formof identical oral cap-
sules.”
“Participants and investiga-
tors were blinded to the groupmembership
of men in the trial until the last follow-up
assessment was completed. There were no
breaches of protocol”
Comment: participants and personnel
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Participants and investigators were
blinded to the groupmembership ofmen in
the trial until the last follow-up assessment
was completed.”
Comment: outcome assessment blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “32 (21%) men in the intervention
and 26 (17%) in the placebo group with-
drew consent or were lost during the trial.
”
Comment: For the primary outcome, an
ITT analysis was presented and attrition
bias was considered as low
For the secondary outcome of cognitive
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impairment or dementia at long-term fol-
low-up : “Seventy-three of these men took
part in a later telephone survey in 2008
and completed the Telephone Interview for
Cognitive Status (TICS) questionnaire”,
“41 (27%) in the intervention group and
32 (21%) in the placebo group”. Data on
dementia diagnosis were available on all
172/299 (57.5%) participants who were
alive in 2008
Comment: high risk of attrition bias for
this long-term secondary outcome
Selective reporting (reporting bias) Low risk Comment: All outcomes specified in the
Methods were reported in the Results. Pro-
tocol not available
Other bias Low risk No other risks identified
Grodstein 2007
Methods Substudy of the Physicians’ Health Study II, a randomised, double-blind, placebo-con-
trolled, 2 x 2 x 2 x 2 factorial trial testing ß-carotene, vitamin E, ascorbic acid, and a
multivitamin for their role in preventing chronic diseases including total and prostate
cancer, cardiovascular disease, and age-related eye disease among 14,641 male physicians
aged 50 years or older
The trial was done from 1997 to 1 June 2011. The cognitive function substudy began
in 1998. Those eligible for the cognitive substudy were PHS II participants older than
65 years in November 1998
The Physicians’ Health Study II was a continuation of the Physicians’ Health Study,
which began in 1982 and had randomised male participants to low-dose aspirin and ß-
carotene. Participants included those continuing their original ß-carotene assignment
from the Physicians’ Health Study and newer recruits randomised from 1998 onwards
Participants Location: not reported
Recruitment: The Physicians’ Health Study II. Quote: “In July 1997, invitations to
enrol in PHS II were mailed to eligible participants from PHS I who had been part of
an earlier trial of aspirin and ß-carotene among 22071 physicians aged 40 to 84 years
in 1982. Second, in July 1999, invitation letters were mailed to a new group of male
physicians identified from a list provided by the American Medical Association.”
Quote: “PHS I participants who are willing and eligible for participation in PHS II will
retain their randomized ß-carotene assignment from PHS I and will be also randomized
to vitamin E...”
“new physician participants will be randomly assigned to the same interventions”
Number randomised:
• 2967 ß-carotene (2031 continuing from PHS and 936 newer recruiters)
• 2989 placebo (2021 continuing from PHS and 968 newer recruiters)
Participant (baseline) characteristics (at entry PHS III):
All participants were men.
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Age, mean:
• Patients from PHS at entry in PHS II
◦ ß-carotene: 70.9
◦ placebo: 71.0
• Newly recruited
◦ ß-carotene: 72.9
◦ placebo: 72.8
Inclusion criteria: not reported
Exclusion criteria: history of cirrhosis or active liver disease, patients receiving antico-
agulants, or reported a serious illness that may interfere with study participation
Men were also required to forgo current use of multivitamins or individual supplements
containing more than 100% of the recommended daily allowance of vitamin E, vitamin
C, ß-carotene, or vitamin A during PHS II follow-up
For those newly recruited: no history of cancer, active liver disease, current renal disease,
peptic ulcer, or gout
Quote: “Only physicians who comply with the pill-taking regimen at least two-thirds of
the time and remain willing and eligible to participate will be subsequently randomized”
Interventions Intervention:
1. ß-carotene (Lurotin, 50 mg on alternate days, or its placebo; BASF, Florham Park,
New Jersey);
2. vitamin E (synthetic alfa-tocopherol, 400 IU on alternate days, or its placebo;
BASF);
3. ascorbic acid (synthetic ascorbic acid, 500 mg daily, or its placebo; BASF);
4. multivitamin (Centrum Silver or its placebo daily; Pfizer, New York, New York)
NB: Grodstein 2007 reported on the ß-carotene and Grodstein 2013 on multivitamin
supplementation.
Comparator group: placebo ß-carotene.
Exposure to study intervention:
2031 patients in ß-carotene and 2021 placebo continued from the PHS study (started
in 1982) in which they were receiving ß-carotene versus placebo ß-carotene. As most of
the cognitive assessments were done in 2001, some of the patients continuing from PHS
had been exposed to ß-carotene (or placebo ß-carotene) for about 19 years, whereas the
“new recruiters” had been exposed from 1997 to 2001, thus for about 4 years
The mean time from randomisation to cognitive assessment was 18 years (range, 15-
20 years) in 4052 continuing participants from the PHS,and was 1 year in 2021 new
recruits (range, 2 months-3 years)
Quote: “PHS participants, who remained blinded to beta carotene assignment.”
Quote: “Treatment assignment to beta carotene or beta carotene placebo was retained
from the PHS (although participants may have stopped taking beta carotene during the
18-month interval between studies), and the men were newly randomized to receive
vitamin E, ascorbic acid, multivitamin, or placebo.”
Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes:
A global composite score averaging 5 tests of global cognition, verbal memory, and
category fluency
The cognitive battery included the Telephone Interview for Cognitive Status (TICS);
immediate and delayed recall on the East Boston Memory Test (EBMT); delayed recall
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of a 10-word list; and a category fluency task
The cognitive function substudy began in 1998.
The beta carotene arm of the PHS II continued until May 2003, its planned stopping
date, but most of the assessments were done in 2001
Quote: “Second cognitive assessments were begun in 2002. The beta carotene arm was
terminated prior to completion of second assessments (second and third assessments
were planned to allow further data collection in the continuing trial of other vitamins)
. Nonetheless, some data from the second interview were available (n = 4074, with 88.
3% participation of those who were contacted before termination of the beta carotene
study).”
Eligible cognitive outcomes:
• global cognitive function measured with TICS*
• episodic memory (verbal memory) measured using an average of z-scores* for
immediate and delayed recall on the EBMT and delayed recall of a 10-word list
• executive functioning measured with category fluency: animals named during 1
minute*
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
* outcome data used in statistical analyses
Notes Funding source: “This study was supported by grants from the National Institutes of
Health (CA34944, CA40360, CA97193, HL26490, HL34595, and AG15933), and
from BASF Corporation (Florham Park, New Jersey), Wyeth (New Jersey), and DMS
(New Jersey). Dr Grodstein was partially supported by a New Scholars in Aging award
from the Ellison Medical Foundation. Role of the Sponsor: No supporting organization
had any role in the study design; conduct of the study; collection, management, analysis,
and interpretation of the data; or preparation, review, or approval of the manuscript.“
Declaration of interest: “None reported”.
Treatment adherence:
ß-carotene study:
“Overall, 79.3% reported taking at least 2 of 3 of their study pills; this was similar in
those assigned to active treatment (79.1%) or placebo (79.5%), and in the continuing
participants from the PHS (79.2%) vs new recruits (79.4%)”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The PHS II is a randomized,
double-blind, placebo-controlled, 2x2x2x2
factorial trial“
”Randomization..using a computer-gener-
ated list of random numbers“
Comment: adequate method of random
generation
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Allocation concealment (selection bias) Unclear risk Quote: “The PHS II is a randomized,
double-blind, placebo-controlled, 2x2x2x2
factorial trial”
Comment: method of allocation conceal-
ment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The PHS II is a randomized,
double-blind, placebo-controlled, 2x2x2x2
factorial trial“
Comment: method of blinding not re-
ported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The PHS II is a randomized,
double-blind, placebo-controlled, 2x2x2x2
factorial trial”
“An Endpoint Committee of physicians
blinded to the participants’ treatment as-
signment, will review the medical records
for final confirmation of a reported diag-
nosis”
Comment: Themethod of blinding of out-
come assessment for the cognitive substudy
was not reported. The statement about
the Endpoint Committee is contained in
the design paper which, however, does not
mention any cognitive outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “of the 7045 age-eligible patients,
271 were no longer active PHSII partici-
pants (3.8%) and 4 were deceased (0.06%)
. Of the remaining 6770, we were unable
to reach 315 (4.7%). Of the 6455 partici-
pants contacted, 5956 (92.3%) completed
a cognitive assessment: 4052 from the orig-
inal PHS and 1904 new recruits..” “Partic-
ipation (in the cognitive substudy) was vir-
tually identical in those assigned to beta-
carotene (92.0%) vs placebo (92.6%) and
in continuing participants (from the PHS)
(92.1%) vs new recruits (to PHS II) (92.
7%).”
Selective reporting (reporting bias) Low risk Comment: no differences found between
the protocol (clinicaltrials.gov Identifier:
NCT00270647) and article. In addition,
all outcomes specified in the Methods were
reported in the Results
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Other bias Low risk No other source of bias identified
Grodstein 2013
Methods Substudy of the Physicians’ Health Study II, a randomised, double-blind, placebo-con-
trolled, 2 x 2 x 2 x 2 factorial trial testing ß-carotene, vitamin E, ascorbic acid, and a
multivitamin for their role in preventing chronic diseases including total and prostate
cancer, cardiovascular disease, and age-related eye disease among 14641 male physicians
aged 50 years or older
The trial was done from 1997 to 1 June 2011. The cognitive function substudy began
in 1998
Participants Location: not reported
Recruitment: The Physicians’ Health Study II. Quote: ”In July 1997, invitations to
enrol in PHS II were mailed to eligible participants from PHS I who had been part of an
earlier trial of aspirin and beta-carotene among 22,071 physicians aged 40 to 84 years
in 1982. Second, in July 1999, invitation letters were mailed to a new group of male
physicians identified from a list provided by the American Medical Association.“
The substudy of cognitive function was conducted among PHS II participants aged 65
years or older
Number randomised: 2980 in multivitamin, 2967 in placebo
Participant (baseline) characteristics:
All participants were men.
• Age, mean (SD):
◦ multivitamin: 71.6 (6.0)
◦ placebo: 71.6 (5.9)
Inclusion criteria: not reported
Exclusion criteria: history of cirrhosis or active liver disease, patients receiving antico-
agulants, or reported a serious illness that may interfere with study participation
Men were also required to forgo current use of multivitamins or individual supplements
containing more than 100% of the recommended daily allowance of vitamin E, vitamin
C, ß-carotene, or vitamin A during PHS II follow-up
For those newly recruited: no history of cancer, active liver disease, current renal disease,
peptic ulcer, or gout
Quote: ”Only physicians who comply with the pill-taking regimen at least two-thirds of
the time and remain willing and eligible to participate will be subsequently randomized“
Interventions Intervention:
1. ß-carotene (Lurotin, 50 mg on alternate days, or its placebo; BASF, Florham Park,
New Jersey);
2. vitamin E (synthetic alfa-tocopherol, 400 IU on alternate days, or its placebo;
BASF);
3. ascorbic acid (synthetic ascorbic acid, 500 mg daily, or its placebo; BASF);
4. multivitamin (Centrum Silver or its placebo daily; Pfizer, New York, New York)
NB: Grodstein 2007 reported on the ß-carotene and Grodstein 2013 on multivitamin
supplementation.
Comparator group: placebo multivitamin
Use of additional interventions (common to both treatment arms): Because of the
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factorial design, some participants were also taking vitamin E and/or vitamin C
Exposure to study intervention: Mean time from randomisation to initial cognitive
assessment was 2.5 years (range, 0.18 to 5.3 years) and mean time from randomisation
to the final cognitive assessment was 8.5 years (range, 0.3 to 14.2 years)
Outcomes Primary Outcomes:
A global composite score averaging 5 tests of global cognition, verbal memory, and
category fluency
The cognitive battery included the Telephone Interview for Cognitive Status (TICS);
immediate and delayed recall on the East BostonMemoryTest (EBMT) (verbalmemory)
; the delayed recall of a 10-word list (verbal memory); and a category fluency task
The cognitive function substudy began in 1998. Up to 4 repeated cognitive assessments
by telephone interview were completed over 12 years
Quote: ”The beta-carotene group of the PHS II continued as planned through May
2003... Treatment and follow-up of the vitamin E and C components continued through
August 2007...The multivitamin intervention continued through 1 June 2011..“
Eligible cognitive outcomes:
• global cognitive function measured with TICS
• episodic memory (verbal memory) measured using an average of z-scores* for
immediate and delayed recall on the EBMT and delayed recall of a 10-word list
• executive functioning measured with category fluency: animals named during 1
minute
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
Notes Funding sources, Quote: “National Institutes of Health, BASF, Pfizer, and DSM Nu-
tritional Products.” “By grants CA 097193, CA 34944, CA 40360, HL 26490, HL
34595, AG 15933, and T32-AG000158 from the National Institutes of Health, and an
investigator-initiated grant from BASF. Study agents and packaging were provided by
BASF and Pfizer, and study packaging was provided by DSM Nutritional Products.”
Declarations of interest, quote: “Disclosures can be viewed at www.acponline.org/
authors/icmje/ConflictOfInterestForms.do?msNum M13-1340.“ Several authors re-
ported some conflicts of interest
Treatment adherence:
”83.5% of the multivitamin group and 84.2% of the placebo group reported taking at
least two thirds of their study pills“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The PHS II is a randomized,
double-blind, placebo-controlled, 2x2x2x2
factorial trial”
“Randomization..using a computer-gener-
ated list of random numbers”
Comment: adequate method of random
generation
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Allocation concealment (selection bias) Low risk Quote: “The PHS II is a randomized,
double-blind, placebo-controlled, 2x2x2x2
factorial trial“
Comment: method of allocation conceal-
ment not reported, but likely to be ade-
quate
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The PHS II is a randomized,
double-blind, placebo-controlled, 2x2x2x2
factorial trial”
Comment: method of blinding not re-
ported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The PHS II is a randomized,
double-blind, placebo-controlled, 2x2x2x2
factorial trial“
”An Endpoint Committee of physicians
blinded to the participants’ treatment as-
signment, will review the medical records
for final confirmation of a reported diag-
nosis“
Comment: Themethod of blinding of out-
come assessment for the cognitive substudy
was not reported. The statement about
the Endpoint Committee is contained in
the design paper which, however, does not
mention any cognitive outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was good retention of participants
from the first to the second (96%) and the
third (90%) assessments
Quote: “the fourth assessment was not at-
tempted in many participants because of
trial completion (that is, 2700 (45%) of the
initial 5947 who completed the initial in-
terview were invited to participate at the
fourth assessment before the trial closed on
1 June 2011)”
Comment: 3623 (61%) patients had none
of the assessments at last visit so we consid-
ered there was a high risk of attrition bias
for the final assessment only (time point >
5 to 10 years)
Selective reporting (reporting bias) Low risk Comment: No differences identified be-
tween the protocol ClinicalTrials.gov:
NCT00270647) and the article. All out-
comes specified in the Methods were re-
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ported in the Results
Other bias Low risk No other risks identified
Hankey 2013
Methods Prespecified substudy of the VITATOPS trial, a randomized, 2-arm, parallel group,
placebo-controlled trial
Participants Location: international, multicentre (20 countries from 4 continents)
Number randomised: 8164 participants with recent stroke or TIA randomised in VI-
TATOPS. This substudy was of the 2214 participants who were cognitively unimpaired
- defined as MMSE ≥ 24 six months after the qualifying cerebrovascular event - and
who had 1 or more further MMSEs during follow-up
1110/2214 allocated to B vitamins
1104/2214 allocated to placebo
Participant (baseline) characteristics:
• gender: 67.3% male
• age, mean (SD): 63.6 (11.8)
• baseline cognitive function:
◦ B vitamins group MMSE 28.05 (SD 1.76)
◦ placebo group MMSE 28.09 (SD 1.77)
Inclusion criteria: “patients presenting within 7 months of stroke (ischaemic or haem-
orrhagic) or TIA (eye or brain), as defined by standard criteria, are eligible” (for VI-
TATOPS). For cognitive substudy, MMSE ≥ 24 six months after the qualifying cere-
brovascular event and ≥ 1 further MMSE measured during follow-up
Exclusion criteria: patients taking folic acid or vitamin B6 on medical advice; taking
methotrexate for any reason; pregnant or at risk of pregnancy; limited life expectancy
Interventions Intervention (n = 1110):
Folic acid 2 mg, vitamin B6 25 mg, vitamin B12 500 µg
Comparator (n = 1104):
Placebo
Outcomes Primary outcome for this prespecified substudy was a new diagnosis of cognitive impair-
ment (MMSE score < 24 on ≥ 2 follow-up visits ≥ 6 months after the qualifying stroke
Secondary outcomes were tHcy, the mean MMSE, cognitive decline (i.e. a decline from
baseline, ≥ 6 months after the qualifying stroke, of ≥ 3 points in the MMSE score on
≥ 2 follow-up visits), composite of cognitive impairment and decline
Notes Funded byNational Health and ResearchCouncil of Australia, theUKMedical Research
Council, the Biomedical Research Council of Singapore, the National Heart Foundation
of Australia, the Royal Perth Hospital Medical Research Foundation, and the Health
Department of Western Australia
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “After baseline data have been pro-
vided by the investigator and it is confirmed
that the patient meets the study eligibility
criteria, a central 24-hour telephone service
or an interactive website ... uses random
permuted blocks stratified by hospital to al-
locate a treatment pack number.”
Allocation concealment (selection bias) Low risk Quote: “After baseline data have been pro-
vided by the investigator and it is confirmed
that the patient meets the study eligibility
criteria, a central 24-hour telephone service
or an interactive website ... uses random
permuted blocks stratified by hospital to al-
locate a treatment pack number.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the tablets being either vitamin
supplements or matching placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No specific information about site investi-
gators. Likely blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The 2214 cognitively unimpaired
participants who underwent subsequent
cognitive testing were more likely to be
white, have a qualifying TIA and lacunar
syndrome at baseline, and less likely to
have experienced an early recurrent stroke
within 1 year of randomization ... com-
pared with the 394 cognitively unimpaired
participants who did not proceed to further
cognitive testing.”
“ ..there was no significant difference in
the prevalence of baseline characteristics
among the 2214 cognitively unimpaired
participants allocated B vitamins (n =
1110) compared with placebo (n = 1104),
with the exception of atrial fibrillation (9.
1% B vitamins versus 6.5% placebo; P = 0.
022).”
Selective reporting (reporting bias) Low risk Prespecifed cognitive outcomes fully re-
ported
Other bias Low risk No other risks identified
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Methods Cognitive substudy of the Women’s Health Study, a randomized, placebo-controlled, 2
x 2 factorial trial of vitamin E and low-dose aspirin with follow-up to approximately 10
years
Participants Location: USA, number of sites not reported
Recruitment: female health professionals
Number randomised: 3184 in intervention, 3193 in comparator
Participant (baseline) characteristics:
• Age at randomisation:
◦ vitamin E group: 66.2 (± 4)(range 60.4-89.9)
◦ placebo: 66.3 (± 4.1)(range 60.4-87.1)
• Age at initial cognitive assessment:
◦ vitamin E group : 71.8 (± 4)(range 66.1-95.5)
◦ placebo: 71.9 (± 4.1)(range 66.0-92.8)
• · Gender: women 100%
• · Baseline cognitive function: not assessed
Inclusion criteria:Women 65 years or older participating in theWomen’s Health Study.
Inclusion criteria for the main study: ”Women were eligible if they were 45 years of
age or older; had no history of coronary heart disease, cerebrovascular disease, cancer
(except non-melanoma skin cancer), or other major chronic illness; had no history of
side effects to any of the study medications; were not taking aspirin or nonsteroidal
antiinflammatory medications (NSAIDs) more than once a week (or were willing to
forego their use during the trial); were not taking anticoagulants or corticosteroids; and
were not taking individual supplements of vitamin A, vitamin E, or beta carotene more
than once a week.“
Exclusion criteria: not reported for the cognitive substudy
Interventions Intervention (n = 3184):
Vitamin E supplementation (600 IU α-tocopherol acetate; Natural Source Vitamin E
Association, La Grange Ill) on alternate days
Comparator group (n = 3193):
Placebo
Participants also randomised to aspirin 100 mg on alternate days in 2 x 2 factorial design
Use of additional interventions (common to both treatment arms): not reported
Outcomes The first cognitive assessment was a mean of 5.6 years (range 4.4 to 6.8 years) after
randomisation and the final assessment was a mean of 4 years (range 2.6 to 5.7 years)
later. We considered that all assessments fell into our duration category of > 5-10 years
of treatment and, following the protocol, used the latest, i.e. the final, assessment only
PrimaryOutcomes: global composite score averagingperformance on general cognition,
verbal memory and category fluency
Tests used:
• Telephone Interview of cognitive status (TICS)
• East Boston Memory test immediate and delayed recall
• Delayed recall of the TICS 10-word list
Secondary Outcomes: composite score of verbal memory, averaging performance across
4 measures of verbal memory
Cognitive assessments of general cognition, verbal memory, and category fluency were
administered by telephone at 2-year intervals by trained nurses
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Time from randomisation to final cognitive assessment: approximately 10 years
Eligible cognitive outcomes:
• global cognitive function measured at approximately 10 years, with higher values
indicating benefit
• executive functioning measured at approximately 10 years, with higher values
indicating benefit
• episodic memory measured with TICS 10-word test delayed recall at
approximately 10 years, with higher values indicating benefit
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
Notes Primary aim of studywas to investigate effects of interventions on the primary prevention
of cardiovascular disease and cancer. At the time of initiation of the cognitive substudy,
participants had been treated for a mean of 5.6 years since randomisation
Funding sources, quote: “This work was supported by grants CA47988 and AG15933
from the National Institute of Health”, “The funding agency did not play any role in the
design and conduct of the study; collection, management, analysis, and interpretation
of the data; and preparation, review, or approval of the manuscript”
Declarations of interest, For the sub-study: none reported. For the main study, quote:
“Dr. Ridker reports having received grant support from Bayer. Dr. Cook reports having
served as a consultant to Bayer. Dr. Gaziano reports having served as a consultant to, and
receiving grant support from, Bayer and McNeil. Dr. Hennekens reports having served
as a consultant to Bayer and McNeil and receiving grant support from Bayer”
Treatment adherence
Quote: “compliance was comparable between the 2 groups: as of the final cognitive
assessment, the percentage that reported taking at least two thirds of the assigned pill
was 75.4% for the vitamin E group and 76.9% for the placebo group”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: method of random sequence
generation not reported. Probably ade-
quate
Allocation concealment (selection bias) Unclear risk Comment: method of allocation conceal-
ment not reported. Probably adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The WHS is a double-blind, ....
RCT.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: for the substudy on cognitive
function, blinding of outcome assessment
was not reported
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 18% of patients randomised
and included in the substudy were not in-
cluded in the analysis at last assessment
Selective reporting (reporting bias) Unclear risk Comment: All outcomes in the Methods
were reported in the results. Protocol not
available
Other bias Low risk No other risks identified
Kang 2008
Methods WAFACS study. A 2 x 2 x 2 x 2 factorial, randomised, placebo-controlled trial of 3
antioxidants (vitamin E, vitamin C, and ß-carotene) and B vitamins with 6.6 years of
treatment and 5.4 years of follow-up of cognitive function
The WAFACS study was started in 1998 and continued the WACS study (Kang 2009)
with the introduction of a fourth arm treated with folic acid, vitamin B6, and vitamin
B12
Surviving participants of the WACS were invited to participate in the WAFACS
When the folic acid, vitamin B6, and B12 armwas added, this combination or its placebo
was combined in a retained factorial design with the vitamin C tablet or placebo
Participants Location, Country: United States of America, number of sites not reported. Inclusion
from December 1998 to July 2000
Recruitment: female health professionals
Number randomised: 1071 in intervention, 1093 in comparison, but 1002 and 1007
considered at baseline because had available baseline cognitive assessment
Participant (baseline) characteristics:
• Mean age ± SD (range) at randomisation:
◦ vitamin: 71.3 ± 4.2 (65.3-89.9)
◦ placebo:71.3 ± 4.2 (65.3-90.0)
• Mean age ± SD (range) at initial cognitive assessment:
◦ vitamin: 72.5 ± 4.2 (66.1-90.9)
◦ placebo: 72.5 ± 4.2 (66.1-91.2)
• · Gender: women 100%
• ·Main diagnosis: female health professionals aged ≥ 40y with cardiovascular
disease or ≥ 3 coronary risk factors
Inclusion criteria:
This was a substudy of cognitive function among 2009 participants aged≥ 65 years from
the Women’s Antioxidant and Folic Acid Cardiovascular Study, a randomised placebo-
controlled trial designed to test the effect of a combination of B vitamins on secondary
prevention of cardiovascular disease in female health professionals aged ≥ 40 years with
cardiovascular disease or ≥ 3 coronary risk factors
The substudy was initiated a mean of 1.2 years after randomisation
Exclusion criteria: not reported for the substudy
Exclusion criteria in themain study, quote: ”Womenwere excluded if they had ahistory of
cancer (excluding non-melanoma skin cancer) within the past ten years, any serious non-
CVD illness, or were currently using warfarin or other anticoagulants. To be eligible for
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the folic acid/vitamin B6/B12 component, potential participants in the ongoing eight-
arm trial had to be additionally willing to forgo individual supplements of folic acid,
vitamin B6, and vitamin B12 at levels beyond the US recommended daily allowance“
Interventions Intervention (n = 1002):
2.5 mg folic acid/day, 50 mg vitamin B6/day, and 1 mg vitamin B12/day
Quote: ”5442womenwere assigned to 16 treatment assignments that were combinations
of the 3 antioxidants“ and 1 B vitamin supplement
Quote: ”Every 12 mo, the women were sent a year’s supply of monthly calendar packs
containing active agents or placebo.“
Comparator group (n = 1007): placebo.
Use of additional interventions (common to both treatment arms): not reported.
Outcomes Outcomes of interest in the review:
Primary Outcomes: global composite score averaging all 5 test results measuring general
cognition, verbal memory, and category fluency using z scores
Quote: ”We assessed cognitive function using a telephone cognitive battery with 5 tests
measuring general cognition, verbal memory, and category fluency. “
The following tests were used:
• For general cognition, Telephone Interview of Cognitive Status (TICS);
• For verbal memory, delayed recall of the TICS 10-word list and the immediate
and delayed recalls of the East Boston Memory Test;
• For category fluency, women were asked to name as many animals as possible in 1
min.
Secondary Outcomes: verbal memory composite score, calculated by averaging 4 mea-
sures of verbal memory (the immediate and delayed recalls of both the East Boston
Memory Test and the 10-word list)
Telephone cognitive function testing was administered up to 4 times over 5.4 years
The average time from randomisation to the initial cognitive assessment was 1.2 years
(range: 0.7-1.7 years), and from randomisation to the last assessment was 6.6 years (range:
6.3- 6.9 years).”
Eligible cognitive outcomes:
• global cognitive function measured with TICS at the initial cognitive assessment
(1.2 years); the second cognitive assessment (around 3 years of follow-up) and the
fourth cognitive assessment (6.6 years follow-up), with higher values indicating benefit*
• episodic memory: composite(delayed East Boston memory, immediate East Boston
memory, delayed TICS-10) at the initial cognitive assessment (1.2 years); the second
cognitive assessment (around 3 years of follow-up) and the fourth cognitive assessment
(6.6 years follow-up)
• executive functioning measured with Category fluency, animal naming test at the
initial cognitive assessment (1.2 years); the second cognitive assessment (around 3 years
of follow-up) and the fourth cognitive assessment (6.6 years follow-up), with higher
values indicating benefit*.
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
* outcome data used in statistical analyses
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Notes Funding sources, quote: “Folic acid, vitamin B-6, vitamin B-12, and placebos were
provided by the BASF Corporation (Mount Olive, NJ)”
“Supported by grants AG15933 and HL47959 from the National Institutes of Health”
Declarations of interest, quote: “None of the authors declared a conflict of interest.“
”Other Financial Disclosures: Dr Gaziano has received investigator initiated study sup-
port in the form of vitamin pills and packaging from Wyeth. Dr Buring has received
investigator initiated study support in the form of vitamin pills and packaging from
Natural Source Vitamin E Association. Dr. Manson has received investigator-initiated
study support in the form of vitamin pills and packaging from Cognis and BASF.“
Treatment adherence
Quote: ”Compliance was comparable (83%) in the 2 treatment groups“. This statement,
however, seems to have referred to the main study and not to this substudy on cognitive
function,
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: no information
Comment: method of random sequence
generation not reported
Allocation concealment (selection bias) Unclear risk Quote: no information
Comment: method of allocation conceal-
ment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: Protocol: ”Participants and investi-
gators will be blinded to treatment assign-
ment.“
Comment: method of blinding not re-
ported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The telephone cognitive inter-
views were administered by trained inter-
viewers”
From the main study: “An endpoints com-
mittee of physicians who were blinded to
randomized treatment assignment adjudi-
cated all primary and secondary cardiovas-
cular outcome events. Study medications
and end point ascertainment were contin-
ued in a blinded fashion until the sched-
uled end of the trial, July 31, 2005.”
Comment: It was not specifically reported
whether cognitive assessors were blinded,
but we considered this to be highly likely
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Participants received 3 follow-up
cognitive assessments approximately every
2 y.... 94%completed at least one follow-up
assessment, and 83% completed ≥ 3 of 4
assessments. In the fourth assessment, 24%
of participants were not contacted for their
assessment because only a short interval had
passed between their third interview and
the end of the trial in July 2005.“
Comment: Although the authors provided
some explanation for not seeing some pa-
tients at last visit (visit 4), the number of
patients not undergoing cognitive evalua-
tion was considerable: 956/2009 (47.5%)
at visit 4 and 314/2009 (15.6%) at visit 3.
RIsk of bias related to incomplete outcome
data considered high for visit 4
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
Methods were presented in the Results. In
addition, the outcomes reported in the pro-
tocol were reported as well in the article
Other bias Low risk Quote: “155 women (7%) were unreach-
able, had declined participation, or had
died; thus, 2009 (93%) women completed
the initial telephone cognitive assessment.
”
Comment: inclusion was probably not
consecutive, however, reasons for not in-
cluding in the substudy were given and the
number excluded appeared balanced be-
tween the 2 groups
Kang 2009
Methods 2 x 2 x 2 factorial, randomised, placebo-controlled trial of 3 antioxidants (vitamin E,
vitamin C, and ß-carotene) with 8.9 years (range 7.8-9.6) of follow-up
Participants Location:Country: USA and Puerto Rico, no of sites etc. not reported. FromDecember
1998 to July 2000
Quote: “FromNovember 1994 toOctober 1996 an introductory letter, informed consent
form, and enrolment questionnaire were mailed to female health professionals who were
originally identified through state licensing boards and professional organizations in the
continental United States, Alaska and the Commonwealth of Puerto Rico”
“Potential candidates were also drawn from a cohort of women with prevalent CVD
participating in the long-running Nurses’ Health Study”
Recruitment: female health professionals
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Number randomised:
2824 in cognitive substudy
• overall, vit E: 1428;
• overall, vit C: 1406;
• overall, betaCarot: 1406;
• placebo vit E, C, betaCarot: 353;
• placebo vit E: 1396;
• placebo vit C: 1418;
• placebo betaCarot: 1418.
Participant (baseline) characteristics:
Mean age (± SD, range) at randomisation:
• overall, vit E: 69.1 (4.3; 62.6-87.4)
• placebo vit E: 69.0 (4.2; 62.6-87.9)
• overall, vit C: 69.0 (4.2; 62.6-86.9)
• placebo vit C: 69.1 (4.3; 62.6-87.9)
• overall, betaCarot: 69.1 (4.3; 62.6-87.9)
• placebo betaCarot: 69.0 (4.2; 62.6-87.6)
Mean age (± SD, range) at initial cognitive assessment:
• overall, vit E: 72.6 (4.3; 66.1-90.9)
• placebo vit E: 72.5 (4.2; 66.1-91.3)
• overall, vit C: 72.5 (4.2; 66.1-90.5)
• placebo vit C: 72.6 (4.3; 66.1-91.3)
• overall, betaCarot: 72.6 (4.3; 66.2-91.3)
• placebo betaCarot: 72.5 (4.2; 66.1-91.2)
Gender: women 100%
Main diagnosis: female health professionals aged ≥ 40y with cardiovascular disease or
≥ 3 coronary risk factors
Inclusion criteria: This was a substudy of cognitive function among 2824 participants
aged ≥ 65 years from the Women’s Antioxidant Cardiovascular Study, a randomised
placebo-controlled trial designed to test the effect of a antioxidants on secondary pre-
vention of cardiovascular disease in female health professionals aged ≥ 40 years with
cardiovascular disease or ≥ 3 coronary risk factors
Exclusion criteria: not reported for the substudy
Exclusion criteria in themain study, quote: “Womenwere excluded if they had ahistory of
cancer (excluding non-melanoma skin cancer) within the past ten years, any serious non-
CVD illness, or were currently using warfarin or other anticoagulants. To be eligible for
the folic acid/vitamin B6/B12 component, potential participants in the ongoing eight-
arm trial had to be additionally willing to forgo individual supplements of folic acid,
vitamin B6, and vitamin B12 at levels beyond the US recommended daily allowance”
Only women who were compliant (taking at least two-thirds of the pill) during the 12-
week pre-randomisation run-in period were randomised
Interventions Intervention (overall, vitamin E: 1428; overall, vitamin C: 1406; overall, betaCarot:
1406)
Vitamin E at a dose of 402 mg (600 IU) every other day, ß-carotene (50 mg every other
day) and vitamin C (500 mg daily)
Every 12 months, the women were sent a year’s supply of monthly calendar packs con-
taining active agents or placebo
Comparator group: placebo (placebo vitamin E, vitamin C, ß-carotene: 353; placebo
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vit E: 1396; placebo vitamin C: 1418; placebo ß-carotene: 1418)
Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes: global composite score averaging all 5 test results measuring general
cognition, verbal memory, and category fluency using z scores
Quote: “We assessed cognitive function by telephone and administered 5 testsmeasuring
general cognition, verbal memory and category fluency.”
The following tests were used:
• Telephone Interview of Cognitive Status (TICS)
• delayed recall of the TICS 10-word list and the immediate and delayed recalls of
the East Boston Memory Test (data not extractable per instrument)
• category (animal) fluency
Secondary Outcomes: ’verbal memory’ composite score, calculated by averaging 4 mea-
sures of the immediate and delayed recalls of both the East Boston Memory Test and the
TICS 10-word list
Telephone cognitive function testing was administered up to 4 times over 5.4 years
The substudy was initiated a mean of 3.5 years after randomisation. Quote: “The average
time from randomization to the initial cognitive assessment was 3.5 years (range 3.1-4.
7), and from randomization to the last assessment was 8.9 years (range 7.8-9.6)”
Eligible cognitive outcomes:
• global cognitive function measured with TICS
• executive function measured with category fluency
Notes Also known as the WACS study.
Funding sources, quote: “Vitamin E and its placebo were provided by Cognis Corpo-
ration (LaGrange, IL); all other agents and their placebos were provided by BASF Cor-
poration (Mount Olive, NJ).” “This work is supported by grants AG15933, HL046959
from the National Institutes of Health.”
Declarations of interest, quote: “none.“ ”Other Financial Disclosures: Dr Gaziano has
received investigator initiated study support in the form of vitamin pills and packaging
from Wyeth. Dr Buring has received investigator initiated study support in the form of
vitamin pills and packaging fromNatural Source Vitamin EAssociation. Dr.Manson has
received investigator-initiated study support in the form of vitamin pills and packaging
from Cognis and BASF.“
Treatment adherence
”average compliance (defined as taking at least two-thirds of assigned study medications)
during follow-up was 83% and did not differ significantly between the two groups“. This
statement, however, seemed to have referred to the main study and not to this substudy
on cognitive function
”At the end of the study, compliance (defined as taking at least two-thirds of study pills)
was comparable across all groups (range 64-68%).“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized in a 2 × 2 × 2 factorial
design.”
Comment: method of random sequence
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generation not reported. Probably ade-
quate
Allocation concealment (selection bias) Unclear risk Comment: method of allocation conceal-
ment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “matching placebo“
Comment: same study as Kang 2008 (re-
ported vitamin B arm) in which more de-
tailed description of the methods stated
that ”Participants and investigators will be
blinded to treatment assignment.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The telephone cognitive inter-
views were administered by trained inter-
viewers, who were masked to the partici-
pants’ randomized treatment assignment.”
From the main study: “An endpoints com-
mittee of physicians who were blinded to
randomized treatment assignment adjudi-
cated all primary and secondary cardiovas-
cular outcome events. Study medications
and end point ascertainment were contin-
ued in a blinded fashion until the sched-
uled end of the trial, July 31, 2005.”
Comment: Physicians were blinded to
treatment assignment in the main study.
The nurses were the assessors in this cog-
nitive substudy and were apparently not
aware of treatment assignment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk In this review, we used outcome data from
the first cognitive assessment (after a mean
of 3.5 years) - this included 2824 of 3170
eligible participants (89%) - and the fourth
cognitive assessment (after a mean of 8.
9 years) - this included 1586 participants
(50%). No information was given about
the treatment assignments of missing par-
ticipants. We considered there to be an un-
clear risk of attrition bias for the first as-
sessment and a high risk for the final assess-
ment
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
Methods were presented in the Results. In
addition, the outcomes specified in the pro-
tocol were reported in the article
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Other bias Low risk No other risks identified
Kesse-Guyot 2011
Methods Substudy of the SU.VI.MAX, a randomised, double-blind, placebo-controlled, primary
prevention trial
Participants Location: France, number of sites not reported for the cognitive substudy
Recruitment: selected French participants aged 45-60 years who were enrolled in the
SU.VI.MAX study (1994-2002). Quote: ”A total of 12,741 individuals were included
for a planned follow-up of 8 y. At the end of the supplementation (2002), a total of 6850
subjects who agreed to participate in a post-supplementation follow-up were included
in the SU.VI.MAX 2 study, which sought to investigate the effect of nutrition on the
quality of aging.“
Sample size:
Number randomised: 6850 of the 12741 people randomised in the SU.VI.MAX study
had agreed to participate in the follow-up study (SU.VI.MAX 2), which included a
cognitive evaluation, but the authors reported only on the 5583 participants who were
aged 45-60 years at the onset of the treatment period
Number completed: 4447 (see Inclusion criteria below*)
Participant (baseline) characteristics:
• Age at baseline: placebo (n = 2071): 52.1 ± 4.6, supplementation (n = 2376): 52.1
± 4.5
• Age at cognitive evaluation: placebo (n = 2071): 65.5 ± 4.6, supplementation (n =
2376): 65.5 ± 4.5
• Male sex: placebo: 52.2% (n = 1080), supplementation: 51.7% (n = 1229)
*Inclusion criteria:Quote: ”Of the 6850 participants in the SU.VI.MAX2 study, for the
current analysis we selected participants who were 45-60 y old at baseline, had undergone
a cognitive evaluation, and had available baseline data for serum antioxidants, smoking
status, and alcohol consumption.“
Exclusion criteria: not reported
Interventions Intervention (n = 2376): daily vitamin C (120 mg), beta-carotene (6 mg), vitamin E (30
mg), selenium (100 µg), and zinc (20 mg) in combination
Comparison (n = 2071): placebo
N.B. Intervention period was 8 years (1994-2002). Cognitive outcomes in SU.VI.MAX
2 were measured in 2007-9, a mean of 5.9 (± 0.4) years after the end of the intervention
in both groups
Outcomes Outcomes of interest in the review:
1. Episodic memory: RI-48 test
2. Executive function: category fluency
3. Speed of processing: time taken to complete the Delis-Kaplan trail-making test
(TMT)
Notes Funding source: ”Supported by the Agence Nationale de Recherche (no. ANR-05-
PNRA- 010), Direction Générale de la Santé (Ministry of Health), Mederic, Sodexo,
Ipsen, the Mutuelle Générale de l’Education Nationale (MGEN), and Pierre Fabre.
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Mederic and MGEN are French health insurance organizations that are complemen-
tary to the national health insurance system. Ipsen and Pierre Fabre are private pharma-
ceutical companies. They provided financial support for the overall implementation of
the research project. Sodexo, a catering company, provided financial support for several
teamwork events with researchers and study participants. Because French public research
is independent, the sponsors were not involved in the analysis or interpretation of the
findings.“
Declarations of interest: ”None of the authors had a conflict of interest“.
Treatment adherence: ”At the end of the trial phase (2002), 84% of the participants
reported having taken at least three-fourths of the capsules independent of the allocated
supplementation group“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random treatment allocation was
performed by block-sequence generation
stratified by sex and age group.”
Comment: Should be adequate, since team
included statisticians and computing staff
who handled the data
Allocation concealment (selection bias) Low risk Quote: “Randomization was concealed
from subjects and all investigators except
for the few who were in charge of capsule
labelling.“
Comment: Should be adequate.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”Capsules were prepared in 52
weekly packages of 7 capsules and delivered
each year in a box labelled with the partic-
ipant’s number and a 10-digit lot number“
”..a matching placebo“.
”The absence of an easy way to distin-
guish antioxidant from placebo capsules
was tested in a pilot study“, ”double-blind“
Comment: Blinding of participants and
personnel seemed adequate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Once a possible event is suspected,
all relevant records,...are collected from the
hospitals, laboratories, or institutions or
from the participants by the SU.VI.MAX
medical investigators and are examined at
the study coordinating centre”
Comment: It was not reported if outcome
assessment was blinded for adverse events.
However, the blinding should be adequate
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for cognitive function since the patients
and investigators were well blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 1136 of 5583 (20%) of the eli-
gible patients were not included in the anal-
ysis because of missing cognitive data
Selective reporting (reporting bias) Unclear risk Comment: Cognitive outcomes were not
mentioned in the protocol of the main
study
Other bias High risk Participants in this study were those who
responded to an invitation 6 years after the
end of the parent study. The authors de-
scribed this subsample of the original trial
population as “more compliant and health
conscious, as shown by the comparison
between included and excluded subjects.”
This may work to reduce any difference be-
tween groups
Kryscio 2017
Methods PREADVISE (Prevention of Alzheimer’s Disease by Vitamin E and Selenium Trial)
Ancillary study to SELECT (primary aim prevention of prostate cancer)
Began as a double-blind RCT in 2002, transformed into a cohort study from 2009-15
Randomised, double-blind, 2 x 2 factorial design
Participants Location: 130 SELECT clinical sites in the US, Canada and Puerto Rico
Recruitment: 7540 non-dementia men already enrolled in SELECT were recruited into
PREADVISE between 2002 and 2008. 7338 had at least one follow-up visit. 4271 con-
sented to continue annual telephone follow-up after the RCT was closed and supple-
ments stopped in 2009/10. Of these, 3786 were screened by telephone at least once
Number randomised: 7540
Participant characteristics:
Age: Mean (SD) 67.5 (5.3) at PREADVISE baseline
Gender: all participants were male
Inclusion criteria: SELECT participants aged 62 years and over (age 60 years if black)
Exclusion criteria: dementia, active neurologic and/or neuropsychiatric conditions that
affect cognition, as well as history of serious head injury (> 30-minute loss of conscious-
ness within the last five years prior to enrolment) and substance abuse
Interventions Supplements were taken for 5.4 ± 1.2 years
2 x 2 factorial design: vitamin E 400 IU/day, selenium 200 mcg/day, placebo
Outcomes Dementia incidence was the primary outcome of PREADVISE.
It was determined by one of two methods. First tier screening was the Memory Impair-
ment Screen (MIS). A score≤ 5/8 triggered a second tier screen which was the expanded
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Consortium to Establish a Registry in Alzheimer’s Disease (CERADe) battery during
the RCT and the modified Telephone Interview for Cognitive Status (TICSm) during
the cohort study
Method 1: Participants with T score ≤ 35 on CERADe or total score ≤ 35 on TICSm
were encouraged to obtain a memory work-up and share medical records with PREAD-
VISE.Medical records were reviewed by a team of 2-3 expert neurologists and 2-3 expert
neuropsychologists to determine a consensus diagnosis
Method 2: Participants who did not obtain a memory work-up were assessed by addi-
tional measures collected during the study: AD8 Dementia Screening Interview, self-re-
ported medical history, self-reported medication use, and cognitive test scores including
the MIS, CERAD T Score, NYU Paragraph Delayed Recall, and TICSm. An AD8 ≥ 1
(at any time during follow-up) plus a self-reported dementia diagnosis, use of a memory
enhancing prescription drug (i.e. donepezil, rivastigmine, galantamine, memantine), or
cognitive score≥ 1.5 standard deviations below expected performance yielded a demen-
tia diagnosis. The diagnosis date was assigned to the earliest event
Notes “PREADVISE was ancillary to SELECT, a randomized controlled trial of the same
antioxidant supplements for preventing prostate cancer. SELECT closed in 2009 due to
a futility analysis.” “The RCT was scheduled to continue supplements until 2012 but in
September 2008, the SELECT Data and Safety Monitoring Committee recommended
that supplements be discontinued due to lack of efficacy on prostate cancer incidence.
Study sites closed over the next two years, during which time both PREADVISE and
SELECT transitioned into cohort studies. RCT participants were asked to continue in
the cohort study ..”
PREADVISE had intended to recruit 10,400 men to achieve 80% power to detect a
hazard ratio of 0.6
Power was reduced by under-recruitment, loss of sites and participants whenRCT closed,
and difficulties with case ascertainment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomized”. No details. Large multisite
cancer prevention trial. Likely adequate
Allocation concealment (selection bias) Low risk No details. Large multisite cancer preven-
tion trial. Likely adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”. No details. Likely ade-
quate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blind”. No details. Likely ade-
quate
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The transition from RCT to cohort study
was associated with loss of approximately
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half the participants to follow-up. “Fortu-
nately ... the major cost was sample size (re-
duction in person-years of follow-up) since
no new large selection biases were intro-
duced.”
“All PREADVISE participants who com-
pleted at least one follow-up visit were in-
cluded in the current analyses (intent-to-
treat analysis, ITT), whether they partici-
pated in just the RCT or both the RCT and
cohort studies.”
Selective reporting (reporting bias) Low risk
Other bias Low risk “... despite randomization occurring at SE-
LECT baseline rather than PREADVISE
enrolment, there were no perceivable dif-
ferences between study arms in terms of
medical history, APOE 4genotype, or ini-
tial MIS.”
Lewerin 2005
Methods 2-arm, double-blinded, parallel group RCT, 4 months treatment and follow-up
Participants Location: one centre, Goteborg, Sweden
Recruitment: outpatient clinic
Number randomised: 126 in intervention, 69 in comparison.
Participant (baseline) characteristics in Vitamin (n = 126) and placebo (n = 69)
Age:
• vitamin 75.7 (± 4.7);
• placebo 75.6 (± 4.0)
• whole group (n = 209) mean age: 76 years and 5 months. Median 76 years (range
70-93)
Gender (males %):
• vitamin: 38% (48/126)
• placebo: 44% (30/69)
Inclusion criteria: community-dwelling subjects. Inclusion criteria not reported
Exclusion criteria: quote: “Those who had taken any vitamin supplements during the
last 3 months or pharmacological doses of vitamin B12, folic acid and/or vitamin B6
during the last 3 years were not allowed to enter the study”
Interventions Intervention (n = 126):
Daily tablet containing 500 µg cyanocobalamin, 800 µg folic acid, and 3 mg vitamin
B6 hydrochloride (manufactured and supplied by Recip AB, Årsta, Sweden)
Comparator group (n = 69): daily oral placebo
The duration of treatment was 4 months.
Use of additional interventions (common to both treatment arms):
Use of cardiovascular medication:
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• vitamin: 47%
• placebo: 49%
Use of antiepileptics, neuroleptics, or antidepressants (%)
• vitamin: 22%
• placebo: 23%
Outcomes Outcomes evaluated: postural-Locomotor-Manual test and cognitive tests
Postural-Locomotor-Manual test:
• Movement time
• Postural phase
• Locomotor phase
• Manual phase
• Simultaneity index
Cognitive tests:
• Digit span forward
• Digit span backward
• Identical forms
• Visual reproduction
• Synonyms
• Block design
• Digit symbol
• Thurstone’s picture memory test
• Figure classification
No clear distinction between primary and secondary outcomes
In Lewerin 2003, cognitive and functional tests not reported in the Methods
Cognitive testing was conducted by the same psychologist at baseline and after 4 months
Follow-up: 4 months (measurements before and after treatment). Mean or median fol-
low-up not reported
Eligible cognitive outcomes:
• executive functioning measured with synonyms at 4 months, on a scale from not
reported to 30 with higher values indicating benefit*
• episodic memory measured with Thurstone’s picture memory test at 4 months,
on a scale from not reported to 28 with higher values indicating benefit
• episodic memory measured with identical forms (Dureman 1959) at 4 months,
on a scale from not reported to 60 with higher values indicating benefit
• episodic memory measured with Wechsler visual reproduction at 4 months, on a
scale from not reported to 14 with higher values indicating benefit*
• working memory measured with Wechsler digit span forward at 4 months, on a
scale from not reported to 9 with higher values indicating benefit
• working memory measured with Wechsler digit span backward at 4 months, on a
scale from not reported to 8 with higher values indicating benefit*
• speed of processing measured with Wechsler digit symbol at 4 months, on a scale
from 0 to 90 with higher values indicating benefit*
• speed of processing measured with Thurstone’s figure classification at 4 months,
on a scale from not reported to 30 with higher values indicating benefit
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
* outcome data used in statistical analyses
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Notes Funding sources, quote: “Supported by grants from the Hjalmar Svensson Foundation,
the Göteborg Medical Society, the Medical Faculty at Göteborg University, theWilhelm
andMartina Lundgren Foundation, and theMagnus Strandqvist Foundation. Recip AB
supported the study and provided the vitamin and placebo tablets”
Declarations of interest, quote: “None of the authors had a personal or financial conflict
of interest with respect to this study“
Treatment adherence: quote ”To ensure compliance, all subjects received a specified
blinded number of tablets, and at the end of the study, the number of remaining tablets
was compared with the initial number and planned intake during the study“
Data on treatment adherence were not clearly reported in the results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Of these 195 subjects, 126 were
randomly assigned to receive vitamin ther-
apy and 69 to receive placebo.”
Comment: method of random sequence
generation not reported
Allocation concealment (selection bias) Unclear risk Quote: “Of these 195 subjects, 126 were
randomly assigned to receive vitamin ther-
apy and 69 to receive placebo.“
Comment: method of allocation conceal-
ment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “and all subjects in the placebo
group received an identical (other than
the vitamin content) placebo tablet. ” To
ensure compliance, all subjects received a
specified blinded number of tablets...“
”The tablet was identical in shape and com-
position to the placebo tablet apart from
the vitamin content“; ”double-blind“ study
Comment: Both participants and physi-
cians were apparently blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Cognitive testing was conducted
by the same psychologist (GS) at baseline
and after 4 mo.”
Comment: Blinding of outcome assessors
was not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “From flow diagram, 30/209
(14%) did not provide cognitive outcome
data.”
Comment: no information about group al-
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location of excluded participants
Selective reporting (reporting bias) Unclear risk Comment: protocol not available
Other bias Low risk Comment: no other risks identified
Maylor 2006
Methods 3-arm, parallel group, randomised, placebo-controlled trial with 6 months duration of
treatment and follow-up
Participants Location:Twocentres (Coleraine,UK andClermont-Ferrand, France) recruited younger
participants (55-70 years) and another two centres (Rome, Italy and Grenoble, France)
recruited older participants (70-87 years)
Recruitment: Participants were recruited through posters, leaflets, local television and
radio, and community groups and organizations serving older individuals living inde-
pendently
Sample size:
Number randomised: 201 younger participants (55-70 years), 232 older participants
(70-87 years)
Number completed study with compliance > 80% and included in analysis: 188
younger, 199 older
Participant baseline characteristics (baseline characteristics provided only for study
completers):
Age in years, mean (SD):
• 15 mg/d: younger 61.4 (4.55), older 74.3 (3.91)
• 30 mg/d: younger 61.7 (4.57), older 74.6 (3.89)
• placebo: younger 62.3 (4.09), older 74.2 (3.58)
Gender, males/females:
• 15 mg/d: younger 30/30, older 34 /32
• 30 mg/d: younger 31/34, older 34 /32
• placebo: younger 32/31, older 35 /32
Inclusion criteria:
1. men and women aged between 55 and 87 years;
2. BMI between 20 and 30 kg/m2
3. good health;
4. MMSE score greater than 23;
5. geriatric depression scale score less than 6.
Exclusion criteria:
“Participants were excluded from further involvement in the study according to the fol-
lowing criteria: (l) tobacco consumption of more than 10 g/day; (2) alcohol consump-
tion of more than 30 (men) or 20 (women) g/day; {3) unconventional dietary habits
(for example, vegetarians, vegans); (4) use of a mineral supplement during the preceding
3 months; (5) use of more than three (55-70 years) or four (70-87 years) prescription
drugs per day; (6) use of antidepressants, laxatives, or hormone replacement therapy;
(7) pathological diseases, including cancer and diabetes. For participants satisfying the
inclusion criteria, a biochemistry profile was performed, which included a full blood
profile and tests of kidney and liver function. On the basis of these data, participants
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were excluded if there was insufficient renal and hepatic performance, malabsorption or
inflammatory chronic pathologies, and were included if there was negative serology for
the HIV and hepatitis C viruses.”
Quote: “49 % of the initial 842 volunteers being excluded from the study at screening
on the basis of cognitive impairment, depression, pathological conditions, medications,
and so on”
Interventions Intervention
Intervention A: Zn supplementation as zinc gluconate 15 mg/day, two tablets at the
same time each day (usually after breakfast) for 6 months
Intervention B: Zn supplementation as zinc gluconate 30 mg/day, two tablets at the
same time each day (usually after breakfast) for 6 months
Comparator group: placebo/zinc gluconate 0 mg/day, two tablets at the same time each
day (usually after breakfast) for 6 months
Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes: Cognitive measures (Cambridge Automated Neuropsychological
Test Battery, CANTAB)
Visual memory was tested by pattern recognition memory; working memory was tested
by spatial span and spatial working memory (SWM); and attention was tested by reaction
time and matching to sample visual search (MTS)
Quote: “Cognitive Function was assessed in the laboratory at baseline (before supple-
mentation) and after 3 and 6 months of supplementation, using different (parallel) ver-
sions of the CANTAB tests on each occasion.“
Secondary Outcomes: serum and urinary zinc
Quote: “Participants fasted overnight for 12h before blood and urine samples were taken
on each of these occasions to determine Zn levels.”
Notes Funding sources, quote: “European Commission ’Quality of Life and Management of
Living Resources’ Fifth Framework Programme. contract no. QLKl-CT-2001-00168.”
Declarations of interest: not reported
Treatment adherence
“Compliance was less than 80% for three older participants and so they were also ex-
cluded.”
Outcome data were not reported separately for the Zinc and placebo groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Participants were assigned to one
of three levels of Zn supplementation
(placebo or 0 mg/d, 15 mg/d and 30 mg/
d) according to the same standardised ran-
dom order in each centre.“
Comment: not described how sequence
generation was done. The possibility that
this was quasi-randomised could not be
ruled out
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Allocation concealment (selection bias) Unclear risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “…Zn supplementation (0, 15 or
30 mg/d) was administered as zinc glu-
conate, participants taking two tablets at
the same time each day (usually after break-
fast) for 6 months. (Tablets were identified
by a code so that neither the experimenter
nor the participants knew the dose. The
code was not broken until the study had
been completed and all the data had been
entered into computer files ready for anal-
ysis)”
Comment: Although a placebo was men-
tioned, there was no description of its ap-
pearance or whether it could be distin-
guished from the zinc supplements
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: as above. Unclear whether
blinding was adequate
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There was no description of
the completeness of outcome data for each
main outcome, including attrition and ex-
clusions from the analysis
Selective reporting (reporting bias) High risk Comment: CANTABdata for the different
interventional groups was shown graphi-
cally only. Number of participants for each
outcome was not reported
Other bias Unclear risk Baseline characteristicswere shownonly for
participants who completed the trial
McMahon 2006
Methods 2-arms, placebo-controlled, randomised clinical trial with intervention of 2 years and
follow-up duration of 2 years. No mean or median (range) follow-up reported
Participants Location: Dunedin, New Zealand, number of centres involved unclear
Recruitment: Department of Human Nutrition, University of Otago
Number randomised: 138 in intervention, 138 in comparison
Participant (baseline) characteristics:
Age, years, mean (SD)
• placebo (n=126): 73.4 ± 5.7
• vitamin (n=127): 73.6 ± 5.8
Female sex, n (%):
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• placebo (n=126): 65 (52)
• vitamin (n=127): 47 (37)
Inclusion criteria:· age of 65 years or older. Those with a fasting homocysteine concen-
tration of at least 13 µmol/L and a normal plasma creatinine concentration (133 µmol/L
(1.5 mg/dL) in men and 115 µmol/L (1.3 mg/dL) in women) were invited to participate
in the trial
Exclusion criteria:
• ineligible if they had suspected dementia;
• were taking medications known to interfere with folate metabolism (e.g. oral
hypoglycaemic agents or antiepileptic agents);
• were taking vitamin supplements containing folic acid, vitamin B12, or vitamin
B6;
• were being treated for depression;
• had diabetes or had a history of stroke or transient ischaemic attacks.
Quote: “Five participants (three in the placebo group and two in the vitamin group) had
a baseline MMSE score of less than 26.”
Interventions Intervention (n=138):
Treatment capsules contained the filler plus 1000 µg of folate (the calcium salt of l-5-
methyltetrahydrofolate), 500 µg of vitamin B12 (cobalamin), and 10 mg of vitamin B6
(pyridoxine) (Merck Eprova)
Comparator group (n=133): placebo.
The placebo capsules contained a blend of magnesium stearate and microcrystalline
cellulose as a filler
All capsules were gelatin-coated, identical in colour and shape, and packaged in blister
packs
Outcomes Primary outcomes: scores on tests of cognition including Mini-Mental State Examina-
tion, Wechsler Paragraph Recall test, Category Word Fluency test, Rey Auditory Verbal
Learning Test, trials I-V, Rey Auditory Verbal Learning Test, trial VII, Raven’s Progressive
Matrices, Controlled Oral Word Association Test, Part B of the Reitan Trail Making
Test, the National Adult Reading Test (at baseline)
Secondary Outcomes: biochemical measurements, including plasma concentrations of
homocysteine, folate, and vitamin B12
Eligible cognitive outcomes:
• global cognitive function measured with MMSE at 1 and 2 years, with higher
values indicating benefit
• executive functioning measured with Raven’s Progressive Matrices at 1 and 2
years, with higher values indicating benefit
• executive functioning measured with Part B of the Reitan Trail Making at 1 and 2
years, with lower values indicating benefit
• executive function measured with Category Word Fluency test (total no. of words
generated in three 1-min tests) at 1 and 2 years, with higher values indicating benefit
• episodic memory measured with Rey Auditory Verbal Learning, Trials I-V at 1
and 2 years, with higher values indicating benefit*
• episodic memory measured with Wechsler Paragraph Recall test at 1 and 2 years,
with higher values indicating benefit
• episodic memory measured with Rey Auditory Verbal Learning, Trial VII at 1 and
2 years, with higher values indicating benefit
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Notes Funding sources: supported by an Otago Research Grant, Merck Eprova for providing
the vitamin and placebo capsules
Declarations of interest: No potential conflict of interest relevant to this article was
reported
Treatment adherence:
Compliance was assessed by counting returned capsules. Data on compliance were not
reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Before randomization, all eligi-
ble participants were stratified according to
the median values for age and homocys-
teine concentration in the screening pop-
ulation. Random decimals between 0 and
1 were generated for each person in each
of the four strata. Those below the median
of the random numbers in each stratum
were assigned to the vitamin group, and
the remainder were assigned to the placebo
group.”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Unclear risk Quote: “Random decimals between 0 and
1 were generated for each person in each
of the four strata. Those below the median
of the random numbers in each stratum
were assigned to the vitamin group, and
the remainder were assigned to the placebo
group.”
Comment: unclear method of allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “We conducted a two-year, dou-
ble-blind, placebo-controlled, randomized
clinical trial”
“All capsules were gelatin-coated, identical
in color and shape, and packaged in blister
packs.”
Comment: Participants andpersonnel were
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “One of the authors administered
all the cognitive tests.”
Comment: unclear whether outcome as-
sessment was blinded
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: < 10% of randomised patients
were not included in the analysis
Selective reporting (reporting bias) Low risk Comment: All the primary and secondary
outcomes mentioned in the Methods and
protocol were reported
Other bias Low risk Comment: none identified
MRC/BHF 2002
Methods 2 x 2 factorial randomised placebo-controlled study of antioxidant vitamins and simvas-
tatin. Mean duration of follow-up 5 years
Participants Location: 69 Hospitals in the UK
Recruitment: Medical collaborators from 69 UK hospitals appointed senior nurses to
run special clinics for the study. With the permission of their relevant consultant col-
leagues, records of patient discharges and of special wards or clinics were used to identify
potentially eligible candidates for the study. The coordinating centre used this informa-
tion to seek agreement, in the name of the local collaborator, from general practitioners
to invite patients to the local study clinic
Sample size:
• Number randomised: 10,269 in intervention, 10,267 in comparison
• Number completed: 10,241 in intervention, 10,228 in comparison
Participant (baseline) characteristics:
Inclusion criteria:
1. Male or female aged 40 to 80 years;
2. High risk of coronary heart disease death over the next 5 years:
◦ (i) coronary disease: definite or probable clinical diagnosis of myocardial
infarction, unstable angina, stable angina, PTCA or CABG;
◦ (ii) occlusive disease of non-coronary arteries: clinical, angiographic, or
ultrasound diagnosis of carotid artery stenosis (e.g. transient ischaemic attack or non-
disabling stroke not thought to be haemorrhagic), carotid endarterectomy, leg artery
stenosis (e.g. intermittent claudication) or surgery;
◦ (iii) diabetes mellitus: clinical diagnosis of insulin-dependent or non-insulin-
dependent diabetes;
◦ or (iv) treated hypertension: use of antihypertensive drug therapy in male
aged 65 years or over (in order to be at sufficiently high risk of vascular events);
3. No clear indications for the study treatments: the patient is not already taking
HMG CoA reductase inhibitors or high-dose vitamin E supplements, and neither the
patient nor the patient’s doctor considers there to be any definite need to do so;
4. No clear contraindications to the study treatments:
◦ (i) baseline plasma cholesterol: < 3.5mmol.L−1;
◦ (ii) chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function
(i.e. alanine transaminase > 1·5 x upper limit of normal);
◦ (iii) severe renal disease or evidence of renal impairment (i.e. creatinine > 2 x
upper limit of normal);
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◦ (iv) inflammatory muscle disease (such as dermatomyositis or polymyositis)
or creatine kinase > 3 x upper limit of normal;
◦ (v) concurrent treatment with cyclosporin (or a condition likely to result in
organ transplantation and the need for cyclosporin);
◦ (vi) concurrent treatment with fibrates or high-dose niacin. (N.B. patients
on cholesterol-lowering diets or drugs - other than HMG CoA reductase inhibitors,
fibrates or high-dose niacin - could still be entered in the study);
◦ or (vii) child-bearing potential (i.e. premenopausal woman who is not
sterilised or using a reliable method of contraception);
5. No other predominant medical problem:
◦ (i) severe heart failure or some importantly life-threatening condition other
than vascular disease (such as very severe chronic airways disease or any cancer other
than non-melanoma skin cancer);
◦ (ii) psychiatric disorder, senility or physical disability (such as severely
disabling stroke);
◦ Or (iii) recent history of alcohol or drug abuse;
6. Eligible patients who completed a pre-randomisation run-in phase on active
treatment were randomly allocated to receive simvastatin (40 mg daily) or matching
placebo tablets and, in a ‘2 x 2 factorial’ design, antioxidant vitamins (600 mg vitamin
E, 250 mg vitamin C, and 20 mg beta-carotene daily) or matching placebo capsule.
Exclusion criteria:
People were ineligible if they had life-threatening conditions, such as chronic liver dis-
ease, severe renal disease, severe heart failure, severe chronic airways disease, or diagnosed
cancer (other than non-melanoma skin cancer). Those taking high-dose vitamin E sup-
plements were not randomised
Interventions Intervention (n=10,241): 600 mg synthetic vitamin E, 250 mg vitamin C and 20 mg
β-carotene administered orally once per day for an average of 5 years
Comparator group (n=10,228): “Matching placebo in specially prepared calendar
packs”
Use of additional interventions (common to both treatment arms): factorial design
also included simvastatin
Outcomes Outcomes of interest in the review:
Global cognitive function measured with TICSm
(The main comparisons for antioxidant vitamin supplementation were analyses of total
coronary heart disease events and of fatal coronary heart disease events during the sched-
uled treatment period. Cognitive function was a secondary outcome. Quote: ”It had
been suggested that antioxidant vitamins (in particular, vitamin E) might slow cognitive
decline, so the modified Telephone Interview for Cognitive Status (TICS-m) question-
naire was administered to participants during their final follow-up“)
Notes Funding sources: “The study was funded by the UK Medical Research Council, the
British Heart Foundation, Merck & Co (manufacturers of simvastatin: J Tobert, R To-
miak, J Young, A Tate, E John, F Walker, G Warner) and Roche Vitamins Ltd (manu-
facturers of the vitamins: R Salkeld, E Stöcklin, M Wahl).”
Declarations of interest: “P Sleight has received honoraria and costs for participating
in meetings.”
Treatment adherence: Compliance with study treatment was assessed at each follow-up
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by reviewing the calendar packed capsules remaining and for those who had stopped,
the reasons for doing so were sought
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The central telephone randomisa-
tion system used a minimisation algorithm
to balance the treatment groups with re-
spect to eligibility criteria and other major
prognostic factors.”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Comment: “central telephone randomisa-
tion system”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: “identical tablets”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:Outcome assessors at study cen-
tres not aware of treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Relatively low dropout rate and
high number of participants completed fol-
low-up at 5 years
Selective reporting (reporting bias) Low risk Comment: single cognitive outcome mea-
sure reported
Other bias Low risk Comment: no other risks identified
Rossom 2012
Methods Women’s Health Initiative Memory Study
Post hoc analysis of a 2-arm randomised double-blind placebo-controlled trial
Participants Location: US multicentre
Recruitment: Forty Women’s Health Initiative (WHI) clinical centres across the United
States. Participants were enrolled between 1994 and 1999
Number randomised: 2034 in intervention, 2109 in comparison
Participant (baseline) characteristics:
• Age: mean 71 years (65-80)
◦ vitamin D/calcium: mean 70.7 years
◦ placebo: mean 70.9 years
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• Gender: women 100%
• Main diagnosis: postmenopausal women aged 65 and older without probable
dementia or cognitive impairment at baseline
Inclusion criteria: women aged 65 and older without probable dementia or cognitive
impairment at baseline who participated in the WHI Calcium and Vitamin D Trial
Other inclusion criteria specified in the main study: Eligible women were 50 to 79 years
of age at the initial screening and had no evidence of a medical condition associated with
a predicted survival of less than three years and no safety, adherence, or retention risks
Exclusion criteria: diseases associated with significant risk of mortality (invasive cancer
in the previous 10 years; any history of breast cancer or a suspicion of breast cancer at the
time of screening; acute myocardial infarction, stroke, or transient ischaemic attack in
the previous 6 months; known chronic active hepatitis or severe cirrhosis), safety (blood
cell count indicative of disease, severe hypertension, current use of oral corticosteroids)
, and adherence or retention (unwillingness or inability to complete baseline study re-
quirements)
Interventions Intervention (n=2034):
1000 mg of calcium carbonate and 400 IU of vitamin D3
Two tablets per day in divided doses and with meals
Comparator group (n=2109): placebo
Two tablets per day in divided doses and with meals
Supplements or placebo were provided by GlaxoSmithKline.
Active tablets, chewable or swallowable (after July 1997), contained 500 mg of elemental
calcium (as calcium carbonate) and 200 IU of vitamin D
Use of additional interventions (common to both treatment arms):
Use of personal supplemental calcium up to 1000 mg/day and vitamin D up to 600 IU/
day in addition to the study tablets was allowed
Calcium supplement use, n (%):
• vitamin D/calcium: 1061 (52.2)
• placebo 1196 (56.7)
Vitamin D supplement use, n (%):
• vitamin D/calcium: 929 (45.7)
• placebo 1047 (49.6)
See also Notes below
Outcomes Outcomes of interest to the review:
Quote: “The Women’s Health Initiative Calcium and Vitamin D trial (CaD) was de-
signed to determine whether calcium plus vitamin D3 supplementation prevents hip
fracture and colorectal cancer”
WHIMS (the Women’s Health Initiative Memory Study) was an ancillary study
Primary outcomes of WHIMS: classifications of probable dementia, mild cognitive
impairment and cognitively normal
Quote: “A diagnosis of dementia was based on Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, criteria.”
Quote: “A diagnosis of MCI was based on accepted criteria at the time of WHIMS
initiation, operationally defined as performance in the 10th or lower percentile on at least
one Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) test based on
CERAD norms, a report from the designated informant of functional impairment on
the part of the participant that was not severe enough to interfere with basic activities
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of daily living, no evidence of a psychiatric or medical condition that could account for
the cognitive decline, and absence of adjudicated dementia.”
Secondary outcomes: global cognitive function as assessed annually using the Modi-
fied Mini Mental State Examination (3MS) and domain-specific cognitive functions as
assessed annually in a subset of 1420 CaD participants using the WHISCA cognitive
battery
The WHISCA cognitive battery included the Digit Span Forward and Backward Test,
the PrimaryMental Abilities Vocabulary test, theCardRotationsTest, letter and semantic
fluency tests, the California Verbal Learning Test, the Benton Visual Retention Test, and
the Finger Tapping Test
Depressive symptoms were measured using the Burnham screening algorithm
Probable dementia or MCI were assessed during a mean follow-up of 7.8 years
Domain-specific measures of cognitive function were obtained in the 1420 women
enrolled in the CaD trial and WHISCA seen for an average of 4.9 (treatment) and 5.0
(placebo) annual visits through 2007
Eligible cognitive outcomes:
• global cognitive function measured with Modified MMSE (3MS)
• episodic memory measured with Benton Visual Retention Test
• episodic memory measured with California Verbal Learning Test
• speed of processing measured with finger tapping
• executive function measured with letter and category fluency at 5 years
Notes “AllWHIMS participants ... were also participants in theWHIHormone Therapy trials.
Some were also participants in a third trial of dietary modification to compare a low-fat
eating pattern to a usual ad-libitum diet.”
Funding sources, quote: “The WHI program is funded by the National Heart, Lung,
and Blood Institute, National Institutes of Health, U.S. Department of Health and
Human Services through Contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-
9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221.”
“Sponsor’s Role: The sponsors did not play any role in the design or conduct of the
study; collection, management, analysis, or interpretation of the data; or preparation,
review, or approval of the manuscript”
Declarations of interest, quote: “Dr. Rossom’s work on this manuscript was supported
in part by the Veterans Health Administration through Clinical and Health Services Re-
search and Development Grants 04SCRCOE-001 and HFP-98-001. Dr. JoAnn Man-
son and colleagues at Brigham and Women’s Hospital, Harvard Medical School, are
recipients of funding from the National Institutes of Health to conduct the VITamin D
and OmegA-3 TriaL, a large-scale randomized trial of vitamin D and omega-3s in the
prevention of cancer and cardiovascular disease”
Treatment adherence
“Adherence was assessed annually in a structured interview and by weighing remaining
pills.”
Adherence (defined as ≥ 80%):
• vitamin D/calcium: 1446 (72.3%)
• placebo: 1566 (75.5%)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “Eligible womenwere randomly as-
signed in a double-blind fashion to receive
supplements or placebo (provided byGlax-
oSmithKline) in equal proportionswith use
of a permuted-block algorithm stratified
according to clinical center and age“
Comment: method of random sequence
generationnot reported, probably adequate
Allocation concealment (selection bias) Unclear risk Quote: “Eligible womenwere randomly as-
signed in a double-blind fashion to receive
supplements or placebo (provided byGlax-
oSmithKline) in equal proportionswith use
of a permuted-block algorithm stratified
according to clinical center and age”
Comment: method of allocation conceal-
ment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “1,000 mg of calcium carbonate
and 400 IU of vitamin Dor identical place-
bos.“ , “Eligible women were randomly as-
signed in a double-blind fashion”
Comment: Participants andpersonnel were
apparently blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “A central adjudication panel of ex-
perts at theWHIMSClinical Coordinating
Center (Wake Forest School of Medicine,
Winston-Salem, NC) made classifications.
“
Comment: not reported but assessors were
probably blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All primary outcomes were ana-
lyzed on a time to-event basis according to
the intention-to-treat principle.”
Comment: All patients included in the post
hoc analysis were considered for the main
outcome whereas only a subset was anal-
ysed for cognitive tests
Selective reporting (reporting bias) Low risk Comment: All outcomes described in the
methods or protocol (ClinicalTrials.gov
number, NCT00000611) were reported in
the results
Other bias Low risk No other risks identified
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Methods 2 x 2 factorial placebo-controlled randomised trial
Participants Location: UK multicentre
Recruitment: potentially eligible patients identified from hospital discharge records of
88UKhospitals. Randomisation took place between September 1998 andOctober 2001
Number randomised: 6033 B vitamins, 6031 placebo
Participant (baseline) characteristics:
• Age: mean age 64.2 (8.9) years
◦ B vitamins: 1885 < 60y; 2414 ≥ 60y and < 70y; 1734 ≥ 70y
◦ placebo: 1880 < 60y; 2414 ≥ 60y and < 70y; 1737 ≥ 70y
• Gender:
◦ B vitamins: 83% male
◦ placebo: 83% male
• Main diagnosis: myocardial infarction
Inclusion criteria: aged 18-80 years, myocardial infarction > 3months before screening,
taking a statin or clear indication for statin therapy
Exclusion criteria: clear indication for folic acid, contraindications to study treatments,
other predominant medical problem which might limit compliance with 5 years of study
treatment
Interventions Participants randomised in 2 x 2 factorial design to (folic acid 2mg + vitamin B12 1mg)
or placebo and to simvastatin 20 mg or 80 mg
Outcomes Outcomes relevant to this review: TICSm, verbal fluency test, diagnosis of dementia. All
cognitive outcomes measured at final follow-up, after a mean of 6.7 (1.5) person-years
Notes “The study was funded by Merck (manufacturers of simvastatin and suppliers of the
vitamins).” “The funders had no role in the design and conduct of the study; collection,
management, analysis and interpretation of the data; and preparation, review and ap-
proval of the manuscript.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The central telephone randomiza-
tion system used a minimization algorithm
to balance the treatment groups with re-
spect to major prognostic factors”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Quote: “central telephone randomisation
system”
Comment: adequate method of allocation
concealment
Blinding of participants and personnel
(performance bias)
Unclear risk Comment: no information regarding par-
ticipants and personnel blinding
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All outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All such information is reviewed
by coordinating center clinical staff, blind
to study treatment allocation, and events
are coded according to prespecified criteria”
Comment: outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: For 3173/12064 (26%) of the
eligible patients, TICSm was not available
Selective reporting (reporting bias) Low risk Comment: no cognitive outcomes were in-
cluded in the original protocol published
in 1998. Additional information was ob-
tained from the authors: “The cognitive as-
sessment was added during the study (be-
fore any unblinding) and included in the
Data Anaysis Plan but had not been spec-
ified in the original Protocol.” We consid-
ered there to be a low risk of this introduc-
ing any bias
Other bias Low risk Comment: no other risks identified
Stott 2005
Methods Factorial 2 X 2 x 2, randomised, placebo-controlled, double-blind study with 3 active
treatments with 12-week treatment and 1-year follow-up
Participants Location: United Kingdom and the Netherlands, 2 centres
Recruitment: hospital-based
Number randomised: 185
Participant (baseline) characteristics:
• Age, mean ± SD:
◦ placebo: 72.8 ± 5.4
◦ folic acid plus vitamin B12: 72.9 ± 6.0
◦ riboflavin (vitamin B2): 74.6 ± 5.3
◦ vitamin B6: 74.7 ± 6.1
◦ folic acid plus vitamin B12 plus vitamin B2: 76.5 ± 8.0
◦ folic acid plus vitamin B12 plus vitamin B6: 72.6 ± 6.4
◦ vitamin B6 plus vitamin B2: 74.2 ± 6.8
◦ folic acid plus vitamin B12 plus vitamin B2 plus vitamin B6: 74.0 ± 6.5
• Gender (male/female):
◦ placebo: 14/10
◦ folic acid plus vitamin B12: 12/11
◦ riboflavin (vitamin B2): 10/13
◦ vitamin B6: 11/12
◦ folic acid plus vitamin B12 plus vitamin B2: 10/13
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◦ folic acid plus vitamin B12 plus vitamin B6: 12/11
◦ vitamin B6 plus vitamin B2: 10/13
◦ folic acid plus vitamin B12 plus vitamin B2 plus vitamin B6: 9/14
• ·Main diagnosis: patients aged ”65 y with ischemic vascular disease“
Inclusion criteria: age ≥ 65 y and Ischaemic vascular disease, defined as one or more of
the following: history of angina pectoris, previous acute myocardial infarction, evidence
of major ischaemia or previous acute myocardial infarction on the basis of a 12-lead elec-
trocardiogram, ischaemic stroke, transient ischaemic attack, intermittent claudication,
or surgery for peripheral arterial disease
Exclusion criteria: acute vascular event < 1 wk previously; major surgery < 1 mo previ-
ously; any other major acute illness < 1 mo previously; severe renal impairment (serum
creatinine > 400 µmol/L); severe hepatic impairment; malignancy within the previous
year (excluding local skin cancer); severe congestive heart failure (New York Heart As-
sociation class IV); total anterior cerebral infarct with major residual disability; malab-
sorption; inability to give informed consent (e.g. due to dementia or dysphasia); major
cognitive impairment (Mini-Mental State Examination score < 19); existing treatment
with riboflavin, vitamin B6, vitamin B12, or folic acid preparations; haemoglobin con-
centration < 10 g/dL; and mean cell volume > 100 fL plus either a low red blood cell
folate concentration (< 280 ng/mL) or a low serum vitamin B12 concentration (< 250
pg/mL)
Interventions Intervention:
Folic acid 2.5 mg plus vitamin B12 400 mcg; vitamin B6 25 mg; riboflavin (vitamin
B2) 25 mg; placebo in a 2 x 2 x 2 factorial design
1. folic acid plus vitamin B12: 23
2. vitamin B6: 23
3. riboflavin (vitamin B2): 23
4. folic acid plus vitamin B12 plus vitamin B2: 23
5. folic acid plus vitamin B12 plus vitamin B6: 23
6. vitamin B6 plus vitamin B2: 23
7. folic acid plus vitamin B12 plus vitamin B2 plus vitamin B6: 23
Comparator: placebo: 24
Intervention or placebo were continued for 12 weeks. The daily dose was provided in a
total of 2 capsules (1 red and 1 white), irrespective of patient group
Quote: ”The patients initially entered a single-blind, placebo, run-in phase lasting be-
tween 2 and 4 weeks. Patients who successfully completed the run-in phase were ran-
domly allocated“
Use of additional interventions (common to both treatment arms): not reported
Outcomes Overall cognitive function was assessed by using the Telephone Interview for Cognitive
status (TICSm) at both baseline visits and at 6 and 12 months; attention and speed
of information processing were assessed by using the Letter Digit Coding Test (at both
baseline visits and 12 months)
Serious adverse events, including incident vascular events, were recorded at each review
Notes Funding sources, quote: “Supported by a grant from the Healthcare Foundation (ref-
erence 112/57).”
Declarations of interest, quote: “None of the authors had any conflicting or competing
interests, and the funder of the study had no role in data collection, analysis, or inter-
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pretation of the data or in the writing of the report.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Allocation was determined at a site
remote from the clinical study (Robertson
Centre for Biostatistics) in randomized per-
muted blocks of 8, stratified by hospital
center.”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Quote: “Allocation was determined at a site
remote from the clinical study (Robertson
Centre for Biostatistics) in randomized per-
muted blocks of 8, stratified by hospital
center.“
Comment: adequate method of allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Treatment allocation was con-
cealed from the patients and the investiga-
tors (double-blind).”
Comment: adequate method of partici-
pants and personnel blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Treatment allocation was con-
cealed from the patients and the investiga-
tors (double-blind).“
Comment: adequate method of outcome
assessment blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Numbers of participants miss-
ing outcome data calculated from tables.
18/185 (10%)missing data for TICSm at 1
year. 39/185 (21%)missingdata for LDCT
at 1 year. Dropouts not mentioned in pa-
per. No reasons for missing data given. Pre-
sumed completers analysis
Selective reporting (reporting bias) High risk Quote: from ISRCTN registry “Retrospec-
tively registered”
“Primary outcome measures:
1. SerumHCY, plasma vonWillebrand fac-
tor, vitamin levels (red cell folate, serum vi-
tamin B12, B2, and B6)
2. Piloting of telephone follow-up of cog-
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nition (Telephone Interview for Cognitive
Status (TICSm)) and of disability (Barthel
Index and short Instrumental Activities for
Daily Living (ADL) scale). Secondary out-
comemeasures: not provided at time of reg-
istration.”
Comment: Disability and IADL (relevant
to this review) not reported in paper
Other bias Low risk Comment: no other risks identified
Toole 2004
Methods 2-arm, parallel group, double-blind, randomised controlled trial (the Vitamin Interven-
tion for Stroke Prevention (VISP) Trial)
Participants Location: 56 centres in USA, Canada and Scotland
Recruitment: university-affiliated hospitals, community hospitals, private neurology
practices, and Veterans Affairs medical centres
Number randomised: 3680 (1853 in low-dose vitamin group, 1827 in high-dose vita-
min group)
Participant (baseline) characteristics:
• Age, mean (SD):
◦ low-dose: 66.2 (10.8)
◦ high-dose: 66.4 (10.8)
• Gender:
◦ low-dose: 37.2% female
◦ high-dose: 37.7% female
• Baseline cognitive function, MMSE mean (SD):
◦ low-dose: 26.9 (3.3)
◦ high-dose: 26.9 (3.4)
Inclusion criteria: non-disabling ischaemic stroke (Modified Rankin Stroke Scale ≤ 3)
with onset≤ 120 days before randomisation; total homocysteine level≥ 25th percentile
for North American stroke population; age ≥ 35 years, compliance ≥ 75% with low-
dose vitamins for 1 month before randomisation
Exclusion criteria: potential sources of emboli, other major neurological illness, life
expectancy < 2 years, untreated anaemia or untreated B12 deficiency, systolic blood
pressure > 185 mmHg or diastolic blood pressure > 105 mmHg, refractor depression,
severe cognitive impairment, alcoholism or other substance abuse, use within 30 days of
medications that affect total homocysteine level, childbearing potential, participation in
another trial with active intervention, general anaesthesia or hospital stay of ≥ 3 days,
invasive cardiac or carotid procedures within 30 days of randomisation
Interventions Intervention (n=1827)
High-dosemultivitamin formulation contained the reference daily intakes recommended
by the US Food and Drug Administration for vitamins except for its content of folic
acid, vitamin B6 and vitamin B12. Folic acid 2.5 mg, vitamin B6 25 mg, vitamin B12
0.4 mg
Comparator (n=1853)
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Low-dose multivitamin formulation contained the reference daily intakes recommended
by the US Food and Drug Administration for vitamins (contained folic acid 20 µg,
vitamin B6 0.2 mg, vitamin B12 6 µg)
Outcomes Outcomes relevant to review:
mean MMSE at 1-year follow-up
Notes “All eligible participants were given the low-dose vitamin formulation for 1 month to
determine compliance, assessed by pill counts. Only persons taking at least 75% of the
vitamins during the run-in phase were eligible to be randomized.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were randomized to
the high-dose or low-dose vitamin groups
within strata defined by clinic, sex and age
(≥ 70 years, < 70 years). Permuted block
randomization (with block size randomly
selected as 4 or 6) was used.”
Allocation concealment (selection bias) Low risk Quote: “The allocation of participants was
programmed by the statistical coordinating
center, encrypted, and entered into a data
entry program installed on a study com-
puter at each site. After computer verifi-
cation that all eligibility criteria had been
met, participants were randomly assigned
1 of 20 medication codes. Allocation in-
formation was accessible only to the drug
distribution center, which bottled and dis-
tributed the vitamins to clinics, and to se-
lected coordinating center personnel who
could assist with randomization in case of
computer failure.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both pill formulationsweremanu-
factured (Magno-Humphries Laboratories,
Tigard, Ore) to be indistinguishable by ex-
ternal colour, weight or dissolution in wa-
ter. No request was ever made to break the
blind.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Both pill formulationsweremanu-
factured (Magno-Humphries Laboratories,
Tigard, Ore) to be indistinguishable by ex-
ternal colour, weight or dissolution in wa-
ter. No request was ever made to break the
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blind.” No information specifically on site
investigators. Blind probably maintained
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Mean MMSE score available for 3097/
3680 (84.2%) participants at 1-year fol-
low-up. No information on missing partic-
ipants, including group allocation
Selective reporting (reporting bias) High risk Protocol-specified MMSE at 24 months
not reported. Number of participants with
MMSE score in each treatment group at 12
months not reported
Other bias Low risk No other risks identified
Van der Zwaluw 2014
Methods Multicentre, double-blind, randomised, placebo-controlled trial, with 2-year duration
of treatment and 2-year duration of follow-up
Participants Location: 3 research centres in the Netherlands: VU University Medical Center (Ams-
terdam), Erasmus Medical Center (Rotterdam), and Wageningen University (WU, Wa-
geningen)
Recruitment: Dutch elderly men and women who participated in the B-PROOF (B-
Vitamins for the Prevention of Osteoporotic Fractures) study which assessed the efficacy
of oral supplementation with 400 µg folic acid and 500 µg vitamin B in the prevention
of fractures, with cognitive performance as secondary outcome
Most participants were recruited via registries of municipalities in surroundings of the
research centres
The study was conducted between October 2008 and March 2013.
Number randomised: 1516 in intervention, 1511 in comparison
Participant (baseline) characteristics:
• Age (mean, SD):
◦ total population (n=2919): 74.1 years (6.5)
◦ cognitive sub-sample (n=856):
⋄ B vitamin (n=425): 72.6 years (5.7)
⋄ placebo (n=431): 72.6 years (5.8)
• Gender (males, n %):
◦ total population (n=2919): 1459 (50)
◦ cognitive sub-sample (n=856):
⋄ B vitamin (n=425): 244 (57)
⋄ placebo (n=431): 255 (59)
• Main diagnosis: not reported
Inclusion criteria: age 65 years or older, having an elevated plasma homocysteine level
(12-50 µmol/L), being competent to make own decisions, and having a compliant tablet
intake (≥ 85%) in the run-in period
Exclusion criteria: cancer diagnosis within the last 5 years except for basal cell carcinoma
and squamous cell carcinoma, bedridden, serum creatinine level > 150 µmol/L, current
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or recent (< 4 months) use of intramuscular injections of vitamin B12 or folic acid
supplementations (> 300 µmol), and participation in other intervention studies
6% of the study population had a MMSE < 25.
Interventions Intervention (n=1516):
B vitamin group: 400 µg folic acid and 500 µg vitamin B12 daily
Comparator group (n=1511): placebo.
Treatment was continued for 2 years.
Use of additional interventions (common to both treatment arms): Both tablets
contained 15 µg (600 IU) vitamin D3.
Outcomes Outcomes of interest in review:
Quote: “The primary goal of the B-PROOF study was [to] assess the efficacy of oral
supplementation with folic acid and vitamin B12 in the prevention of fractures, with
cognitive performance as a secondary outcome.”
The ’primary’ outcome of the cognitive study was “the difference between treatment
groups in performance on episodic memory after 2 years of supplementation.”
’Secondary’ cognitive outcomes were “differences in performance at follow-up on atten-
tion and working memory, information processing speed, executive function, and single
test scores.”
Quote: “Cognitive performance was assessed at baseline and at the end of the interven-
tion period by well-trained research assistants following a standard protocol. We used
the MiniMental State Examination (MMSE) and an extensive, sensitive, and validated
neuropsychological test battery” ..that “consisted of the Rey Auditory Verbal Learning
Test (RAVLT), Digit Span forward and backward, Trail Making Test (TMT) parts A
and B, Stroop Color-Word Test, Symbol Digit Modalities Test, and Letter Fluency (3
letters)”
Quote: “To compare results of the individual cognitive tests and to limit the number
of dependent variables, crude test scores were clustered into compound scores for the 4
neuropsychological domains”
“For all 4 cognitive domains, predefined interaction terms of treatment with sex, baseline
age (< 80, ≥ 80 years), plasma HCY (< 14.4, ≥ 14.4 µmol/L), and APOE genotype
(APOE e4 or not) were tested”
Cognitive outcomes:
• global cognitive function measured with MMSE at 2 years, with higher values
indicating benefit
• executive functioning measured with Trial making test (part B/partA) at 2 years,
with lower values indicating benefit
• executive functioning measured with Stroop Interference (part 3 - (part 1 + part
2/2/)) at 2 years, with lower values indicating benefit
• working memory measured with Digit span backward at 2 years, with higher
values indicating benefit
• working memory measured with Digit span forward at 2 years, with higher values
indicating benefit
• episodic memory measured with RAVLT-Decay (delayed recall trial 5) at 2 years,
with higher values indicating benefit
• episodic memory measured with RAVLT- trials I-V, immediate Recall max 75
words at 2 years, with higher values indicating benefit
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• episodic memory measured with RAVLT- trial 9 Recognition max 30 words at 2
years, with higher values indicating benefit
• speed of processing measured with Trail making part A at 2 years, with lower
values indicating benefit
• speed of processing measured with Stroop 1 and 2 mean at 2 years, with lower
values indicating benefit
• speed of processing measured with Symbol digit modalities test at 2 years, with
higher values indicating benefit
• verbal fluency measured with Verbal Fluency - total no at 2 years, with higher
values indicating benefit
Notes Funding sources, quote: “B-PROOF was supported and funded by The Netherlands
Organization for Health Research and Development (ZonMw, grant 6130.0031), the
Hague; unrestricted grant from NZO (Dutch Dairy Association), Zoetermeer; MCO
Health, Almere; NCHA (Netherlands Consortium Healthy Ageing) Leiden/Rotterdam;
Ministry of Economic Affairs, Agriculture and Innovation (project KB-15-004-003),
the Hague; Wageningen University, Wageningen; VU University Medical Center, Am-
sterdam; and Erasmus Medical Center, Rotterdam. All organizations are based in the
Netherlands. The sponsors had no role in the design or implementation of the study, data
collection, data management, data analysis, data interpretation, or in the preparation,
review, or approval of the manuscript.“
Declarations of interest, quote: “The authors report no disclosures relevant to the
manuscript.”
Treatment adherence
“Average compliance to treatment was 90%, and 84% of all participants had an overall
compliance ≥ 80%. Compliance was equal for both treatment groups”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomizationwas done by an in-
dependent person by means of computer-
generated randomization numbers in strat-
ified permuted blocks of size 4, stratified by
study center, sex, age (65-79 years, ≥ 80
years), and HCY levels (12-17 mmol,≥ 18
mmol)“
Comment: computer-generated sequence
Allocation concealment (selection bias) Low risk Quote: “Randomization was done by an
independent person”.
Comment: allocation probably concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Participants and employees of the
study were blinded until data analyses were
finished.“
Comment: participants and personnel
blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Participants and employees of the
study were blinded until data analyses were
finished.”
Comment: outcome assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: from CONSORT flow diagram,
22-24% attrition from each group
Comment: significant loss of participants,
but reasons given and appeared balanced
between groups
Selective reporting (reporting bias) Low risk Comment: No differences identified in the
outcomes reported in the protocol (clini-
caltrials.gov: NCT00696514) and the arti-
cle. All outcomes specified in the Methods
were reported in the Results
Other bias Low risk Comment: no other apparent sources of
bias
Walker 2012
Methods 2 x 2 x 2 factorial design, parallel group, double-blinded, multicentre, duration of treat-
ment 24 months, duration of follow-up 24 months
Participants Location: Australia. 3 sites: 2 urban and 1 rural
Recruitment:The population-based sample was recruited by a direct mailing of a screen-
ing survey and consent form to 105,000 randomly selected adults aged from 60 to 74
years
Number randomised: 453 in intervention, 456 in comparison
Participant (baseline) characteristics:
• Age, mean (±SD):
◦ overall: 65.94 ± 4.24
◦ folic acid-vitamin B12: 65.92 ± 4.30
◦ placebo: 65.97 ± 4.18
• Gender, male, n (%):
◦ overall: 358 (39.8)
◦ folic acid-vitamin B12: 181 (40.5)
◦ placebo: 177 (39.1)
• Main diagnosis: elevated psychological distress (Kessler Distress 10 Scale > 15)
Inclusion criteria: cohort of community-dwelling older 60-74 y adults with elevated
psychological distress (Kessler Distress 10-Scale; scores > 15); did not engage in physical
activity at public health-recommended levels as indicated by International Physical Ac-
tivity Questionnaire scores; did not take folic acid, vitamin B12, or vitamin B complex
supplements; had no history of dementia, bipolar disorder, or current suicide risk; had
competent literacy skills; and did not have amedical condition that would contraindicate
exercise or folic acid use
Exclusion criteria: High likelihood of a depressive disorder with K10 scores of ≥ 30
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were excluded. Those individuals with low concentrations of red blood cell folate (< 250
nmol/L) and vitamin B12 (<130 nmol/L), and abnormal thyroid stimulating hormone
concentrations (0.35-5.0 mU/L) were excluded because participation may have led to
potentially adverse outcomes
Interventions Intervention:
1) Daily oral dose of one tablet consisting of 400 µg folic acid + 100 µg vitamin B12 sup-
plementation (Matchland Pty Ltd, t/aNewProducts Development -ABN57052101176,
Brisbane, Australia) for 24 months
The protocol changed to 2 daily oral doses (200 µg folic acid + 50 µg vitamin B12 each)
from July 2007
Comparator group:
Drug: placebo.
Placebo tablets were manufactured by the same producers of the folic acid + vitamin
B12 tablets and were identical except for the omission of the active substances under
investigation
Use of additional interventions (common to both treatment arms):
Due to the factorial design, in both vitamin and placebo groups, approximately half the
participants received an intervention to promote physical activity and approximately half
info about nutrition for older adults; and approximately half received a mental health
literacy intervention and approximately half received arthritis and painmanagement info
Outcomes Outcomes of interest in the review:
Primary outcomes:
• TICSm total score
Secondary outcomes:
• TICSm subscores: 1) orientation; 2) registration, recent memory, and delayed
recall (immediate and delayed recall reported separately); 3) attention/calculation; and
4) semantic memory, comprehension, and repetition
• Processing speed measured with BTACT
• IQCODE
Notes Funding sources, quote:“Supported by beyond blue: the national depression initiative
and the Australian Government Department of Health and Ageing. HC was supported
by a National Health and Medical Research Council (NHMRC) fellowship no. 525411.
JGW was supported by NHMRC Capacity Building Grant 418020”
“The sponsors had no role in the design and conduct of the study; collection, manage-
ment, analysis, and interpretation of the data; or preparation, review, or approval of the
manuscript.”
Declarations of interest, quote: “None of the authors had any conflicts of interest.“
Treatment adherence
”Adherence was monitored by telephone assessment at 14 time points and by blood assay
at baseline and at 12- and 24-mo assessments.“
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “Randomisation followed the
screening assessment with block size fixed
at eight and using strata comprising loca-
tion, gender and high (19) and low (16-
18) K10 depression scores (conducted by
A.J.M.) using an automated computerised
system.”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Quote: “using an automated computerised
system“.
Comment: adequate method of allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Participants, interviewers, investi-
gators and the survey administrators were
masked to active intervention and folic
placebo (sic) allocation.”
Comment: Participants andpersonnel were
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Participants, interviewers, investi-
gators and the survey administrators were
masked to active intervention and folic
placebo (sic) allocation.”
Comment: Outcome evaluators were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”Of those who were recruited into
the trial, the dropout rate was low, with
only 123 (13.5%) participants withdraw-
ing from the time of randomisation to the
24-mo assessment”
Comment: Reasons for withdrawal bal-
anced across groups
Selective reporting (reporting bias) High risk Comment: All cognitive results were re-
ported, but not all were reported in suf-
ficient detail for inclusion. Results of this
study were therefore missing from some
analyses
Other bias Low risk Comment: no other important risks iden-
tified
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Methods 2-arm, parallel group, placebo controlled, double-blind RCT. Duration of treatment 6
months, duration of follow-up 6 months
Participants Location: Germany, single centre
Recruitment: recruited by newspaper advertisement in Hannover region. Institute of
Food Science, University of Hanover
Number randomised: not reported. Baseline measures were taken from 241 women.
Data are reported for 220 who completed the study
Participant (baseline) characteristics (provided for those who completed):
• Age, median (5th-95th percentile)
◦ overall: 63 years (60-74)
◦ vitamin: 63 years (60-74)
◦ placebo: 64 years (60-75)
• Gender: female 100%
• Main diagnosis: healthy volunteers
Inclusion criteria: healthy females 60 years or older; no vitamin supplementation for
two months before intervention; no medications that affect vitamin absorption on status
at the time of enrolment
Exclusion criteria: not reported
Interventions Intervention (n=111):
Vitamin capsule (Nobilin Q10) contained 150 mg vitamin C (calcium ascorbate), 50 mg
magnesium (magnesium carbonate), 36 mg vitamin E (D- alfa-tocopherol acetate), 34
mg niacin (nicotinamide), 16 mg pantothenic acid, 9 mg ß-carotene, 3.4 mg pyridoxine
(pyridoxine hydrochloride), 3.2 mg riboflavin, 2.4 mg thiamine (thiamine mononitrate)
, 400 µg folic acid (pteroyl glutamic acid), 200 µg biotin, 60 µg selenium (selenium-
enriched yeast), and 9 µg cobalamin (cyanocobalamin)
One capsule/day at breakfast for 6 months
Comparator group (n=109): placebo
One capsule/day at breakfast for 6 months
Use of additional interventions: 4.5% women received statin medication.
Outcomes Primary Outcomes:
Wechsler Adult Intelligence Scale-Revised (WAIS III)
Intelligence assessed by the Kurztest fuer Allgemeine Intelligenz (KAI)
Mild up to severe memory disorders assessed by a subtest of the Berliner Amnesie Test
(BAT)
Secondary outcomes: levels of homocysteine and methylmalonic acid at baseline and
end of treatment
Eligible cognitive outcomes:
• episodic memory measured with Pattern recognition subtest of Berliner Amnesie
Test (BAT) (higher values indicate benefit)
• speed of processing measured with WAIS-III revised symbol search test (higher
values indicate benefit)
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
*: outcome data included in statistical analyses
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Notes Funding sources: Medicom Pharma. Vitamin capsules (Nobilin Q10R) and placebo
capsules were donated by Medicom Pharma AG, Springe (Germany)
Declarations of interest: no information provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Of these, 109 women had been
randomly assigned to the placebo group
and 111 women to the vitamin group by a
lottery.”
Comment: unclear method of sequence
generation
Allocation concealment (selection bias) Unclear risk Quote: “Of these, 109 women had been
randomly assigned to the placebo group
and 111 women to the vitamin group by a
lottery.”
Comment: unclear method of allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both capsules, the multivitamin
and the placebo, were soft gelatine capsules
filled with soy oil. The oil in the placebo
capsule was colored for identical appear-
ance.”
Comment: probably blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The cognitive tests were per-
formed on the day of blood sampling after
the women had had breakfast.”
Comment: blinding of outcome assess-
ment not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 8.7%(21/241 assessed at baseline) dropped
out, but it is unclear from which group.
Two participants were excluded by the ex-
perimenters for non-compliance. The to-
tal number of patients randomised was un-
clear. Only completers’ data reported
Selective reporting (reporting bias) Low risk All primary and secondary outcomes spec-
ified in the Methods were reported
Other bias Unclear risk There were baseline imbalances in educa-
tional level (higher in vitamin group) and
Symbol Search (better in vitamin group)
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Methods 4-arm, double-blinded, multicentre parallel group RCT, with up to 8 years of treatment
Participants Location: 11 clinical centres in the US
Recruitment: recruited through 11 clinical centres in the US
Sample size: Quote ”Of the 3640 AMD trial participants, 2166 (60%) completed the
AREDS cognitive battery near the end of the trial.“
• Number randomised: 2737 in intervention, 903 in comparison (total 3640)
• Number completed cognitive battery: 1632 in intervention, 534 in comparison
(total 2166)
Group A (Antioxidants) baseline characteristics:
• Age (y), %:
◦ 55-59: 4
◦ 60-64: 16
◦ 65-69: 34
◦ 70-74: 29
◦ 75-80: 16
• Median age, y: 69
• Gender, % female: 55
Group B (Zinc) baseline characteristics:
• Age (y), %:
◦ 55-59: 2
◦ 60-64: 18
◦ 65-69: 29
◦ 70-74: 34
◦ 75-80: 18
• Median age, y: 70
• Gender, % female: 57
Group C (Antioxidants and Zinc) Baseline characteristics:
• Age (y), %:
◦ 55-59: 3
◦ 60-64: 17
◦ 65-69: 33
◦ 70-74: 30
◦ 75-80: 17
• Median age, y: 69
• Gender, % female: 56
Group D (Placebo) Baseline characteristics:
• Age (y), %:
◦ 55-59: 3
◦ 60-64: 16
◦ 65-69: 32
◦ 70-74: 31
◦ 75-80: 18
• Median age, y: 69
• Gender, % female: 56
Inclusion criteria:
Aged 55 to 80 years old
Individuals who passed the screening evaluation and were interested in participating in
AREDS were provided with a one-month “run-in” supply of placebo to assess potential
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for tolerance of the inactive ingredients and compliance with the treatment regimen.
They were asked to take two tablets twice a day for 1 month. Participants taking fewer
than 75% of the prescribed tablets were ineligible for enrolment. Participants who had
good compliance with the run-in medication, who had adequate pupillary dilation and
no disqualifying lesions noted on photographs sent to the Reading Center for grading,
and who signed a second consent form were stratified into AMD categories at the time
of randomisation
Exclusion criteria:
Had to be free of any illness or condition that would make long-term follow-up or
compliance with study medications unlikely or difficult
Interventions Intervention (n=1632): Two study medication tablets were to be taken orally each
morning and 2 each evening to meet the total daily dose requirement
Group A (Antioxidants): 500 mgVitamin C, 400 IUVitamin E and 15mg beta carotene
daily
Group B (Zinc and Copper): 80 mg zinc oxide and 2 mg cupric oxide daily
Group C (Antioxidants and Zinc and Copper): 500 mg Vitamin C, 400 IU Vitamin E,
15 mg beta carotene, 80 mg zinc oxide, 2 mg cupric oxide daily
Comparator group (n=534): placebo taken orally that was identical in external appear-
ance and similar in internal appearance and taste
N.B. Data from groups A and B and the placebo group were included in this review
Use of additional interventions (common to both treatment arms): no
Outcomes Outcomes of interest in the review:
The primary purpose of the study was to investigate the effects of the interventions on
the progression of age-related macular degeneration
The AREDS cognitive function battery included six validated cognitive tests with eight
components: 1) The Modified Mini-Mental State Examination (3MS); 2) Animal Cat-
egory; 3) Letter Fluency; 4) Logical Memory Part I and 5) Logical Memory Part II,
Wechsler Memory Scale Revised; 6) Immediate Recall and 7) Word List Mean, Bushke
Selective Reminding Test; and 8) Digits Backwards
Notes This was a cognitive substudy of AREDS, the Age-Related Eye Disease Study.
Funding sources: “Supported by contracts from the National Eye Institute and the
National Institute on Aging, National Institutes of Health, Department of Health and
Human Services, Bethesda, MD, with additional support from Bausch & Lomb Inc,
Rochester, NY”
Declarations of interest: none declared. “The Writing Team for this report and the
AREDS investigators have no commercial or proprietary interest in the supplements
used in this study”
Treatment adherence: At each visit, participants returned their used study medication
bottles and any unused tablets, and received new bottles of their study medication.
“Estimated pill counts showed that most patients took 75% or more of the assigned
medications and adherence was balanced by treatment”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “Eligibility verification and random
treatment assignment were performed by
the Coordinating Center using the on-site
computers, with procedures to protect the
integrity of randomization and to provide
randomization backup in case of hardware
malfunction. Multiple levels of data en-
cryption ensure the integrity of the treat-
ment assignment files.” “Each treatment
assignment database residing on the hard
drives at each Clinical Center is encrypted
and includes check numbers to insure tam-
per free operation and proper sequential
treatment assignments. There were no cases
of database corruption during randomiza-
tion.”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Quote: “Eligibility verification and random
treatment assignment were performed by
the Coordinating Center using the on-site
computers, with procedures to protect the
integrity of randomization and to provide
randomization backup in case of hardware
malfunction. Multiple levels of data en-
cryption ensure the integrity of the treat-
ment assignment files.“ “Each treatment
assignment database residing on the hard
drives at each Clinical Center is encrypted
and includes check numbers to insure tam-
per free operation and proper sequential
treatment assignments. There were no cases
of database corruption during randomiza-
tion.”
Comment: adequate allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Four participants (0.1%) were re-
ported to have been unmasked during the
trial.”
“AREDS is a double-masked study. The
AREDS participants, investigators and
Reading Center personnel are masked to
study-wide outcome data and treatment as-
signments.”
Comment: low risk for personnel and par-
ticipants. Although 4 participants were
“unmasked”, this is likely to have been for
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Yaffe 2004 (Continued)
safety reasons
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: “AREDS is a double-masked
study. The AREDS participants, investi-
gators and Reading Center personnel are
masked to study-wide outcome data and
treatment assignments.“
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Another limitation is that not all
participants in the trial had cognitive test-
ing.”
“Of the 3,640 AMD trial participants, 2,
166 (60%) completed the AREDS cogni-
tive battery near the end of the trial. Of
the 1,474 participants without cognitive
testing, 330 died before the implementa-
tion of the cognitive study, and 1,144 re-
fused or were otherwise unable to partic-
ipate. Participants without cognitive test-
ing were more likely to be older, have more
ocular abnormalities, and be less educated
compared with those participating in the
ancillary study.” No information was given
about the treatment allocation of partici-
pants and non-participants in the cognitive
sub-study
Comment: high risk of differential non-
participation
Selective reporting (reporting bias) Unclear risk Comment: This was an ancillary study and
did not have a protocol of its own. The
AREDS study design did not mention any
cognitive outcomes
Other bias Low risk Comment: no other risks identified
AD:Alzheimer ′sdisease
AD8: Ascertain Dementia 8-Item Informant Questionnaire (AD8) Dementia Screening Interview
ADAS-cog: Alzheimer’s Disease Assessment Scale - cognitive
ADL: Activities of Daily Living
AMD: Age-related Macular Degeneration
APOE ǫ4: Apolipoprotein-E gene, ǫ4 allele
AREDS: The Age-Related Eye Disease Study
BASF: BASF is a registered chemical company, BASF originally stood for Badische Anilin- und Soda-Fabrik.
BAT: Berliner Amnesie Test
BDI: Beck Depression Inventory
betaCarot: ß-carotene
B-PROOF: B-Vitamins for the Prevention of Osteoporotic Fractures study
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BTACT: Brief Test of Adult Cognition by Telephone
CaD: Calcium and Vitamin D
CANTAB: Cambridge Automated Neuropsychological Test Battery
CDR: Clinical Dementia Rating scale
CERAD: Consortium to Establish a Registry for Alzheimer’s Disease
CERAD e: expanded Consortium to Establish a Registry in Alzheimer’s Disease
CERAD T: CERAD battery total score
CoA: coenzyme A reductase
CONSORT: Consolidated Standards of Reporting Trials
CVD: CardioVascular Disease
CVLT: California Verbal Learning Test
DCT: Digit Cancellation Test
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
EBMT: East Boston Memory Test
FA: Folic acid
F00: ICD-10 code for dementia in Alzheimer’s disease
F01: ICD-10 code for vascular dementia
F03:ICD−10codef orunspecif ieddementia
F-TICSm: modified Telephone Interview for Cognitive Status
G30: ICD-10 code for Alzheimer’s disease
GDS: Geriatric Depression Scale
HbA1c: Hemoglobin A1c
HCY: homocysteine
HMG-COA: 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase
holoTC: Holotranscobalamin
IADL: Instrumental Activities of Daily Living
IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly
IQR: Interquartile range
ISRCTN: International Standard Randomised Controlled Trial Number
KAI: Kurztest fuer Allgemeine Intelligenz
K10: Kessler Distress 10-Scale
LDCT: Letter Digit Coding Test.
MCI: Mild cognitive impairment
MI: Memory Impairment
MIS: Memory Impairment Screen
MMA: Methylmalonic acid
MMSE: Mini-Mental State Examination
MoCA: Montreal Cognitive Assessment
MRI: Magnetic resonance imaging
msec: millisecond
MTS: Matching To Sample visual search test
n: number
NYU: New York University
PHS: Physicians’ Health Study
RAVLT: Rey Auditory Verbal Learning Test
RBC: Red blood cell
RDA: recommended daily allowances
RI-48: rappel indicé-48 items (cued-recall test-48 items)
SD: standard deviation
SF-36: 36-item Short Form Survey
SU.FOL.OM3: SUpplementation with FOlate, vitamin B6 and B12 and/or OMega-3 fatty acids trial
RCT: randomised clinical trial
SWM: spatial working memory
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TCogS: Telephone Cognitive Screen
TIA: Transient Ischaemic Attack
TICS: Telephone Interview for Cognitive Status
TICSm: Modified Telephone Interview for Cognitive Status
TMT: Trail Making Test
VISP: Vitamin Intervention for stroke prevention trial
vit: vitamin
Vit D: vitamin D supplementation
WACS: Women’s Antioxidant and Cardiovascular Study
WADLS: Western Australian Data Linkage System
WAFACS: Women’s Antioxidant and Folic Acid Cardiovascular Study
WAIS: Wechsler Adult Intelligence Scale
WHI: Women’s Health Initiative
WHIMS: Women’s Health Initiative Memory Study
WHISCA: Women’s Health Initiative study of Cognitive Aging
wk: week
y: year
Zn: zinc
3MS: The Modified Mini-Mental State Examination
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbasi 2013 No cognitive outcomes
ACTRN12607000321448 Ineligible population: participants had MCI
Alavi 2014 Ineligible population. Additional detail: included in related Cochrane review focussing on the MCI
study population
Almeida 2010 Subpopulationof included study focussing on depressionoutcome. Participants also included inHankey
2013
Anonymous 2003 Ineligible population
Arwert 2003 Ineligible intervention
Benton 1995 Ineligible population
Bryan 2002 Ineligible intervention: duration of intervention 5 weeks
Chan 2010 Ineligible experimental intervention: combined experimental intervention
Cheng 2016 Wrong design: non-randomised
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(Continued)
Chew 2015 Wrong design: RCT with 2x2 factorial design (omega-3 fatty acids; lutein and zeaxanthin; the com-
bination; double placebo) with a second randomisation to multivitamin supplements with or without
beta carotene and with or without high dose of zinc. The analyses of effects of beta carotene and zinc
were not eligible, as no tests for interaction were performed for omega-3, lutein and zeaxanthin
Corless 1987 Wrong population
De Jager 2012 Ineligible population: participants had MCI
Dhesi 2004 Ineligible intervention: vitamin D delivered parenterally
Flicker 2011 Wrong population: all had vitamin D deficiency
Ford 2008 Ineligible outcomes
Harris 2015 Ineligible intervention: included plant extracts and probiotics as well as vitamins and minerals
Hvas 2004 Ineligible population: 56% cognitively impaired at baseline
Imaoka 2016 Ineligible population: participants cognitively impaired at baseline
Krikorian 2010 Ineligible population: participants had CDR (Clinical Dementia Rating scale) classification consistent
with MCI
Kwok 2017 Ineligible population: We were unable to obtain separate data for participants with mild cognitive
impairment (CDR 0.5) and normal cognition (CDR 0) at baseline
Li 2015 Ineligible population. Baseline cognitive status unclear. Data presented pictorially only (bar charts).
Baseline mean MMSE < 23
Liu 2015 Study withdrawn prior to participant enrolment (ClinicalTrials.gov Identifier: NCT01317849)
Loriaux 1985 Ineligible experimental intervention
Macpherson 2012 Ineligible population: participants had subjective cognitive decline
Maniam 2004 Other reason. Additional details: potentially eligible RCT described only in an abstract published in
2004. No related full report has been identified and the likelihood such report will be published in
future was judged to be minimal
McNeill 2007 No eligible outcomes
Miller 2016 No eligible outcomes
Murray-Kolb 2011 Ineligible population: age range 19-55 years
NCT00903695 Ineligible population: participants had MCI
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(Continued)
NCT01095211 Ineligible population: duration of intervention 45 days
NCT01708005 Ineligible intervention: combined vitamins, endophospholipids, and omega-3 fatty acids
NCT02185222 Ineligible population: participants had memory complaint
NCT02467153 No eligible outcomes
Ng 2017 Ineligible intervention: combined protein, calorie, and vitamin supplements
Ong 2016 Ineligible intervention: no placebo control
Pase 2015 Ineligible intervention: combined experimental intervention
Pathansali 2006 Ineligible intervention: duration of intervention 4 weeks
Petersen 2005 Ineligible population. Additional detail: included in related Cochrane review focussing on population
with MCI
Pettersen 2017 Ineligible intervention: no placebo control
Quick 2013 Ineligible design
Rietsema 2014 Ineligible design
Schietzel 2016 Ineligible intervention: no placebo control
Smith 1999 Ineligible population: Excluded if MMSE < 18, but no information on mean MMSE; likely to have
included participants with dementia or MCI
Summers 2010 Ineligible experimental intervention: combined experimental intervention
Van Uffelen 2007 Ineligible population. Additional detail: included in related Cochrane review focussing on population
with MCI
Wouters-Wesseling 2005 Ineligible experimental intervention: combined experimental intervention
MCI :Mildcognitiveimpairment
CDR:ClinicalDementiaRatingscale
MMSE:MiniMentalStateExamination
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Characteristics of studies awaiting assessment [ordered by study ID]
Sanchez 2011
Methods Cluster double-blind, placebo controlled trial with 18 month follow-up
Participants Location: metropolitan Santiago, Chile, 15 health centres, 20 participants selected from each health centre
Setting of recruitment and treatment: GP practices
Number randomised: not known
Participant (baseline) characteristics: not known
Inclusion criteria: Potential study subjects will be identified from the registry of older people participating in the
PACAM in 15 health centres
1. men and women aged 70 to 79 years
2. participating in the National Health Service Nutrition Program for Older People (PACAM)
Exclusion criteria:
1. diabetes (fasting blood glucose greater than or equal to 126 mg/dL)
2. hypothyroidism (thyroid stimulating hormone (TSH) greater than 6 mlU/L)
3. serum creatinine greater than or equal to 30 mg/mL
4. serum vitamin B12 level less than 120 or greater than 700 pmol/L or vitamin B12 supplemented
5. cerebrovascular disease
6. previous gastrointestinal surgery
7. unexplained weight lost greater than or equal to 3 kg in the previous 3 months
8. low cognitive development (Mini-mental test less than 20, and Pfeffer test greater than 5)
Interventions Intervention:
1. 1 mg B12 pill taken daily and a routine PACAM food
2. placebo pill and the PACAM food fortified to provide 1 mg of B12 as consumed on a daily basis
Comparator group:
Routine PACAM food and a placebo pill
All subjects in the three study arms will receive both a pill and the food supplement in order to maintain the double
blind nature of the study
A routine fortified food program provided monthly is delivered by the Ministry of Health under the PACAM
programme through the health centres. The nutritional products are 1 kg of Años Dorados (a cereal-legume and
vegetable powdered food) which provides 400 kcal/100 g and multiple micronutrients (including B12 1.4 µg/100
g) and 1 kg of Bebida Láctea, a micronutrient fortified milk-based drink (including B12 2.8 µg/100 g ). The
recommended serving size of these supplements provides daily 1.4 µg or 58.3% of the daily B12 recommended intake
(World Health Organization (WHO) 2002) and 20% of daily energy needed by older people
The pill will be identical in size, shape, colour, smell, and taste for both the intervention and the placebo arms of the
trial. The intervention pill and the fortified milk base drink will each contain 1 mg of B12
Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes:
1. serum vitamin B12 status, assessed at initial visit and 3, 9, and 18 months
2. haematological and biochemical parameters, assessed at initial visit and 3, 9, and 18 months
3. peripheral nerve conduction, assessed at initial visit, 3, and 18 months
4. compound muscle action potential (CMAP) amplitude, distal motor latency, and F-wave latency (a measure of
conduction time from the distal stimulation site to the spinal cord), assessed at initial visit, 3, and 18 months
5. Mini-mental score: Mini Mental State Examination (MMSE), assessed at initial visit and 18 months
Secondary Outcomes:
1. serum folate, homocysteine, methyl malonic acid, holotranscobalamin, assessed at initial visit and 3, 9, and 18
months
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Sanchez 2011 (Continued)
2. neurological battery evaluation includes sensory pathways of conduction of afferent sensory pathways of small
diameter, quantitative thermal and somatosensory responses, specific neurosensory pathways, and visual evoked
potential. Assessed at initial visit, 3, and 18 months.
3. cognitive function: Test Wechsler, Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), Test
Hamilton and Trail Making Test, assessed at initial visit and 18 months
Compliance with the nutrition intervention is defined for this study as collecting more than 1 kg per month of the
fortified food as documented by the health centres. Compliance for the pill intervention will be monitored based on
collection of the pills supplement from the health centre, 12 out of 18 months will be considered compliant
A subsample of 120 subjects (8 per cluster, 40 per arm) will undergo neurophysiological tests
Notes Funding sources: Chilean National Science and Technology Research Fund (FONDECYT 1070592) (Fondo de
Desarrollo Científico y Tecnológico (Chile) (ref: FONDECYT Nº 1070592)), Ministry of Health (Chile)
Declarations of interest, quote: “The authors declare that they have no competing interests.”
Reasons for classification as “study awaiting classification”:
This study is marked as “completed” in ISRCTN registry (last edited 11-10-2011), but no results are available. We
made several attempts to contact authors of the protocol, but received no replies
CERAD:ConsortiumtoEstablishaRegistryf orAlzheimer ′sDisease
CMAP: compound muscle action potential
PACAM: National Health Service Nutrition Program for Older People
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D A T A A N D A N A L Y S E S
Comparison 1. B vitamins versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall cognitive functioning 10 Std. Mean Difference (Random, 95% CI) Subtotals only
1.1 3-12 months of
supplementation (final
measurement data)
3 2556 Std. Mean Difference (Random, 95% CI) 0.00 [-0.08, 0.08]
1.2 3-12 months of
supplementation (change from
baseline data)
2 317 Std. Mean Difference (Random, 95% CI) -0.03 [-0.26, 0.19]
1.3 > 1-2 years of
supplementation (final
measurement data)
5 6956 Std. Mean Difference (Random, 95% CI) -0.01 [-0.08, 0.06]
1.4 > 1-2 years of
supplementation (change from
baseline data)
1 241 Std. Mean Difference (Random, 95% CI) 0.06 [-0.20, 0.31]
1.5 > 2-5 years of
supplementation (final
measurement data)
4 3985 Std. Mean Difference (Random, 95% CI) -0.01 [-0.11, 0.09]
1.6 > 5-10 years of
supplementation (final
measurement data)
3 10249 Std. Mean Difference (Random, 95% CI) -0.01 [-0.09, 0.07]
2 Episodic memory 10 Std. Mean Difference (Random, 95% CI) Subtotals only
2.1 3-12 months of
supplementation (final
measurement data)
4 1442 Std. Mean Difference (Random, 95% CI) 0.02 [-0.08, 0.12]
2.2 3-12 months of
supplementation (change from
baseline data)
2 430 Std. Mean Difference (Random, 95% CI) 0.04 [-0.15, 0.23]
2.3 > 1-2 years of
supplementation (final
measurement data)
4 5625 Std. Mean Difference (Random, 95% CI) 0.05 [-0.03, 0.13]
2.4 > 1-2 years of
supplementation (change from
baseline data)
1 241 Std. Mean Difference (Random, 95% CI) 0.06 [-0.19, 0.32]
2.5 > 2-5 years of
supplementation (final
measurement data)
3 3523 Std. Mean Difference (Random, 95% CI) -0.05 [-0.15, 0.05]
2.6 > 5-10 years of
supplementation (final
measurement data)
1 1053 Std. Mean Difference (Random, 95% CI) -0.10 [-0.22, 0.02]
3 Executive function 7 Std. Mean Difference (Random, 95% CI) Subtotals only
3.1 3-12 months of
supplementation (final
measurement data)
3 536 Std. Mean Difference (Random, 95% CI) 0.14 [-0.18, 0.46]
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3.2 3-12 months of
supplementation (change from
baseline data)
1 171 Std. Mean Difference (Random, 95% CI) 0.39 [0.07, 0.71]
3.3 > 1-2 years of
supplementation (final
measurement data)
3 2976 Std. Mean Difference (Random, 95% CI) -0.01 [-0.15, 0.13]
3.4 > 2-5 years of
supplementation (final
measurement data)
2 2648 Std. Mean Difference (Random, 95% CI) -0.06 [-0.13, 0.02]
3.5 > 5-10 years of
supplementation (final
measurement data)
1 1049 Std. Mean Difference (Random, 95% CI) 0.02 [-0.10, 0.15]
4 Speed of processing 7 Std. Mean Difference (Random, 95% CI) Subtotals only
4.1 3-12 months of
supplementation (final
measurement data)
2 289 Std. Mean Difference (Random, 95% CI) -0.04 [-0.28, 0.19]
4.2 3-12 months of
supplementation (change from
baseline data)
3 487 Std. Mean Difference (Random, 95% CI) 0.12 [-0.34, 0.58]
4.3 > 1-2 years of
supplementation (final
measurement data)
2 1030 Std. Mean Difference (Random, 95% CI) 0.03 [-0.09, 0.15]
4.4 > 1-2 years of
supplementation (change from
baseline data)
1 241 Std. Mean Difference (Random, 95% CI) -0.04 [-0.29, 0.21]
4.5 > 2-5 years of
supplementation (final
measurement data)
1 818 Std. Mean Difference (Random, 95% CI) -0.08 [-0.22, 0.06]
5 Incidence of MCI or dementia 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 > 2-5 years of
supplementation
1 1803 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.69, 1.48]
6 All-cause mortality 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 3-12 months of
supplementation
1 201 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.33]
6.2 >1 to 2 years of
supplementation
1 3680 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.66, 1.11]
6.3 >2-5 years of
supplementation
1 1127 Risk Ratio (M-H, Random, 95% CI) 1.98 [1.22, 3.21]
6.4 >5-10 years of
supplementation
1 12064 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.95, 1.12]
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Comparison 2. Antioxidants versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall cognitive functioning 5 Mean Difference (Random, 95% CI) Subtotals only
1.1 3-12 months Vitamin E
supplementation
1 Mean Difference (Random, 95% CI) 1.4 [1.18, 1.62]
1.2 3-12 months Beta
Carotene supplementation
1 Mean Difference (Random, 95% CI) -0.14 [-0.37, 0.09]
1.3 > 2-5 years antioxidants
(Vitamin E + Vitamin C + Beta
Carotene) supplementation
1 Mean Difference (Random, 95% CI) 0.09 [-0.05, 0.23]
1.4 > 2-5 years Vitamin E
supplementation
1 Mean Difference (Random, 95% CI) 0.01 [-0.23, 0.25]
1.5 > 2-5 years Vitamin C
supplementation
1 Mean Difference (Random, 95% CI) 0.16 [-0.08, 0.40]
1.6 > 2-5 years Beta Carotene
supplementation
1 Mean Difference (Random, 95% CI) -0.18 [-0.42, 0.06]
1.7 > 5-10 years antioxidants
(Vitamin E + Vitamin C + Beta
carotene) supplementation
1 Mean Difference (Random, 95% CI) 0.6 [-0.20, 1.40]
1.8 > 5-10 years Vitamin C
supplementation
1 Mean Difference (Random, 95% CI) 0.46 [0.14, 0.78]
1.9 > 5-10 years Beta Carotene
supplementation
1 Mean Difference (Random, 95% CI) -0.13 [-0.46, 0.20]
1.10 > 10 years Beta Carotene
supplementation
1 Mean Difference (Random, 95% CI) 0.18 [0.01, 0.35]
2 Episodic memory 4 Mean Difference (Random, 95% CI) Subtotals only
2.1 3-12 months Beta
Carotene supplementation
1 Mean Difference (Random, 95% CI) 0.02 [-0.05, 0.08]
2.2 > 2-5 years Vitamin E
supplementation
1 Mean Difference (Random, 95% CI) -0.02 [-0.07, 0.03]
2.3 > 2-5 years Vitamin C
supplementation
1 Mean Difference (Random, 95% CI) -0.05 [-0.10, -0.00]
2.4 > 2-5 years Beta Carotene
supplementation
1 Mean Difference (Random, 95% CI) 0.01 [-0.05, 0.07]
2.5 > 5-10 years antioxidants
(Vitamin E + Vitamin C + Beta
Carotene) supplementation
1 Mean Difference (Random, 95% CI) -0.3 [-1.30, 0.70]
2.6 > 5-10 years Vitamin E
supplementation
2 Mean Difference (Random, 95% CI) 0.02 [-0.05, 0.09]
2.7 > 5-10 years Vitamin C
supplementation
1 Mean Difference (Random, 95% CI) -0.14 [-0.22, -0.06]
2.8 > 5-10 years Beta Carotene
supplementation
1 Mean Difference (Random, 95% CI) 0.02 [-0.05, 0.09]
2.9 > 10 years Beta Carotene
supplementation
1 Mean Difference (Random, 95% CI) -0.06 [-0.11, -0.02]
3 Executive function 4 Mean Difference (Random, 95% CI) Subtotals only
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3.1 3-12 months Beta
Carotene supplementation
1 Mean Difference (Random, 95% CI) 0.07 [-0.48, 0.62]
3.2 > 2-5 years Vitamin E
supplementation
1 Mean Difference (Random, 95% CI) 0.42 [0.06, 0.78]
3.3 > 2-5 years Vitamin C
supplementation
1 Mean Difference (Random, 95% CI) -0.03 [-0.39, 0.33]
3.4 > 2-5 years Beta Carotene
supplementation
1 Mean Difference (Random, 95% CI) 0.22 [-0.14, 0.58]
3.5 > 5-10 years antioxidants
(Vitamin E + Vitamin C + Beta
Carotene) supplementation
1 Mean Difference (Random, 95% CI) -0.4 [-0.99, 0.19]
3.6 > 5-10 years Vitamin E
supplementation
2 Mean Difference (Random, 95% CI) 0.11 [-0.26, 0.48]
3.7 > 5-10 years Vitamin C
supplementation
1 Mean Difference (Random, 95% CI) -0.25 [-0.70, 0.20]
3.8 > 5-10 years Beta Carotene
supplementation
1 Mean Difference (Random, 95% CI) 0.01 [-0.44, 0.46]
3.9 > 10 years Beta Carotene
supplementation
1 Mean Difference (Random, 95% CI) 0.01 [-0.36, 0.38]
4 Incidence of dementia 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 > 2-5 years of
supplementation
1 20536 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.61, 1.64]
5 All-cause mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 > 2-5 years antioxidants
(Vitamin E + Vitamin
C + + Beta Carotene)
supplementation
1 20536 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.97, 1.11]
Comparison 3. Vitamin D3 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall cognitive functioning 1 Mean Difference (Random, 95% CI) Subtotals only
1.1 3-12 months of
supplementation
1 4122 Mean Difference (Random, 95% CI) 0.0 [-0.24, 0.24]
1.2 > 1-2 years of
supplementation
1 3910 Mean Difference (Random, 95% CI) 0.0 [-0.25, 0.25]
1.3 > 2-5 years of
supplementation
1 3515 Mean Difference (Random, 95% CI) -0.2 [-0.53, 0.13]
1.4 > 5-10 years of
supplementation
1 918 Mean Difference (Random, 95% CI) -0.1 [-0.81, 0.61]
2 Episodic memory 1 Mean Difference (Random, 95% CI) Subtotals only
2.1 > 5-10 years of
supplementation
1 1420 Mean Difference (Random, 95% CI) 0.05 [-0.03, 0.13]
3 Executive function 1 Mean Difference (Random, 95% CI) Subtotals only
3.1 > 5-10 years of
supplementation
1 1420 Mean Difference (Random, 95% CI) 0.0 [-0.08, 0.08]
4 Speed of processing 1 Mean Difference (Random, 95% CI) Subtotals only
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4.1 > 5-10 years of
supplementation
1 1420 Mean Difference (Random, 95% CI) 0.03 [-0.05, 0.11]
5 Incident MCI 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 > 5-10 years of
supplementation
1 4143 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.72, 1.23]
6 Incident all-cause dementia 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 > 5-10 years
supplementation
1 4143 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.70, 1.71]
Comparison 4. Zinc + copper versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall cognitive functioning 1 Mean Difference (Random, 95% CI) Subtotals only
1.1 > 5-10 years of
supplementation
1 1072 Mean Difference (Random, 95% CI) 0.6 [-0.19, 1.39]
2 Episodic memory 1 Mean Difference (Random, 95% CI) Subtotals only
2.1 > 5-10 years of
supplementation
1 1072 Mean Difference (Random, 95% CI) -0.7 [-1.74, 0.34]
3 Executive function 1 Mean Difference (Random, 95% CI) Subtotals only
3.1 > 5-10 years of
supplementation
1 1072 Mean Difference (Random, 95% CI) -0.3 [-0.89, 0.29]
Comparison 5. Complex multivitamin versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall cognitive functioning 1 Mean Difference (Random, 95% CI) Subtotals only
1.1 > 2-5 years of
supplementation
1 5947 Mean Difference (Random, 95% CI) 0.04 [-0.09, 0.17]
1.2 > 5-10 years of
supplementation
1 2324 Mean Difference (Random, 95% CI) 0.12 [-0.14, 0.38]
2 Episodic memory 2 Mean Difference (Random, 95% CI) Subtotals only
2.1 3-12 months of
supplementation
1 124 Mean Difference (Random, 95% CI) 33.17 [-28.12, 94.
46]
2.2 > 2-5 years of
supplementation
1 5942 Mean Difference (Random, 95% CI) -0.01 [-0.05, 0.03]
2.3 > 5-10 years of
supplementation
1 2324 Mean Difference (Random, 95% CI) -0.01 [-0.07, 0.05]
3 Executive function 1 Mean Difference (Random, 95% CI) Subtotals only
3.1 > 2-5 years of
supplementation
1 5942 Mean Difference (Random, 95% CI) -0.02 [-0.33, 0.29]
3.2 > 5-10 years of
supplementation
1 2324 Mean Difference (Random, 95% CI) -0.22 [-0.65, 0.21]
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4 Speed of processing 1 Mean Difference (Random, 95% CI) Subtotals only
4.1 3-12 months of
supplementation
1 127 Mean Difference (Random, 95% CI) -14.71 [-57.22, 27.
80]
Analysis 1.1. Comparison 1 B vitamins versus control, Outcome 1 Overall cognitive functioning.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 1 B vitamins versus control
Outcome: 1 Overall cognitive functioning
Study or subgroup B-Vitamins Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 3-12 months of supplementation (final measurement data)
Hankey 2013 691 712 -0.0372 (0.0534) 54.9 % -0.04 [ -0.14, 0.07 ]
McMahon 2006 127 126 -0.0498 (0.1258) 9.9 % -0.05 [ -0.30, 0.20 ]
Walker 2012 447 453 0.076 (0.0667) 35.2 % 0.08 [ -0.05, 0.21 ]
Subtotal (95% CI) 1265 1291 100.0 % 0.00 [ -0.08, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.94, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 3-12 months of supplementation (change from baseline data)
Ford 2010 127 128 0 (0.1252) 82.5 % 0.0 [ -0.25, 0.25 ]
Stott 2005 42 20 -0.1897 (0.2722) 17.5 % -0.19 [ -0.72, 0.34 ]
Subtotal (95% CI) 169 148 100.0 % -0.03 [ -0.26, 0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
3 > 1-2 years of supplementation (final measurement data)
Hankey 2013 617 621 -0.0083 (0.0568) 21.0 % -0.01 [ -0.12, 0.10 ]
Kang 2008 1002 1007 0.0095 (0.0446) 26.1 % 0.01 [ -0.08, 0.10 ]
McMahon 2006 126 127 0.0237 (0.1257) 7.0 % 0.02 [ -0.22, 0.27 ]
Van der Zwaluw 2014 1278 1278 0.0513 (0.0396) 28.5 % 0.05 [ -0.03, 0.13 ]
Walker 2012 447 453 -0.165 (0.0668) 17.5 % -0.17 [ -0.30, -0.03 ]
Subtotal (95% CI) 3470 3486 100.0 % -0.01 [ -0.08, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.88, df = 4 (P = 0.10); I2 =49%
Test for overall effect: Z = 0.33 (P = 0.74)
4 > 1-2 years of supplementation (change from baseline data)
Ford 2010 118 123 0.0554 (0.1289) 100.0 % 0.06 [ -0.20, 0.31 ]
Subtotal (95% CI) 118 123 100.0 % 0.06 [ -0.20, 0.31 ]
-0.5 -0.25 0 0.25 0.5
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(. . . Continued)
Study or subgroup B-Vitamins Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
5 > 2-5 years of supplementation (final measurement data)
Andreeva 2011 446 425 0.082 (0.068) 25.0 % 0.08 [ -0.05, 0.22 ]
Durga 2007 405 413 -0.149 (0.07) 24.3 % -0.15 [ -0.29, -0.01 ]
Hankey 2013 219 243 0.0792 (0.0932) 17.9 % 0.08 [ -0.10, 0.26 ]
Kang 2008 911 923 -0.0283 (0.0467) 32.8 % -0.03 [ -0.12, 0.06 ]
Subtotal (95% CI) 1981 2004 100.0 % -0.01 [ -0.11, 0.09 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.80, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.22 (P = 0.83)
6 > 5-10 years of supplementation (final measurement data)
Hankey 2013 155 150 0.1199 (0.1146) 10.5 % 0.12 [ -0.10, 0.34 ]
Kang 2008 521 532 -0.0929 (0.0617) 27.0 % -0.09 [ -0.21, 0.03 ]
SEARCH 2010 4427 4464 0 (0.0212) 62.5 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 5103 5146 100.0 % -0.01 [ -0.09, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.27, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 0.31 (P = 0.75)
-0.5 -0.25 0 0.25 0.5
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Analysis 1.2. Comparison 1 B vitamins versus control, Outcome 2 Episodic memory.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 1 B vitamins versus control
Outcome: 2 Episodic memory
Study or subgroup B-Vitamins Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 3-12 months of supplementation (final measurement data)
Dangour 2015 91 93 0.0586 (0.1475) 12.8 % 0.06 [ -0.23, 0.35 ]
Eussen 2006 65 40 0.018 (0.201) 6.9 % 0.02 [ -0.38, 0.41 ]
McMahon 2006 127 126 0.0477 (0.1258) 17.6 % 0.05 [ -0.20, 0.29 ]
Walker 2012 447 453 0.006 (0.0667) 62.7 % 0.01 [ -0.12, 0.14 ]
Subtotal (95% CI) 730 712 100.0 % 0.02 [ -0.08, 0.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
2 3-12 months of supplementation (change from baseline data)
Ford 2010 127 128 0.0614 (0.1253) 61.4 % 0.06 [ -0.18, 0.31 ]
Lewerin 2005 113 62 0.0042 (0.158) 38.6 % 0.00 [ -0.31, 0.31 ]
Subtotal (95% CI) 240 190 100.0 % 0.04 [ -0.15, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
3 > 1-2 years of supplementation (final measurement data)
Kang 2008 1002 1007 0 (0.0446) 33.4 % 0.0 [ -0.09, 0.09 ]
McMahon 2006 124 125 -0.0598 (0.1268) 8.5 % -0.06 [ -0.31, 0.19 ]
Van der Zwaluw 2014 1231 1236 0.0513 (0.0403) 36.1 % 0.05 [ -0.03, 0.13 ]
Walker 2012 447 453 0.176 (0.0668) 22.0 % 0.18 [ 0.05, 0.31 ]
Subtotal (95% CI) 2804 2821 100.0 % 0.05 [ -0.03, 0.13 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.56, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 1.31 (P = 0.19)
4 > 1-2 years of supplementation (change from baseline data)
Ford 2010 118 123 0.0633 (0.1289) 100.0 % 0.06 [ -0.19, 0.32 ]
Subtotal (95% CI) 118 123 100.0 % 0.06 [ -0.19, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
5 > 2-5 years of supplementation (final measurement data)
Andreeva 2011 446 425 0.054 (0.0678) 29.6 % 0.05 [ -0.08, 0.19 ]
Durga 2007 405 413 -0.1359 (0.07) 28.5 % -0.14 [ -0.27, 0.00 ]
-1 -0.5 0 0.5 1
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(. . . Continued)
Study or subgroup B-Vitamins Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Kang 2008 911 923 -0.066 (0.0467) 41.9 % -0.07 [ -0.16, 0.03 ]
Subtotal (95% CI) 1762 1761 100.0 % -0.05 [ -0.15, 0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.97, df = 2 (P = 0.14); I2 =50%
Test for overall effect: Z = 1.02 (P = 0.31)
6 > 5-10 years of supplementation (final measurement data)
Kang 2008 521 532 -0.1016 (0.0617) 100.0 % -0.10 [ -0.22, 0.02 ]
Subtotal (95% CI) 521 532 100.0 % -0.10 [ -0.22, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
Test for subgroup differences: Chi2 = 6.02, df = 5 (P = 0.30), I2 =17%
-1 -0.5 0 0.5 1
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Analysis 1.3. Comparison 1 B vitamins versus control, Outcome 3 Executive function.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 1 B vitamins versus control
Outcome: 3 Executive function
Study or subgroup B-Vitamins Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 3-12 months of supplementation (final measurement data)
Dangour 2015 91 93 -0.1689 (0.1477) 34.9 % -0.17 [ -0.46, 0.12 ]
Eussen 2006 61 38 0.3474 (0.2082) 27.2 % 0.35 [ -0.06, 0.76 ]
McMahon 2006 127 126 0.269 (0.1263) 37.9 % 0.27 [ 0.02, 0.52 ]
Subtotal (95% CI) 279 257 100.0 % 0.14 [ -0.18, 0.46 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 6.40, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 0.84 (P = 0.40)
2 3-12 months of supplementation (change from baseline data)
Lewerin 2005 110 61 0.3901 (0.1611) 100.0 % 0.39 [ 0.07, 0.71 ]
Subtotal (95% CI) 110 61 100.0 % 0.39 [ 0.07, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.015)
3 > 1-2 years of supplementation (final measurement data)
Kang 2008 1000 1007 -0.0672 (0.0447) 45.9 % -0.07 [ -0.15, 0.02 ]
McMahon 2006 124 125 0.2329 (0.1272) 19.7 % 0.23 [ -0.02, 0.48 ]
Van der Zwaluw 2014 352 368 -0.0667 (0.0746) 34.4 % -0.07 [ -0.21, 0.08 ]
Subtotal (95% CI) 1476 1500 100.0 % -0.01 [ -0.15, 0.13 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.10, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.11 (P = 0.91)
4 > 2-5 years of supplementation (final measurement data)
Durga 2007 405 413 -0.0383 (0.0699) 31.0 % -0.04 [ -0.18, 0.10 ]
Kang 2008 909 921 -0.0661 (0.0468) 69.0 % -0.07 [ -0.16, 0.03 ]
Subtotal (95% CI) 1314 1334 100.0 % -0.06 [ -0.13, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
5 > 5-10 years of supplementation (final measurement data)
Kang 2008 519 530 0.0246 (0.0618) 100.0 % 0.02 [ -0.10, 0.15 ]
Subtotal (95% CI) 519 530 100.0 % 0.02 [ -0.10, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 8.80, df = 4 (P = 0.07), I2 =55%
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Analysis 1.4. Comparison 1 B vitamins versus control, Outcome 4 Speed of processing.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 1 B vitamins versus control
Outcome: 4 Speed of processing
Study or subgroup B-Vitamins Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 3-12 months of supplementation (final measurement data)
Dangour 2015 91 93 0 (0.1475) 65.0 % 0.0 [ -0.29, 0.29 ]
Eussen 2006 65 40 -0.1221 (0.2011) 35.0 % -0.12 [ -0.52, 0.27 ]
Subtotal (95% CI) 156 133 100.0 % -0.04 [ -0.28, 0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
2 3-12 months of supplementation (change from baseline data)
Ford 2010 127 128 -0.2758 (0.1258) 38.0 % -0.28 [ -0.52, -0.03 ]
Lewerin 2005 113 62 0.2683 (0.159) 35.6 % 0.27 [ -0.04, 0.58 ]
Stott 2005 37 20 0.4739 (0.2813) 26.4 % 0.47 [ -0.08, 1.03 ]
Subtotal (95% CI) 277 210 100.0 % 0.12 [ -0.34, 0.58 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 10.49, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 0.50 (P = 0.62)
3 > 1-2 years of supplementation (final measurement data)
Ford 2010 150 149 -0.042 (0.116) 28.9 % -0.04 [ -0.27, 0.19 ]
Van der Zwaluw 2014 358 373 0.0598 (0.074) 71.1 % 0.06 [ -0.09, 0.20 ]
Subtotal (95% CI) 508 522 100.0 % 0.03 [ -0.09, 0.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
4 > 1-2 years of supplementation (change from baseline data)
Ford 2010 118 123 -0.0391 (0.1289) 100.0 % -0.04 [ -0.29, 0.21 ]
Subtotal (95% CI) 118 123 100.0 % -0.04 [ -0.29, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
5 > 2-5 years of supplementation (final measurement data)
Durga 2007 405 413 -0.0785 (0.07) 100.0 % -0.08 [ -0.22, 0.06 ]
Subtotal (95% CI) 405 413 100.0 % -0.08 [ -0.22, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 1.74, df = 4 (P = 0.78), I2 =0.0%
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Analysis 1.5. Comparison 1 B vitamins versus control, Outcome 5 Incidence of MCI or dementia.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 1 B vitamins versus control
Outcome: 5 Incidence of MCI or dementia
Study or subgroup B-Vitamins Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 > 2-5 years of supplementation
Hankey 2013 50/908 49/895 100.0 % 1.01 [ 0.69, 1.48 ]
Subtotal (95% CI) 908 895 100.0 % 1.01 [ 0.69, 1.48 ]
Total events: 50 (B-Vitamins), 49 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 B vitamins versus control, Outcome 6 All-cause mortality.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 1 B vitamins versus control
Outcome: 6 All-cause mortality
Study or subgroup B-Vitamins Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 3-12 months of supplementation
Dangour 2015 0/99 1/102 100.0 % 0.34 [ 0.01, 8.33 ]
Subtotal (95% CI) 99 102 100.0 % 0.34 [ 0.01, 8.33 ]
Total events: 0 (B-Vitamins), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 >1 to 2 years of supplementation
Toole 2004 99/1827 117/1853 100.0 % 0.86 [ 0.66, 1.11 ]
Subtotal (95% CI) 1827 1853 100.0 % 0.86 [ 0.66, 1.11 ]
Total events: 99 (B-Vitamins), 117 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
3 >2-5 years of supplementation
Andreeva 2011 44/542 24/585 100.0 % 1.98 [ 1.22, 3.21 ]
Subtotal (95% CI) 542 585 100.0 % 1.98 [ 1.22, 3.21 ]
Total events: 44 (B-Vitamins), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.0057)
4 >5-10 years of supplementation
SEARCH 2010 983/6033 951/6031 100.0 % 1.03 [ 0.95, 1.12 ]
Subtotal (95% CI) 6033 6031 100.0 % 1.03 [ 0.95, 1.12 ]
Total events: 983 (B-Vitamins), 951 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 9.36, df = 3 (P = 0.02), I2 =68%
0.01 0.1 1 10 100
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Analysis 2.1. Comparison 2 Antioxidants versus control, Outcome 1 Overall cognitive functioning.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 2 Antioxidants versus control
Outcome: 1 Overall cognitive functioning
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 3-12 months Vitamin E supplementation
Anand 2011 1.4 (0.1139) 100.0 % 1.40 [ 1.18, 1.62 ]
Subtotal (95% CI) 100.0 % 1.40 [ 1.18, 1.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.29 (P < 0.00001)
2 3-12 months Beta Carotene supplementation
Grodstein 2007 -0.14 (0.1194) 100.0 % -0.14 [ -0.37, 0.09 ]
Subtotal (95% CI) 100.0 % -0.14 [ -0.37, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
3 > 2-5 years antioxidants (Vitamin E + Vitamin C + Beta Carotene) supplementation
MRC/BHF 2002 0.09 (0.07) 100.0 % 0.09 [ -0.05, 0.23 ]
Subtotal (95% CI) 100.0 % 0.09 [ -0.05, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
4 > 2-5 years Vitamin E supplementation
Kang 2009 0.01 (0.1225) 100.0 % 0.01 [ -0.23, 0.25 ]
Subtotal (95% CI) 100.0 % 0.01 [ -0.23, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
5 > 2-5 years Vitamin C supplementation
Kang 2009 0.16 (0.1225) 100.0 % 0.16 [ -0.08, 0.40 ]
Subtotal (95% CI) 100.0 % 0.16 [ -0.08, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
6 > 2-5 years Beta Carotene supplementation
Kang 2009 -0.18 (0.1225) 100.0 % -0.18 [ -0.42, 0.06 ]
Subtotal (95% CI) 100.0 % -0.18 [ -0.42, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
7 > 5-10 years antioxidants (Vitamin E + Vitamin C + Beta carotene) supplementation
Yaffe 2004 0.6 (0.4104) 100.0 % 0.60 [ -0.20, 1.40 ]
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(. . . Continued)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 100.0 % 0.60 [ -0.20, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
8 > 5-10 years Vitamin C supplementation
Kang 2009 0.46 (0.1633) 100.0 % 0.46 [ 0.14, 0.78 ]
Subtotal (95% CI) 100.0 % 0.46 [ 0.14, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
9 > 5-10 years Beta Carotene supplementation
Kang 2009 -0.13 (0.1684) 100.0 % -0.13 [ -0.46, 0.20 ]
Subtotal (95% CI) 100.0 % -0.13 [ -0.46, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
10 > 10 years Beta Carotene supplementation
Grodstein 2007 0.18 (0.0869) 100.0 % 0.18 [ 0.01, 0.35 ]
Subtotal (95% CI) 100.0 % 0.18 [ 0.01, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.038)
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Analysis 2.2. Comparison 2 Antioxidants versus control, Outcome 2 Episodic memory.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 2 Antioxidants versus control
Outcome: 2 Episodic memory
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 3-12 months Beta Carotene supplementation
Grodstein 2007 0.015 (0.033) 100.0 % 0.02 [ -0.05, 0.08 ]
Subtotal (95% CI) 100.0 % 0.02 [ -0.05, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 > 2-5 years Vitamin E supplementation
Kang 2009 -0.02 (0.0255) 100.0 % -0.02 [ -0.07, 0.03 ]
Subtotal (95% CI) 100.0 % -0.02 [ -0.07, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
3 > 2-5 years Vitamin C supplementation
Kang 2009 -0.05 (0.0255) 100.0 % -0.05 [ -0.10, 0.00 ]
Subtotal (95% CI) 100.0 % -0.05 [ -0.10, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
4 > 2-5 years Beta Carotene supplementation
Kang 2009 0.01 (0.0306) 100.0 % 0.01 [ -0.05, 0.07 ]
Subtotal (95% CI) 100.0 % 0.01 [ -0.05, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
5 > 5-10 years antioxidants (Vitamin E + Vitamin C + Beta Carotene) supplementation
Yaffe 2004 -0.3 (0.5099) 100.0 % -0.30 [ -1.30, 0.70 ]
Subtotal (95% CI) 100.0 % -0.30 [ -1.30, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
6 > 5-10 years Vitamin E supplementation
Kang 2006 -0.01 (0.0204) 58.8 % -0.01 [ -0.05, 0.03 ]
Kang 2009 0.06 (0.0357) 41.2 % 0.06 [ -0.01, 0.13 ]
Subtotal (95% CI) 100.0 % 0.02 [ -0.05, 0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.90, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.55 (P = 0.58)
7 > 5-10 years Vitamin C supplementation
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(. . . Continued)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Kang 2009 -0.14 (0.0408) 100.0 % -0.14 [ -0.22, -0.06 ]
Subtotal (95% CI) 100.0 % -0.14 [ -0.22, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.43 (P = 0.00060)
8 > 5-10 years Beta Carotene supplementation
Kang 2009 0.02 (0.0357) 100.0 % 0.02 [ -0.05, 0.09 ]
Subtotal (95% CI) 100.0 % 0.02 [ -0.05, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
9 > 10 years Beta Carotene supplementation
Grodstein 2007 -0.063 (0.024) 100.0 % -0.06 [ -0.11, -0.02 ]
Subtotal (95% CI) 100.0 % -0.06 [ -0.11, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0087)
Test for subgroup differences: Chi2 = 17.68, df = 8 (P = 0.02), I2 =55%
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Analysis 2.3. Comparison 2 Antioxidants versus control, Outcome 3 Executive function.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 2 Antioxidants versus control
Outcome: 3 Executive function
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 3-12 months Beta Carotene supplementation
Grodstein 2007 0.07 (0.2817) 100.0 % 0.07 [ -0.48, 0.62 ]
Subtotal (95% CI) 100.0 % 0.07 [ -0.48, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
2 > 2-5 years Vitamin E supplementation
Kang 2009 0.42 (0.1837) 100.0 % 0.42 [ 0.06, 0.78 ]
Subtotal (95% CI) 100.0 % 0.42 [ 0.06, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
3 > 2-5 years Vitamin C supplementation
Kang 2009 -0.03 (0.1837) 100.0 % -0.03 [ -0.39, 0.33 ]
Subtotal (95% CI) 100.0 % -0.03 [ -0.39, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
4 > 2-5 years Beta Carotene supplementation
Kang 2009 0.22 (0.1837) 100.0 % 0.22 [ -0.14, 0.58 ]
Subtotal (95% CI) 100.0 % 0.22 [ -0.14, 0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
5 > 5-10 years antioxidants (Vitamin E + Vitamin C + Beta Carotene) supplementation
Yaffe 2004 -0.4 (0.2986) 100.0 % -0.40 [ -0.99, 0.19 ]
Subtotal (95% CI) 100.0 % -0.40 [ -0.99, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
6 > 5-10 years Vitamin E supplementation
Kang 2006 -0.04 (0.1378) 61.1 % -0.04 [ -0.31, 0.23 ]
Kang 2009 0.35 (0.2296) 38.9 % 0.35 [ -0.10, 0.80 ]
Subtotal (95% CI) 100.0 % 0.11 [ -0.26, 0.48 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.59 (P = 0.56)
7 > 5-10 years Vitamin C supplementation
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(. . . Continued)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Kang 2009 -0.25 (0.2296) 100.0 % -0.25 [ -0.70, 0.20 ]
Subtotal (95% CI) 100.0 % -0.25 [ -0.70, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
8 > 5-10 years Beta Carotene supplementation
Kang 2009 0.01 (0.2296) 100.0 % 0.01 [ -0.44, 0.46 ]
Subtotal (95% CI) 100.0 % 0.01 [ -0.44, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
9 > 10 years Beta Carotene supplementation
Grodstein 2007 0.01 (0.1882) 100.0 % 0.01 [ -0.36, 0.38 ]
Subtotal (95% CI) 100.0 % 0.01 [ -0.36, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 9.22, df = 8 (P = 0.32), I2 =13%
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Analysis 2.4. Comparison 2 Antioxidants versus control, Outcome 4 Incidence of dementia.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 2 Antioxidants versus control
Outcome: 4 Incidence of dementia
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 > 2-5 years of supplementation
MRC/BHF 2002 31/10269 31/10267 100.0 % 1.00 [ 0.61, 1.64 ]
Subtotal (95% CI) 10269 10267 100.0 % 1.00 [ 0.61, 1.64 ]
Total events: 31 (Experimental), 31 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 2.5. Comparison 2 Antioxidants versus control, Outcome 5 All-cause mortality.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 2 Antioxidants versus control
Outcome: 5 All-cause mortality
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 > 2-5 years antioxidants (Vitamin E + Vitamin C + + Beta Carotene) supplementation
MRC/BHF 2002 1446/10269 1389/10267 100.0 % 1.04 [ 0.97, 1.11 ]
Subtotal (95% CI) 10269 10267 100.0 % 1.04 [ 0.97, 1.11 ]
Total events: 1446 (Experimental), 1389 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Vitamin D3 versus placebo, Outcome 1 Overall cognitive functioning.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 3 Vitamin D3 versus placebo
Outcome: 1 Overall cognitive functioning
Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 3-12 months of supplementation
Rossom 2012 2028 2094 0 (0.1215) 100.0 % 0.0 [ -0.24, 0.24 ]
Subtotal (95% CI) 2028 2094 100.0 % 0.0 [ -0.24, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 > 1-2 years of supplementation
Rossom 2012 1918 1992 0 (0.128) 100.0 % 0.0 [ -0.25, 0.25 ]
Subtotal (95% CI) 1918 1992 100.0 % 0.0 [ -0.25, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 > 2-5 years of supplementation
Rossom 2012 1718 1797 -0.2 (0.1674) 100.0 % -0.20 [ -0.53, 0.13 ]
Subtotal (95% CI) 1718 1797 100.0 % -0.20 [ -0.53, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
4 > 5-10 years of supplementation
Rossom 2012 450 468 -0.1 (0.3646) 100.0 % -0.10 [ -0.81, 0.61 ]
Subtotal (95% CI) 450 468 100.0 % -0.10 [ -0.81, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Chi2 = 1.14, df = 3 (P = 0.77), I2 =0.0%
-4 -2 0 2 4
Favours placebo Favours intervention
151Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.2. Comparison 3 Vitamin D3 versus placebo, Outcome 2 Episodic memory.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 3 Vitamin D3 versus placebo
Outcome: 2 Episodic memory
Study or subgroup
Favours
vitamin D3 +
calcium Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 > 5-10 years of supplementation
Rossom 2012 690 730 0.05 (0.04) 100.0 % 0.05 [ -0.03, 0.13 ]
Subtotal (95% CI) 690 730 100.0 % 0.05 [ -0.03, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
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Analysis 3.3. Comparison 3 Vitamin D3 versus placebo, Outcome 3 Executive function.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 3 Vitamin D3 versus placebo
Outcome: 3 Executive function
Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 > 5-10 years of supplementation
Rossom 2012 690 730 0 (0.04) 100.0 % 0.0 [ -0.08, 0.08 ]
Subtotal (95% CI) 690 730 100.0 % 0.0 [ -0.08, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 3.4. Comparison 3 Vitamin D3 versus placebo, Outcome 4 Speed of processing.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 3 Vitamin D3 versus placebo
Outcome: 4 Speed of processing
Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 > 5-10 years of supplementation
Rossom 2012 690 730 0.03 (0.04) 100.0 % 0.03 [ -0.05, 0.11 ]
Subtotal (95% CI) 690 730 100.0 % 0.03 [ -0.05, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Vitamin D3 versus placebo, Outcome 5 Incident MCI.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 3 Vitamin D3 versus placebo
Outcome: 5 Incident MCI
Study or subgroup
Vitamin
D3 +
calcium Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 > 5-10 years of supplementation
Rossom 2012 98/2034 108/2109 100.0 % 0.94 [ 0.72, 1.23 ]
Subtotal (95% CI) 2034 2109 100.0 % 0.94 [ 0.72, 1.23 ]
Total events: 98 (Vitamin D3 + calcium), 108 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Vitamin D3 versus placebo, Outcome 6 Incident all-cause dementia.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 3 Vitamin D3 versus placebo
Outcome: 6 Incident all-cause dementia
Study or subgroup
Vitamin
D3 +
calcium Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 > 5-10 years supplementation
Rossom 2012 39/2034 37/2109 100.0 % 1.09 [ 0.70, 1.71 ]
Subtotal (95% CI) 2034 2109 100.0 % 1.09 [ 0.70, 1.71 ]
Total events: 39 (Vitamin D3 + calcium), 37 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Zinc + copper versus placebo, Outcome 1 Overall cognitive functioning.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 4 Zinc + copper versus placebo
Outcome: 1 Overall cognitive functioning
Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 > 5-10 years of supplementation
Yaffe 2004 538 534 0.6 (0.4036) 100.0 % 0.60 [ -0.19, 1.39 ]
Subtotal (95% CI) 538 534 100.0 % 0.60 [ -0.19, 1.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Zinc + copper versus placebo, Outcome 2 Episodic memory.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 4 Zinc + copper versus placebo
Outcome: 2 Episodic memory
Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 > 5-10 years of supplementation
Yaffe 2004 538 534 -0.7 (0.5284) 100.0 % -0.70 [ -1.74, 0.34 ]
Subtotal (95% CI) 538 534 100.0 % -0.70 [ -1.74, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Zinc + copper versus placebo, Outcome 3 Executive function.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 4 Zinc + copper versus placebo
Outcome: 3 Executive function
Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 > 5-10 years of supplementation
Yaffe 2004 538 534 -0.3 (0.2993) 100.0 % -0.30 [ -0.89, 0.29 ]
Subtotal (95% CI) 538 534 100.0 % -0.30 [ -0.89, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Complex multivitamin versus control, Outcome 1 Overall cognitive functioning.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 5 Complex multivitamin versus control
Outcome: 1 Overall cognitive functioning
Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 > 2-5 years of supplementation
Grodstein 2013 2980 2967 0.04 (0.0663) 100.0 % 0.04 [ -0.09, 0.17 ]
Subtotal (95% CI) 2980 2967 100.0 % 0.04 [ -0.09, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
2 > 5-10 years of supplementation
Grodstein 2013 1165 1159 0.12 (0.1327) 100.0 % 0.12 [ -0.14, 0.38 ]
Subtotal (95% CI) 1165 1159 100.0 % 0.12 [ -0.14, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
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Analysis 5.2. Comparison 5 Complex multivitamin versus control, Outcome 2 Episodic memory.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 5 Complex multivitamin versus control
Outcome: 2 Episodic memory
Study or subgroup Favours multivitamins Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 3-12 months of supplementation
Cockle 2000 65 59 33.17 (31.2702) 100.0 % 33.17 [ -28.12, 94.46 ]
Subtotal (95% CI) 65 59 100.0 % 33.17 [ -28.12, 94.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
2 > 2-5 years of supplementation
Grodstein 2013 2978 2964 -0.01 (0.0204) 100.0 % -0.01 [ -0.05, 0.03 ]
Subtotal (95% CI) 2978 2964 100.0 % -0.01 [ -0.05, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
3 > 5-10 years of supplementation
Grodstein 2013 1165 1159 -0.01 (0.0306) 100.0 % -0.01 [ -0.07, 0.05 ]
Subtotal (95% CI) 1165 1159 100.0 % -0.01 [ -0.07, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 1.13, df = 2 (P = 0.57), I2 =0.0%
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Analysis 5.3. Comparison 5 Complex multivitamin versus control, Outcome 3 Executive function.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 5 Complex multivitamin versus control
Outcome: 3 Executive function
Study or subgroup Multivitamin Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 > 2-5 years of supplementation
Grodstein 2013 2978 2964 -0.02 (0.1582) 100.0 % -0.02 [ -0.33, 0.29 ]
Subtotal (95% CI) 2978 2964 100.0 % -0.02 [ -0.33, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
2 > 5-10 years of supplementation
Grodstein 2013 1165 1159 -0.22 (0.2194) 100.0 % -0.22 [ -0.65, 0.21 ]
Subtotal (95% CI) 1165 1159 100.0 % -0.22 [ -0.65, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 0.55, df = 1 (P = 0.46), I2 =0.0%
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Analysis 5.4. Comparison 5 Complex multivitamin versus control, Outcome 4 Speed of processing.
Review: Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Comparison: 5 Complex multivitamin versus control
Outcome: 4 Speed of processing
Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 3-12 months of supplementation
Cockle 2000 66 61 -14.71 (21.6884) 100.0 % -14.71 [ -57.22, 27.80 ]
Subtotal (95% CI) 66 61 100.0 % -14.71 [ -57.22, 27.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Biological plausibility of vitamins and minerals
Supplement* Route Biological plausibility
Vitamins
Vitamin A antioxidant;
anti-inflammatory;
anti-cholinesterase;
beta-amyloid inhibition
Carboxylic formofVitaminAknownas all-
trans retinoic acid has been shown to have
memory restorative function and it may be
attributed to its anti-cholinesterase, anti-
oxidative and anti-inflammatory potential
(Sodhi 2013). Vitamin A and ß-carotene
may also inhibit the formation, extension
and destabilising effects of beta-amyloid
fibrins. Plasma or cerebrospinal fluid con-
centrations of vitamin A and beta-carotene
have been reported to be lower in AD pa-
tients, and increased Vit A/beta carotene
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(Continued)
concentrations have been clinically shown
to slow the progression of dementia (Ono
2012).
Vitamin D neuronal activity Vitamin D receptor (VDR) and 1, al-
pha-hydroxylase, the terminal calcitriol-ac-
tivating enzyme, are distributed through-
out both the foetal and adult brain. This
is thought to play a role in brain de-
velopment and critical brain functions (
McCann 2008). Significant correlation be-
tween serum 25(OH)D levels and cogni-
tive scores were reported in DeLuca 1975
and Przybelski 2007.
Vitamin E antioxidant;
beta-amyloid inhibition
Vitamin E consists of a group of toco-
pherols and tocotrienols. Apart from lipid
antioxidant activity, other functions in-
clude membrane stabilisation by forming
complexes with the products of lipid hy-
drolysis (Wang 2000). It has been shown
that the antioxidant and free radical scav-
enging activity of Vitamin E inhibits amy-
loid beta protein induced neuronal cell
death and may have implication in preven-
tion and treatment of Alzheimer’s demen-
tia (Behl 1992).
Vitamin K neuronal activity Vitamin K participates in the synthesis of
sphingolipids. Sphingolipids participate in
important cellular events such as prolifer-
ation, differentiation, senescence, and cell-
cell interactions. Sphingolipid metabolism
has been linked to age-related cognitive de-
cline and neurodegenerative diseases such
as Alzheimer’s disease (Ferland 2012). A
cross-sectional study found correlations be-
tween higher serum phylloquinone con-
centration and better cognitive scores in
tests evaluating episodic verbal memory
among healthy older adults (Ferland 2013)
.
Thiamine
(Vitamin B1)
neuronal activity Thiamine is required as a cofactor in the
cellular production of energy and enhances
normal neuronal activities (Osiezagha
2013). Rats with an episode of induced thi-
amine deficiency had cognitive, learning,
and memory impairments (Langlais 1995)
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(Continued)
.
Riboflavin
(Vitamin B2)
neuronal activity Riboflavin (7,8-dimethyl-10-ribityl-isoal-
loxazine) is water-soluble. Symptoms of
neurodegeneration and peripheral neu-
ropathy in riboflavin deficiency have been
documented in animal studies, but not ob-
served in humans. Subclinical riboflavin
deficiencymay contribute to increased con-
centrations of plasma homocysteine and
may be associatedwith increased risk of car-
diovascular disease and impaired handling
of iron (Powers 2003).
Niacin
(Vitamin B3)
vascular:
anti-inflammatory
Niacin is a water-soluble precursor cofac-
tor essential for the formation of dozens
of enzymes. Niacin decreases atheroscle-
rosis development mainly by reducing
LDL cholesterol. It also has modest HDL-
cholesterol-raising and anti-inflammatory
effects (Kühnast 2013).
Niacin deficiency causes pellagra. Its neu-
ropsychiatric symptoms are similar to those
in Alzheimer’s disease or vascular dementia
(Amanullah 2010).
Vitamin B6
(Pyridoxine, pyridoxal, pyridoxamine,
Pyridoxal 5’ phosphate (PLP) and pyridox-
amine 5’ phosphate (PMP), Pyridoxine 5’-
phosphate (PNP))
homocysteine;
neuronal activity
Vitamin B6 is a group of water-soluble
compounds (vitamers). Pyridoxal 5’ phos-
phate (PLP) and pyridoxamine 5’ phos-
phate (PMP) are the active coenzyme forms
of vitamin B6 (ODS 2014).
Vitamin B6 has many important brain
functions such as biosynthesis of neu-
rotransmitters (GABA, dopamine, nora-
drenaline, serotonin), receptor binding,
macronutrient metabolism, and gene ex-
pression. In a study looking at low plasma
B6 levels predicting cognitive decline and
depression in at-risk individuals, low PLP
status was seen as a risk factor for cogni-
tive decline and depression in at-risk pop-
ulations (Scott 2013).
Folic Acid
(Vitamin B9)
antioxidant;
homocysteine; neuronal activity
Folate is a cofactor and promotes the
remethylation of homocysteine -- an amino
acid that can induce DNA strand breakage,
oxidative stress, and apoptosis. Folate is re-
quired for normal development of the ner-
vous system, playing important roles reg-
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(Continued)
ulating neurogenesis and programmed cell
death. Folate deficiency and its resultant
increase in homocysteine levels has been
linked to several neurodegenerative condi-
tions, including stroke, Alzheimer’s disease,
and Parkinson’s disease (Mattson 2003).
Vitamin B12
(cobalamins: cyanocobalamin, hydroxo-
cobalamin, methylcobalamin, hydroxo-
cobalamin)
homocysteine;
neuronal activity
Vitamin B12 acts as a coenzyme in
metabolism of amino acids and fatty acids
required for the synthesis of nucleic acids,
erythrocytes, and in the maintenance of
myelin (Pawlak 2014). Lower vitamin B12
status has been associated with increased
rates of cognitive decline and dementia
(Clarke 2007b; O’Leary 2012).
Pantothenic Acid
(Vitamin B5)
energy; metabolism Pantothenic acid (PA) is a component of
coenzyme A, an essential cofactor in fatty
acid oxidation, lipid elongation, and fatty
acid synthesis (Kelly 2011). This may have
an indirect effect in cognition.
Biotin
(Vitamin H)
energy; metabolism Biotin is also known as Vitamin H and
is part of the B complex group of vita-
mins. They act as cofactors in carboxy-
lase enzymes, fatty acid, and amino acid
metabolism. This may have an indirect ef-
fect in cognition
Vitamin C antioxidant Vitamin C has antioxidant functions and is
required for the synthesis of noradrenaline
from dopamine. It has been reported that
Vitamin C levels have been lower than con-
trols in patients with senile dementia of
Alzheimer’s type (Jeandel 1989). In a lon-
gitudinal and cross-sectional study it was
found that higher vitamin C levels were as-
sociated with better memory performance
(Perrig 1997).
Minerals
Calcium neuronal activity Calcium ions regulate a number of physi-
ological processes including neuronal gene
expression and the neuronal secretion of
neurotransmitters (Delage 2014; Dolphin
2012). Supplementation with calcium to-
getherwith vitaminDwas found tohave no
significant association with incident cogni-
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tive impairment (Rossom 2012).
Ozawa 2012 concluded that, in the gen-
eral Japanese population, higher self-re-
ported dietary intakes of potassium, cal-
cium, and magnesium reduced the risk of
all-cause dementia, especially Vascular De-
mentia (VaD). The proposed mechanism
was through the reduction of of vascular
risk factors
Chromium energy production; metabolism. Chromium is needed for energy produc-
tion and has been found to promote the
effect of insulin involved in metabolism
and storage of protein, carbohydrates and
lipids within the CNS (Anderson 1997;
Institute of Medicine 2011; Ozawa 2012)
. Chromium is involved in metabolism
of nucleic acid, which is needed to build
DNA, the genetic material in cells; and
promotes synthesis of cholesterol and fatty
acids needed for brain function. It may
lower LDL cholesterol and triglyceride lev-
els, raise HDL cholesterol levels and reduce
high blood pressure (Preuss 1997), hence
may affect vascular risk factors.
Insulin resistance is implicated in the
pathophysiological changes associated with
Alzheimer’s disease, and pharmaceutical
treatments that overcome insulin resistance
improve memory function in subjects with
mild cognitive impairment (MCI) and
early Alzheimer’s disease. Chromium (Cr)
supplementation improves glucose disposal
in patients with insulin resistance and dia-
betes. A double-blind RCT suggested that
supplementation with Chromium picoli-
nate can enhance cognitive inhibitory con-
trol and cerebral function in older adults
at risk for neurodegeneration (Krikorian
2010). An additional study reported a pos-
itive correlation between cognitive func-
tion and serum chromium levels (Smorgon
2004).
Copper antioxidant Copper is a component of an antioxidant
enzyme called superoxide dismutase that
protects cells from damage by harmful free
radicals. Copper is necessary for a healthy
nerve system and taste sensitivity (Institute
of Medicine 2011).
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Copper may promote non-amyloidogenic
processing of amyloid precursor protein
(APP) and thereby lower the Aβ produc-
tion in cell culture systems, and it increases
lifetime and decreases soluble amyloid pro-
duction in APP transgenic mice (Borchardt
1999). In Alzheimer patients, a decline of
Aβ levels in CSF is reported in adults in
the treatment group (Kaden 2011).
Iodine neuronal development and structure. Iodine is needed for the synthesis of thy-
roid hormones which, in turn, are needed
for the myelination of the central nervous
system. Iodine is necessary for the normal
development of the brain. A deficiency of
this mineral during critical periods of de-
velopment in gestation can lead to intel-
lectual disability and neurodevelopmental
problems (Bath 2013a). Positive associa-
tion was found between maternal iodine
status and child IQ at age 8 years and read-
ing ability at age 9 years (Bath 2013b).
Iron neuronal activity Iron is needed for development of oligo-
dendrocytes and numerous enzymes that
synthesise neurotransmitters such as nora-
drenaline, serotonin, and dopamine. It is
important for production of the haemo-
globin in red blood cells (Delage 2014;
Institute of Medicine 2011). Regression
analysis showed that non-anaemic iron-de-
ficient adolescent girls who received iron
performed better on a test of verbal learn-
ing and memory than girls in the control
group (Bruner 1996)
Magnesium energy, metabolism Magnesium is involved in hundreds of en-
zyme reactions, including protein synthe-
sis. It plays a role in energy production;
can improve insulin sensitivity in diabetics;
helps regulate blood sugar level; and regu-
lates neuro-muscular transmission
Higher self-reported dietary intakes of
potassium, calcium, and magnesium have
been reported to reduce the risk of all-cause
dementia, especially VaD, in the general
Japanese population (Ozawa 2012).
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Manganese metabolism Manganese is needed to synthesise fatty
acids and cholesterol, and metabolise car-
bohydrates and proteins. It is important for
energy production. It promotes utilisation
of other key nutrients like vitamin B1 (thi-
amine), biotin, choline, ascorbic acid, and
vitamin E (Delage 2014).
Man-
ganese is needed for glucose metabolism,
which helps regulate blood glucose. It is
needed to make manganese superoxide dis-
mutase (MnSOD), one of the key antiox-
idants that protects cells from free radi-
cal damage, and so helps maintains healthy
nerves. It works synergistically with the B-
complex vitamins to generate an overall
feeling of well-being (Institute of Medicine
2011).
Molybdenum metabolism Molybdenum promotes normal cell func-
tion; and functions as a cofactor for three
essential enzymes that play a vital role
in carbohydrate metabolism, utilisation
of iron, sulphite detoxification, and uric
acid formation (Delage 2014; Institute of
Medicine 2011).
Phosphorus metabolism, neuronal structure and func-
tion.
Phosphorus is needed for metabolism of
carbohydrates and fats to produce energy
and is involved in the production of ATP
required for growth and repair of cells and
tissues; it is needed to make cell mem-
branes. It helps the body utilise the B-com-
plex vitamins that support proper muscle
and nerve function (Delage 2014; Institute
of Medicine 2011).
Potassium nerve transmission. Potassium is involved in regulating nerve
transmissions and muscle contractions. It
helps the body handle sodium and so re-
duces the risk of high blood pressure (Berr
2012). It has been found to lower the risk of
stroke and ischaemic heart disease. Potas-
sium is needed for synthesis of protein
from amino acids (Delage 2014; Institute
of Medicine 2011).
Higher self-reported dietary intakes of
potassium, calcium, and magnesium re-
duce the risk of all-cause dementia, espe-
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cially VaD, in the general Japanese popula-
tion (Ozawa 2012).
Selenium antioxidant. Selenium is an important antioxidant espe-
cially in combinationwith vitaminE, in the
central nervous system and other body tis-
sues (Delage 2014; Mehdi 2013; Rahman
2007).
Low selenium levels were found to be asso-
ciated with poorer cognitive function (Berr
2012; Smorgon 2004). Supplementation
with selenium has been associated with im-
proved overall health, reducing oxidative
stress and reducing the risk of dementia
(Mehdi 2013).
Sodium neuronal activity Sodium is essential for regulating muscle
contractions, nerve transmissions essential
for normal CNS physiological mechanisms
and homeostasis (Delage 2014; Institute of
Medicine 2011).
Zinc antioxidant
neuronal activity
Zinc is a constituent of the antioxidant en-
zyme superoxide dismutase that helps re-
duce the harm from free radicals. Zinc reg-
ulates cell division and synthesis of genetic
cell DNA. It is essential for reproduction,
repair, and normal growth within the CNS
(Delage 2014).
Zinc is found in high levels in the brain
where it performs catalytic, structural and
regulatory roles in cellular metabolism.
Zinc is bound to proteins but free zinc is
present in synaptic vesicles and performs
a role in neurotransmission mediated by
glutamate and gamma-aminobutyric acid
(GABA). Short-term deficits of zinc have
been shown to impair certain measures
of mental and neurological function while
long-term deficits of zinc, especially dur-
ing gestation, result in malformation or
deficits in attention, learning, memory and
neuropsychological behaviour (Institute of
Medicine 2011).
Zinc was found to be capable of reducing
post-ischaemic injury to a variety of tis-
sues and organs through a mechanism that
might involve the antagonism of copper re-
activity. Although the evidence for the an-
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tioxidant properties of zinc is compelling,
the mechanisms are still unclear (Powell
2000).
* Only orally-administered supplements taken at any dose for at least 12 weeks are considered. Supplements that combine vitamins
or minerals are eligible as well
Footnotes
Aβ: Amyloid β Protein
AD: Alzheimers’ Disease
APP: amyloid precursor protein
ATP: Adenosine triphosphate
CNS: central nervous system
Cr: Chromium
CSF: CerebroSpinal Fluid
DNA: DeoxyriboNucleic Acid
GABA: Gamma-AminoButyric Acid
HDL: high-density lipoproteins
IQ: Intelligence quotient
LDL: Low-density lipoprotein
MCI: Mild Cognitive Impairment
MnSOD: manganese superoxide dismutase
PLP: Pyridoxal 5’ phosphate
PMP: pyridoxamine 5’ phosphate
PNP: Pyridoxine 5’-phosphate
VaD: Vascular Dementia
VDR: Vitamin D receptor
25(OH)D: serum hydroxyvitamin D
Appendix 2. Sources searched and search strategies
Source Search strategy Hits retrieved
ALOIS (www.medicine.ox.ac.uk/alois)
(Date of most recent search: 25 January
2018)
Basic search: VIT
[Studies within ALOIS are coded VIT if
the intervention is a vitamin or mineral]
Dec 2014: 254
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 3
Jan 2018: 1
MEDLINE In-process and other non-
indexed citations and MEDLINE 1950-
present (Ovid SP)
(Date of most recent search: 25 January
2018)
1. exp *Vitamins/
2. exp *Minerals/
3. exp *Dietary Supplements/
4. Calcium Carbonate/
5. vitamin*.ti,ab.
6. cholecalciferol.ti,ab.
7. ergocalciferol.ti,ab.
Dec 2014: 1320
Jul 2015: 53
Mar 2016: 111
Aug 2016: 103
Mar 2017: 166
Jan 2018: 120
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8. toxiferol.ti,ab.
9. retinol.ti,ab.
10. “retinoic acid”.ti,ab.
11. Vitamin A/
12. Vitamin B 12/
13. Vitamin D/
14. Vitamin E/
15. “beta-carotene”.ti,ab.
16. “alpha-carotene”.ti,ab.
17. “gamma-carotene”.ti,ab.
18. “beta-cryptoanthin”.ti,ab.
19. thiamine.ti,ab.
20. riboflavin.ti,ab.
21. niacin.ti,ab.
22. nicotinamide.ti,ab.
23. pantothenic.ti,ab.
24. pyridoxine.ti,ab.
25. pyridoxal.ti,ab.
26. pyridoxamine.ti,ab.
27. biotin.ti,ab.
28. “folic acid”.ti,ab.
29. Folic Acid/
30. cyanocobalamin.ti,ab.
31. methylcobalamin.ti,ab.
32. “l-ascorbic acid”.ti,ab.
33. “ascorbic acid”.ti,ab.
34. ascorbate.ti,ab.
35. Ascorbic Acid/
36. phylloquinone.ti,ab.
37. phytomeadione.ti,ab.
38. phytonadine.ti,ab.
39. mineral*.ti,ab.
40. multivitamin*.ti,ab.
41. “diet* supplement*”.ti,ab.
42. calcium.ti,ab.
43. Calcium/
44. iron.ti,ab.
45. zinc.ti,ab.
46. sodium.ti,ab.
47. potassium.ti,ab.
48. phosphorus.ti,ab.
49. magnesium.ti,ab.
50. chloride.ti,ab.
51. sulphur.ti,ab.
52. mangansese.ti,ab.
53. cobalt.ti,ab.
54. selenium.ti,ab.
55. copper.ti,ab.
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56. iodine.ti,ab.
57. fluoride.ti,ab.
58. or/1-57
59. *Aging/
60. Aged/
61. “Aged, 80 and over”/
62. Middle Aged/
63. Age Factors/
64. “mild cognitive impairment”.ti,ab.
65. Mild Cognitive Impairment/
66. MCI.ti,ab.
67. AAMI.ti,ab.
68. ACMI.ti,ab.
69. ARCD.ti,ab.
70. CIND.ti,ab.
71. (nMCI or aMCI or mMCI or MCIa).
ti,ab.
72. “old* adults”.ti,ab.
73. elderly.ti,ab.
74. “old* age*”.ti,ab.
75. “middle age*”.ti,ab.
76. seniors.ti,ab.
77. “senior citizens”.ti,ab.
78. “community dwelling”.ti,ab.
79. pensioners.ti,ab.
80. “aged sample”.ti,ab.
81. “aged population”.ti,ab.
82. or/59-81
83. 58 and 82
84. *Cognition/
85. *Cognition Disorders/
86. Memory/
87. Memory Disorders/
88. (cognit* adj3 (func* or declin* or re-
duc* or impair* or improve* or deficit* or
progress* or perform* or abilit*)).ti,ab.
89. “mental perform*”.ti,ab.
90. memory.ti,ab.
91. “executive function*”.ti,ab.
92. Executive Function/
93. Attention/
94. (speed adj2 processing).ti,ab.
95. “episodic memory”.ti,ab.
96. Memory, Episodic/
97. or/84-96
98. 83 and 97
99. randomized controlled trial.pt.
100. controlled clinical trial.pt.
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101. randomized.ab.
102. placebo.ab.
103. drug therapy.fs.
104. randomly.ab.
105. trial.ab.
106. groups.ab.
107. or/99-106
108. exp Animals/ not humans.sh.
109. 107 not 108
110. 98 and 109 [all results]
111. *Vitamins/
112. *Cognition/
113. “Aged, 80 andover”/ orAged/ orMid-
dle Aged/
114. Mild Cognitive Impairment/
115. “mild cognitive impairment”.ti,ab.
116. 113 or 114 or 115
117. 111 and 112 and 116
118. 99 or 100
119. 117 and 118 [results sent directly to
author team]
120. 110 not 119 [results minus those sent
directly to author team. These results will
be screened by the ’crowd’]
Embase
1974-24 January 2018 (Ovid SP)
(Date of most recent search: 25 January
2018)
1. exp *vitamin/
2. exp *mineral/
3. exp diet supplementation/
4. calcium/
5. vitamin*.ti,ab.
6. mineral*.ti,ab.
7. cholecalciferol.ti,ab.
8. ergocalciferol.ti,ab.
9. toxiferol.ti,ab.
10. retinol.ti,ab.
11. retinal.ti,ab.
12. “retinoic acid”.ti,ab.
13. vitamin D/
14. vitamin B complex/ or vitamin B
group/
15. vitamin D/
16. vitamin K epoxide reductase/ or vita-
min K group/
17. colecalciferol/ or calcitriol/ or calcitriol
derivative/
18. ascorbic acid/
19. vitamin supplementation/
20. “beta-carotene”.ti,ab.
21. beta carotene/
Dec 2014: 1275
Jul 2015: 114
Mar 2016: 184
Aug 2016: 94
Mar 2017: 257
Jan 2018: 250
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22. “alpha-carotene”.ti,ab.
23. alpha carotene/
24. “gamma-carotene”.ti,ab.
25. gamma carotene/
26. “beta-cryptoanthin”.ti,ab.
27. thiamine.ti,ab.
28. thiamine/
29. riboflavin.ti,ab.
30. riboflavin/
31. niacin.ti,ab.
32. nicotinic acid/
33. nicotinamide.ti,ab.
34. pantothenic.ti,ab.
35. pyridoxamine.ti,ab.
36. pantothenic acid/
37. pyridoxamine/
38. biotin.ti,ab.
39. biotin/
40. “folic acid”.ti,ab.
41. folic acid/
42. cyanocobalamin.ti,ab.
43. cyanocobalamin/
44. methylcobalamin.ti,ab.
45. “l-ascorbic acid”.ti,ab.
46. “ascorbic acid”.ti,ab.
47. phylloquinone.ti,ab.
48. phytonadine.ti,ab.
49. phytomeadione.ti,ab.
50. multivitamin*.ti,ab.
51. “vitamin* supple*”.ti,ab.
52. “diet* supplement*”.ti,ab.
53. calcium.ti,ab.
54. iron.ti,ab.
55. iron/
56. zinc.ti,ab.
57. zinc/
58. sodium.ti,ab.
59. sodium/
60. potassium.ti,ab.
61. citrate potassium/ or potassium/ or
clavulanate potassium/ or diclofenac potas-
sium/
62. phosphorus.ti,ab.
63. phosphorus/
64. magnesium.ti,ab.
65. magnesium/
66. chloride.ti,ab.
67. chloride/
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68. sulphur.ti,ab.
69. mangansese.ti,ab.
70. cobalt.ti,ab.
71. cobalt/
72. selenium.ti,ab.
73. selenium/
74. copper.ti,ab.
75. copper/
76. iodine.ti,ab.
77. fluoride.ti,ab.
78. fluoride/
79. or/1-78
80. aging/
81. aged/
82. middle aged/
83. mild cognitive impairment/
84. “mild cognitive impairment”.ti,ab.
85. MCI.ti,ab.
86. AAMI.ti,ab.
87. ACMI.ti,ab.
88. ARCD.ti,ab.
89. CIND.ti,ab.
90. (nMCI or aMCI or mMCI or MCIa).
ti,ab.
91. “middle age*”.ti,ab.
92. “old* age*”.ti,ab.
93. “old* adults”.ti,ab.
94. “community dwelling”.ti,ab.
95. “senior citizens”.ti,ab.
96. seniors.ti,ab.
97. pensioners.ti,ab.
98. “aged sample”.ti,ab.
99. “aged population”.ti,ab.
100. or/80-99
101. exp cognition/
102. cognition disorders/
103. episodic memory/ or memory/
104. memory disorder/
105. dementia/
106. Alzheimer disease/
107. dement*.ti,ab.
108. alzheimer*.ti,ab.
109. cognition.ti,ab.
110. cognitive.ti,ab.
111. or/101-110
112. 79 and 100 and 111
113. randomized controlled trial/
114. controlled clinical trial/
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115. placebo.ab.
116. (random* adj2 divide*).ti,ab.
117. (random* adj2 allocate*).ti,ab.
118. trial.ab.
119. “double-blind*”.ti,ab.
120. “single blind*”.ti,ab.
121. or/113-120
122. 112 and 121
123. *Cognition/
124. exp *vitamin/ or exp *vitamin supple-
mentation/
125. exp *mineral/ or exp *mineral supple-
mentation/
126. (vitamin* or mineral*).ti.
127. 124 or 125 or 126
128. exp *aging/
129. (elderly or “middle age*” or “old*
adults” or MCI or “mild cognitive impair-
ment”).ti
130. exp *middle aged/
131. 128 or 129 or 130
132. 123 and 127 and 131
133. 113 or 114
134. 132 and 133
135. 122 not 134
PsycINFO
1806-January week 2 2018 (Ovid SP)
(Date of most recent search: 25 January
2018)
1. exp Aging/
2. exp Cognitive Impairment/
3. “cognit* impair*”.ti,ab.
4. MCI.ti,ab.
5. AAMI.ti,ab.
6. ACMI.ti,ab.
7. ARCD.ti,ab.
8. CIND.ti,ab.
9. (nMCI or aMCI or mMCI or MCIa).ti,
ab.
10. “old* age*”.ti,ab.
11. elderly.ti,ab.
12. “middle age*”.ti,ab.
13. “old* adults”.ti,ab.
14. seniors.ti,ab.
15. “senior citizens”.ti,ab.
16. “community dwelling”.ti,ab.
17. pensioners.ti,ab.
18. or/1-17
19. exp Cognition/
20. exp Dementia/
21. 19 or 20
22. randomi?ed.ti.
Dec 2014: 202
Jul 2015: 15
Mar 2016: 10
Aug 2016: 0
Mar 2017: 14
Jan 2018: 9
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23. (randomly adj2 allocat*).ab.
24. (randomly adj2 divide*).ab.
25. RCT.ti,ab.
26. “double-blind*”.ti,ab.
27. “single blind*”.ti,ab.
28. “randomi?ed trial”.ab.
29. “randomi?ed control* trial”.ab.
30. “random allocation”.ab.
31. “controlled clinical trial”.ti,ab.
32. or/22-31
33. exp Vitamins/
34. exp Dietary Supplements/
35. vitamin*.ti,ab.
36. mineral*.ti,ab.
37. calcium.ti,ab.
38. Calcium/
39. exp Ascorbic Acid/
40. exp Folic Acid/
41. “folic acid”.ti,ab.
42. cholecalciferol.ti,ab.
43. ergocalciferol.ti,ab.
44. toxiferol.ti,ab.
45. retinol.ti,ab.
46. retinal.ti,ab.
47. “retinoic acid”.ti,ab.
48. “beta-carotene”.ti,ab.
49. “alpha-carotene”.ti,ab.
50. “gamma-carotene”.ti,ab.
51. “beta-cryptoanthin”.ti,ab.
52. thiamine.ti,ab.
53. riboflavin.ti,ab.
54. niacin.ti,ab.
55. nicotinamide.ti,ab.
56. pantothenic.ti,ab.
57. pyridoxine.ti,ab.
58. pyridoxal.ti,ab.
59. pyridoxamine.ti,ab.
60. biotin.ti,ab.
61. “folic acid”.ti,ab.
62. cyanocobalamin.ti,ab.
63. methylcobalamin.ti,ab.
64. “l-ascorbic acid”.ti,ab.
65. “ascorbic acid”.ti,ab.
66. ascorbate.ti,ab.
67. phylloquinone.ti,ab.
68. phytomeadione.ti,ab.
69. phytonadine.ti,ab.
70. multivitamin*.ti,ab.
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71. “diet* supplement*”.ti,ab.
72. iron.ti,ab.
73. zinc.ti,ab.
74. sodium.ti,ab.
75. potassium.ti,ab.
76. phosphorus.ti,ab.
77. magnesium.ti,ab.
78. chloride.ti,ab.
79. sulphur.ti,ab.
80. mangansese.ti,ab.
81. cobalt.ti,ab.
82. selenium.ti,ab.
83. copper.ti,ab.
84. iodine.ti,ab.
85. fluoride.ti,ab.
86. 18 or 21
87. or/33-85
88. 86 and 87
89. 32 and 88
90. exp *Vitamins/
91. (vitamin* or mineral*).ti.
92. 90 or 91
93. exp *Cognition/
94. (cognition or cognitive).ti.
95. 93 or 94
96. (elderly or “middle age*” or “old*
adults” or MCI or “mild cognitive impair-
ment”).ti
97. 92 and 95 and 96
98. (randomised or randomised or RCT or
trial).ti.
99. 97 and 98
100. 89 not 99
CINAHL (EBSCOhost)
(Date of most recent search: 25 January
2018)
S1 (MM “Vitamins+“)
S2 (MM “Minerals+”)
S3 (MH“Dietary Supplements”)OR (MH
“Dietary Supplementation”) OR (MH
“Dietary Carbohydrates”) OR (MH “Di-
etary Fiber”) OR (MH “Sodium, Dietary”)
OR (MH “Dietary Fats”) OR (MH “Di-
etary Proteins”) OR (MH “Dietary Su-
crose”)
S4 TX vitamin*
S5 TX mineral*
S6 TX “diet* supple*”
S7 (MH ”Fatty Acids“) OR (MH ”Fatty
Acids, Omega-6“) OR (MH ”Fatty Acids,
Unsaturated“) OR (MH ”Trans Fatty
Dec 2014: 493
Jul 2015: 7
Mar 2016: 35
Aug 2016: 15
Mar 2017: 24
Jan 2018: 23
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Acids“) OR (MH ”Fatty Acids, Monoun-
saturated“) OR (MH ”Fatty Acids, Satu-
rated“) OR (MH ”Fatty Acids, Essential”)
S8 TX “fatty acid*”
S9 (MH “Vitamin A”)
S10 (MH”Vitamin B12“) OR (MH”Vita-
min B Complex“) OR (MH ”Thiamine“)
OR (MH ”Riboflavin“) OR (MH ”Pyri-
doxine“) OR (MH “Carnitine”)
S11 (MH “Folic Acid”)
S12 (MH ”Ascorbic Acid”)
S13 (MH “Vitamin D”) OR (MH “Chole-
calciferol”) OR (MH “Ergocalciferols”)
OR (MH “Calcitriol“)
S14 (MH ”Vitamin E“) OR (MH ”Pan-
tothenic Acid”)
S15 (MH “Vitamin K”) OR (MH “Osteo-
calcin“)
S16 TX “beta-carotene”
S17 TX “alpha-carotene“
S18 TX thiamine
S19 TX riboflavin
S20 TX niacin
S21 TX pantothenic
S22 TX nicotinamide
S23 TX pyridoxine
S24 TX pyridoxal
S25 TX biotin
S26 (MH “Calcium”)
S27 TX calcium
S28 TX iron
S29 (MH “iron”)
S30 (MH “Zinc”)
S31 TX zinc
S32 (MH “Sodium”)
S33 TX sodium
S34 (MH “Potassium“)
S35 TX potassium
S36 (MH “Phosphorus”)
S37 TX phosphorus
S38 (MH “Magnesium“)
S39 TX magnesium
S40 (MH ”Sodium Chloride, Dietary”)
S41 TX chloride
S42 TX sulphur
S43 TX cobalt
S44 TX selenium
S45 TX copper
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S46 TX iodine
S47 TX flouride
S48 S1 OR S2 OR S3 OR S4 OR S5 OR
S6 OR S7 OR S8 OR S9 OR S10 OR S11
OR S12OR S13OR S14OR S15OR S16
OR S17OR S18OR S19OR S20OR S21
OR S22OR S23OR S24OR S25OR S26
OR S27OR S28OR S29OR S30OR S31
OR S32OR S33OR S34OR S35OR S36
OR S37OR S38OR S39OR S40OR S41
OR S42OR S43OR S44OR S45OR S46
OR S47
S49 (MH “Aging“)
S50 (MH”Aged“)OR (MH”Aged, 80 and
Over”)
S51 (MH “Middle Age”)
S52 TX ”Mild Cognitive Impairment”
S53 TX MCI OR AAMI OR ACMI OR
ARCD OR CIND
S54 TX nMCI OR aMCI OR mMCI OR
MCIa
S55 TX elderly
S56 TX “old* adults”
S57 TX ”old* age*”
S58 TX pensioners
S59 TX “community dwelling”
S60 TX seniors
S61 TX ”senior citizen*”
S62 TX “age* sample”
S63 TX ”age* population”
S64 S49ORS50OR S51ORS52OR S53
OR S54OR S55OR S56OR S57OR S58
OR S59OR S60OR S61OR S62OR S63
S65 S48 AND S64
S66 (MH “Cognition”) OR (MH “Cogni-
tion Disorders”) OR (MH “Delirium, De-
mentia, Amnestic, Cognitive Disorders”)
S67 TX cognition
S68 TX memory
S69 (MH ”Memory“) OR (MH ”Mem-
ory Disorders“) OR (MH ”Memory, Short
Term”)
S70 TX “executive function”
S71 TX ”cognitive* declin*”
S72 TX “cognitive* improv*”
S73 TX ”cognitive deficit*”
S74 TX “mental perform*”
S75 TX dementia
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S76 TX alzheimer*
S77 (MH “Dementia+”)
S78 S66ORS67OR S68ORS69OR S70
OR S71OR S72OR S73OR S74OR S75
OR S76 OR S77
S79 S65 AND S78
S80 (MH “Randomized Controlled Tri-
als”)
S81 AB randomly
S82 AB placebo
S83 AB groups
S84 AB RCT
S85 TX ”double blind*”
S86 TX “single blind*”
S87 TX ”controlled clinical trial”
S88 TI randomised
S89 TI randomized
S90 S80ORS81OR S82ORS83OR S84
OR S85 OR S86 OR S87 OR S88
S91 S79 AND S90
ISI Web of Science [includes: Web
of Science (1945-present); BIOSIS Pre-
views (1926-present); MEDLINE (1950-
present); Journal Citation Reports]; BIO-
SIS Previews
(Date of most recent search: 25 January
2018)
(“mild cognitive impairment” OR elderly
OR “age* subjects” OR “old* adult*” OR
“middle age*” OR MCI) AND TOPIC:
(“randomly allocated” OR “random alloca-
tion” OR randomised OR randomized OR
RCT OR “controlled trial” OR “double
blind” OR “single blind”) AND TOPIC:
(vitamin* OR mineral* OR “diet* suppl*”
OR “ascorbic acid” OR “folic acid” OR
iron OR calcium OR sodium OR zinc OR
potassium OR magnesium OR cobalt OR
copper OR iodine) AND TOPIC: (cogni-
tion OR dementia ORmemory OR “exec-
utive function” OR alzheimer*)
Timespan: All years.
Search language=Auto
Dec 2014: 932
Jul 2015: 34
Mar 2016: 100
Aug 2016: 43
Mar 2017: 67
Jan 2018: 55
LILACS (BIREME)
(Date of most recent search: 25 January
2018)
cognition OR “mild cognitive impair-
ment” OR elderly OR “aged subjects” OR
“older adults” OR “middle aged” [Words]
and randomly OR randomised OR ran-
domized OR RCT OR “controlled trial”
[Words] and vitamin OR vitamins OR
mineral OR minerals OR “fatty acid” OR
“folic acid” [Words]
Dec 2014: 28
Jul 2015: 0
Mar 2016: 0
Aug 2016: 1
Mar 2017: 0
Jan 2018: 0
CENTRAL (via CRSO)
(Date of most recent search: 25 January
2018)
#1 MeSH descriptor: [Aged, 80 and over]
explode all trees
Dec 2014: 395
Jul 2015: 10
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#2 MeSH descriptor: [Aged] explode all
trees
#3 MeSH descriptor: [Middle Aged] ex-
plode all trees
#4 MeSH descriptor: [Mild Cognitive Im-
pairment] explode all trees
#5 “cognit* impair*” or MCI
#6 elderly
#7 “old* adults”
#8 “old* age*”
#9 “old* sample”
#10 senior citizens
#11 pensioners
#12 seniors
#13 #1 or #2 or #3 or #4 or #5 or #6 or #
7 or #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Cognition] ex-
plode all trees
#15MeSHdescriptor: [Dementia] explode
all trees
#16 cognit*
#17 memory
#18 “executive function*”
#19 processing
#20 “mental perform*”
#21 dement*
#22 alzheimer*
#23 #14 or #15 or #16 or #17 or #18 or #
19 or #20 or #21 or #22
#24 MeSH descriptor: [Vitamins] explode
all trees
#25 MeSH descriptor: [Minerals] explode
all trees
#26 vitamin*
#27 mineral*
#28 “ascorbic acid”
#29 “folic acid”
#30 MeSH descriptor: [Fatty Acids] ex-
plode all trees
#31 zinc or iron or calcium or sodium or
potassium or magnesium or cobalt or cop-
per or selenium or iodine or flouride or
chloride
#32 “beta-carotene”
#33 “alpha-carotene”
#34 thiamine
#35 riboflavin
#36 niacin
Mar 2016: 50
Aug 2016: 48
Mar 2017: 90
Jan 2018: 54
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#37 biotin
#38 pantothenic
#39 nicotinamide
#40 pyridoxal
#41 “diet* suppl*”
#42 #26 or #27 or #28 or #29 or #30 or #
31 or #32 or #33 or #34 or #35 or #36 or
#37 or #38 or #39 or #40 or #41
#43 #13 and #23 and #42
Clinicaltrials.gov (www.clinicaltrials.gov)
(Date of most recent search: 25 January
2018)
In Intervention studies: [intervention] vi-
tamin* OR mineral* OR “diet* suppl*”
OR “ascorbic acid” OR “folic acid” OR
iron OR calcium OR sodium OR zinc OR
potassium OR magnesium OR cobalt OR
copper OR iodine AND [condition]: cog-
nition OR “mild cognitive impairment”
OR elderly OR “aged subjects” OR “older
adults” OR “middle aged”
Trial Status: all
Dec 2014: 147
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 6
Jan 2018: 8
ICTRP Search Portal (http:/
/apps.who.int/trialsearch) (includes: Aus-
tralian New Zealand Clinical Trials Reg-
istry; ClinicalTrilas.gov; ISRCTN;Chinese
Clinical Trial Registry; Clinical Trials Reg-
istry - India; Clinical Research Informa-
tion Service - Republic of Korea; German
Clinical Trials Register; Iranian Registry
of Clinical Trials; Japan Primary Registries
Network; Pan African Clinical Trial Reg-
istry; Sri LankaClinical TrialsRegistry; The
Netherlands National Trial Register)
(Date of most recent search: 25 January
2018)
In Intervention studies: [intervention] vi-
tamin* OR mineral* OR “diet* suppl*”
OR “ascorbic acid” OR “folic acid” OR
iron OR calcium OR sodium OR zinc OR
potassium OR magnesium OR cobalt OR
copper OR iodine AND [condition]: cog-
nition OR “mild cognitive impairment”
OR elderly OR “aged subjects” OR “older
adults” OR “middle aged”
Trial Status: all
Dec 2014: 25
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 4
Jan 2018: 2
TOTAL before de-duplication Dec 2014: 5071
Jul 2015: 233
Mar 2016: 496
Aug 2016: 304
Mar 2017: 631
Jan 2018: 522
TOTAL: 7257
TOTAL after de-duplication Dec 2014: 3451
Jul 2015: 200
Mar 2016: 399
Aug 2016: 208
Mar 2017: 522
Jan 2018: 431
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TOTAL: 5211
TOTAL after first assessment by the Crowd and CDCIG information specialists Dec 2014: 448
Jul 2015: 81
Mar 2016: 70
Aug 2016: 45
Mar 2017: 43
Jan 2018: 38
TOTAL: 725
Appendix 3. Definitions of design, patient and intervention characteristics as applied in the
stratified analyses exploring between trial variations in intervention effect
Item Definition
Bias-related characteristics*
Concealment of allocation (avoiding selection bias) The guidance from the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011) will be used to judge bias related to
sequence generation and concealment of allocation using the two
Cochrane ’Risk of bias’ items. From these, the statistician will de-
rive a single variable to be used in the stratified analysis: allocation
concealment will be judged at low risk of bias if the investigators
responsible for patient selection were unable to suspect before allo-
cation which treatment was next. Concealment will downgraded
to high risk of bias if there is evidence of inadequate sequence gen-
eration
Blinding of patients and personnel (avoiding performance bias) Low risk of bias will be judged if:
- a credible sham procedure was used; or if a placebo supplement
or pill was used that was reported to be identical in appearance to
the experimental intervention and the specific outcome or group
of outcomes is/are likely to be influenced by lack of blinding
- blinding is absent or suboptimal and the specific outcome, such
as mortality, is not likely to be influenced by lack of blinding
Blinding of outcome assessment (avoiding detection bias) For self-reported/partner-reported outcomes:
Low risk of bias will be judged if:
- self-reported outcomes were assessed AND blinding of patients
was considered adequate AND there was no information to sug-
gest that there was an investigator involved during the process of
outcome assessment; OR if blinding of investigators performing
the outcome assessment was reported AND an attempt to blind
patients was reported
For other outcomes:
Outcome assessment was considered to be blinded if the outcome
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assessment was reported to be blinded
Statistical analyses (avoiding attrition bias) For continuous outcomes
Low risk of bias will be judged if:
- at least 90% of the patients randomised were analysed AND the
difference in percentage of participants not analysed was 5% or
lower across trial arms
- for trials using imputations to handlemissing data: the percentage
of participants with missing data did not exceed 20% AND the
difference in percentage of participants with imputed data was
10% or lower across trial arms AND applied imputation methods
were judged to be appropriate
For binary outcomes of rare events
Low risk of bias will be judged if:
- the event rate is low (e.g. incidence of dementia) AND at least
95% of the patients randomised were analysed AND there is no
evidence of differential reasons for missing data that may alter the
estimate AND the rate ofmissing data does not exceed the expected
event rates
For binary outcomes of non-rare events
Low risk of bias will be judged if:
- at least 90% of the patients randomised were analysed AND the
difference in percentage of participants not analysed was 5% or
lower across trial arms AND there is no evidence of differential
reasons for missing data that may alter the estimate AND the rate
of missing data does not exceed the expected event rates
Trial Size A large trial will be defined by a sample size calculation for the
primary outcome
Follow-up duration For the cognitive outcomes, we will group studies according to
these follow-up cut-offs to describe immediate results (up to 12
weeks), short-term (up to 1 year), medium-term (1 to 2 years) and
longer-term results (more than 2 years). For the secondary outcome
all-cause dementia, only outcome data at 1 year of follow-up or
longer will be considered and therefore the grouping will include
short-term (1 year), medium-term (up to 2 years) and longer-term
results (more than 2 years)
Treatment-related characteristics
Treatment duration Theminimum treatment durationof 3months is considered short-
term, 3 to 12 months as medium-term, and 12 months for long-
term
Dose of treatment Treatment will be analysed as high dose versus low dose according
to previously reported cut-offs
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Mechanisms of action of the supplements** Supplements postulated to share a main mechanism of action in
preventing development of dementia, including:
• Antioxidant properties - affecting superoxide dismutase
(vitamin A, C, D, E, selenium)
• Regulation/lowering levels of homocysteine: vitamins B12,
folate and B6
Participant-related characteristics
Cognition-related criteria No risk of deficiency versus at risk of deficiency for the type of
vitamin and minerals investigated (e.g. presence of malabsorptive
diseases, malnutrition, comorbidities or concomitant medications,
and ethnicity (Vitamin D))
* The descriptions depicted in this Table are in addition to the guidance provided by Cochrane (Higgins 2011).
** Knowledge of possible mechanisms of actions is evolving, and we will consider other possible subgroups for data analysis as new
information arises during the development of the review.
Appendix 4. Composition of Centrum Silver ® used in Grodstein 2013
Vitamin A (IU) 5000*
Vitamin C (mg) 60
Vitamin D (IU) 400
Vitamin E (IU) 45
Vitamin K (µg) 10
Thiamin (mg) 1.5
Riboflavin (mg) 1.7
Niacin (mg) 20
Vitamin B6 (mg) 3
Folic Acid (µg) 400
Vitamin B12 (µg) 25
Biotin (µg) 30
Pantothenic Acid (mg) 10
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Calcium (mg) 200
Iron (mg) 4
Phosphorus (mg) 48
Iodine (µg) 150
Magnesium (mg) 100
Zinc (mg) 15
Selenium (µg) 20
Copper (mg) 2
Manganese (mg) 3.5
Chromium (µg) 130
Molybdenum (µg) 160
Chloride (mg) 72.6
Potassium (mg) 80
Boron (µg) 150
Nickel (µg) 5
Vanadium (µg) 10
Silicon (mg) 2
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There are a number of significant differences between this review and its protocol.
Published protocols anticipated the production of two reviews with distinct populations: cognitively healthy people in midlife (40 years
to 65 years; Denton 2015) and in late life (> 65 years). However, it became apparent that many studies straddled this arbitrary age
boundary so that it was not possible logically to assign them to one review rather than the other. Therefore, it was decided to produce
a single review covering participants in mid- and late-life.
The protocols specified that participants should have been cognitively assessed at baseline. Again, this criterion would have led to
exclusion of a large amount of potentially informative data and was dropped in favour of a more pragmatic approach. If a study stated
that participants were cognitively healthy or if they were a large population sample with no cognitive inclusion criteria, then they were
assumed to be eligible.
The protocol specified only three time points for grouping outcomes: 12 weeks to 1 year, 1 to 2 years and > 2 years. However, we
considered that the very wide variation in durations of follow-up justified further subdivisions at 5 and 10 years. Particularly in the
middle-aged and ’young’ elderly, trial durations as short as 2 years are unlikely to be able to detect effects on the trajectory of age-related
cognitive decline.
Appendix 3 described a stringent method for assessing blinding. In practice, we adopted a more flexible approach and for multicentre
studies with generally rigorous methods, we accepted trial authors’ statements about blinding of participants and investigators in the
absence of further detail.
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